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Abstract  
 
Failure modalities of bone anchoring and skin penetrating devices, such as 
Intraosseous Transcutaneous Amputation Prosthesis (ITAP), stem from the 
lack of dermal cell and tissue attachment at the skin implant interface. As a 
result the implant shaft offers a direct route for harmful pathogens into the 
body. The aim of my thesis is to develop techniques that will enhance dermal 
cell and tissue attachment, in order to create a tight biological seal of implant 
biomaterials currently used for ITAP.  
 
I compared the effects of fibronectin against its cell binding region- a 3-amino-
acid region know as Arginine-Glycine-Aspartic Acid (RGD)- on human dermal 
fibroblast  (HDF)  attachment  to  ITAP  substrates.  Silanization  of  RGD-
polypeptides  provided  a  durable  biological  functionalisation  technique  that 
significantly increased HDF attachment compared with controls. No significant 
difference  was  observed  between  fibronectin  and  RGD-polypeptide 
functionalised substrates in vitro.   
 
I  then  investigated  the  effects  of  porosity  (as  a  function  of  pore  and  strut 
diameter) on soft fibrosis tissue in-growth and vascularisation. Electron Beam 
Manufacturing  (EBM)  provided  an  effective  method  of  creating  precise  3-
dimensional  porous  structures.  Porosity  as  a  function  of  pore  and  strut 
diameter  led  to  optimal  soft  fibrosis  tissue  in-growth  with  700µm  pore  and 
300µm strut diameters exhibiting significantly increased vascularisation over 
other implants groups after 4 weeks in vivo.    
 
The development of these functionalisation techniques, which utilised porous 
structures and silanization of RGD sequences, were combined and applied to 
the  ITAP  device.  An  EBM  porous  flange,  of  700µm  pore  and  300µm  strut 
diameters,  were  silanised  with  RGD-polypeptide  and  compared  with  the 
current clinical standard ITAP device. Implants were tested in a trans-tibial, 
transcutaneous  ovine  model  for  5-months.  Functionalisation  techniques 
employed in this study did not eradicate the failure modalities of ITAP devices, 	 ﾠ 9	 ﾠ
however  they  did  not  detrimentally a ffect  the  formation  of  a  stable 
transcutaneous interface compared with current clinical standards. Significant 
positive  effects  were  observed,  with  the  biological  functionalisation,  using 
silanised RGD-polypeptides, significantly increasing dermal tissue infiltration 
and  porous  structures,  manufactured  by  EBM,  significantly  increasing 
vascularisation.  
 
Functionalisation with silanised RGD-polypeptides to porous structures may 
provide  an  opportunity  to  enhance  the  skin  implant  interface  and  tight 
biological seal for bone anchoring and skin penetrating devices, such as ITAP, 
clinically.    	 ﾠ 10	 ﾠ
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Chapter 1  
1.1- Thesis Outline  
 
I intend to review the background literature and current knowledge to develop 
relevant  research  questions  around  a  research  theme  associated  with 
improving the soft tissue interface adjacent to intraosseous transcutaneous 
amputation  prostheses  (ITAP).  As  a  result  I  have  developed  the  following 
research hypothesis: Soft tissue attachment to ITAP devices will be improved 
by functionalisation, using a protein coated porous implant, compared with 
surfaces that are currently used for ITAP. I have investigated this hypothesis 
in a series of experimental chapters aligned to specific research questions. 
The outline of my thesis is presented below. 
  
Chapter 1- The Introduction  
 
This  chapter  aims  to  review  the  overall  subject  area  of  bone  anchored 
transcutaneous  implant  biomaterials,  from  a  clinical  standpoint  through  to 
biomedical  engineering  techniques  designed  to  enhance  tissue  attachment 
through to new areas such as innervated prostheses, which may well become 
more  of  a  possibility  once  a  reproducible  and  long  lasting  transcutaneous 
device can be engineered.  From reviewing the literature I will present my 
thesis aim and general hypothesis and relevant research questions, which will 
be experimentally tested and explored in the following chapters. A schematic 
diagram showing these questions is shown at the end of the introduction in 
Figure 1.06.  
 
Chapter  2-  Enhancement  of  Human  Fibroblast  Attachment  Using R G D -
polypeptide and Fibronectin Coatings. 
 
This chapter aims to compare the effects of the synthetic Arg-Gly-Asp (RGD)-
polypeptides  and  fibronectin  coatings  on  human  dermal  fibroblast  (HDF) 
attachment  strength  in  vitro.  In  this  chapter  the  development  of  a 
functionalisation technique involving surface modification of titanium alloy that 
affects the attachment of HDF will be investigated.  	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Chapter 3- Optimal Chemical Covalent Attachment of Fibronectin and RGD-
polypeptide coatings. 
 
This chapter aims to develop a full understanding of the loading and release 
kinetics  of  linear  RGD-polypeptides  compared  with  fibronectin  on  titanium 
alloy  substrates,  using  adsorbed  and  covalently  attached  moieties.  A 
methodology  to  create  a  durable  and  robust  biologically  active 
functionalisation  technique  that  ultimately  increases  HDF  attachment  to 
titanium alloy substrates in vitro will be investigated. 
 
Chapter 4- Optimal Structure of Porous Implants for Soft Tissue Integration 
into ITAP. 
 
This chapter aims to determine the effect of porous structures for an ITAP 
device by varying the pore and strut sizes and assessing tissue infiltration and 
vascularisation throughout the implant, in vivo.  
 
Chapter 5- Functionalisation of the ITAP Flange in vivo.   
   
This chapter aims to biologically functionalise a porous ITAP device based on 
information learnt in previous chapters and to limit epithelial downgrowth and 
create a tight biological seal between the dermal and epidermal tissues with 
the implant biomaterial.  
 
Chapter 6- General Discussion. 
 
This chapter will discuss the results of the thesis in its entirety and relate the 
findings  to  the  wider  setting  of  bone-anchored  transcutaneous  devices  for 
clinical use.   
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1.2- Background  
1.2i- Amputation  
  
The word amputate’ originates from the Latin L. amputates, pp of amputare 
literally meaning to “cut off” or “to prune” (Compact Oxford English Dictionary 
2005). Amputation can be a treatment for traumatic injury, infection, vascular 
disease,  cancer  and  congenital  defects.  Surgical  dismemberment  of  the 
diseased limb or extremity removes the affliction, permanently (Branemark et 
al. 2001). 
 
Between 1997 and 2007 there have been, on average, 5,456 new amputation 
referrals to prosthetic service centres per annum in the United Kingdom. By 
gender, two thirds of all new referrals were male. As a function of time, figures 
remained constant. Of these new referrals, the vast majority of amputations 
were lower limb, mostly at either the trans-tibial or trans-femoral level (Luff, 
2007).  The  epidemiology  surrounding  amputation  is  difficult,  as  there  are 
many factors to consider. Data can come from a variety of sources, which 
may be dependent on the type, level of resection or reason for amputation. 
The  above  referral  figures  fit  in  to  the  incidence  figures  for  amputation 
published in 2000 for Europe, North America and East Asia of 2.8-43.9 per 
100,000  individuals  (GLEASG  2000).  Recent  war-zones  in  Iraq  and 
Afghanistan have attributed to an increase in traumatic amputation of limbs. 
UK forces personnel have suffered over 250 amputations between 2006-2011. 
US forces suffered 1,407 traumatic limb amputations during the Iraq war and 
in Afghanistan from the beginning of the conflict to September 2010 (Wallace, 
2012). These figures suggest amputation is a considerable health burden.     
 
1.2ii- Conventional Treatment 
 
Current  treatments  for  amputation  use  prosthetic  devices  that  work  on  a 
modular  suspension  system,  where  a  cup  or  socket  fits  over  the  residual 
stump.  The  prosthetic  limb  and  cup  articulates  using  an  exoskeleton  for 
support (Lyon et al 2000).   
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Modern materials and cutting edge techniques have led to the use of highly 
sophisticated artificial prosthetic limbs which are benefiting amputees but still 
rely on external fixation of cups or sockets around the stump (Thurston, 2007).  
 
The motion of lower limb endoprosthetic joints, have been subject to much 
research, in an attempt to mimic the mechanisms of normal limb form and 
function. Load bearing applications continue to be problematic as the finite 
control of lower limb prostheses appears difficult to achieve, despite advances 
in weight, cosmetic design and appeal (Cochrane et al 2001).   
 
The principles of prosthetic treatment that forms the basis of design today are 
routed in the past (Thurston, 2007). Malone et al. (1981) suggested that a 
multi-faceted approach from the time of surgery could increase rehabilitation 
rates, decrease morbidity and mortality rates making lower limb amputation a 
successful  treatment  option.  Despite  this  approach,  Lyon  et  al.  (2000) 
indicated the importance of the integrity of the skin on the stump of amputees 
as a critical factor.  
 
1.2iii- Problems Implicated by Conventional Treatment 
 
The stump-socket interface is the site of many of the problems associated 
with conventional stump-socket designs. It has been reported that 40.7% of 
lower extremity amputees tested suffered from a dermatological condition of 
the stump (Dudek et al 2005).  
DesGroseiliers et al. (1978) and Lyon et al. (2000) agree that the importance 
of  dermatological  conditions  of  the  stump  is  paramount  for  a  successful 
amputation, however problems with the soft tissues account for 34% of all 
complications. Specific dermatological conditions in these studies ranged in 
both diagnosis and extent. There was high prevalence of contact dermatitis, 
resulting  from  both  chemical  and  physical  stimuli  (Koc  et  al  2008),  callus, 
ulcer  formation,  keloid  scarring,  epidermoid  cyst  formation  and  bacterial 
infections (DesGroseilliers et al 1978, Dudek et al 2005, Koc et al 2008 and 
Lyon et al 2000).       	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The  catalyst  for  many  problems  associated  with  these  conventional 
treatments  stem  from  the  level  of  locomotion.  Factors  namely t h e  fit  of 
prosthetic device, alignment between the stump and prosthesis, anatomy of 
the  stump,  age  of  amputee  and  position  of  level  of  resection  all  relate  to 
dermatological conditions. The severity of which are dependent upon the level 
of activity of the user. 
 
The stump is made up of soft tissue with underlying bone. Irregularities in 
pressure distribution are exacerbated during locomotion compared to low or 
no levels of locomotion. The soft tissues of the stump are not designed to 
tolerate such pressures. This can cause focal point trauma in the soft tissue of 
the stump from pointed calcified osteophytes outcropping from the residual 
bone (Dudek et al 2005 and Portnoy et al 2009).  
 
Koc et al. (2008) found that 73.9% of participants presented with at least a 
single  dermatological  condition  of  the  residuum.  Reasons  for  this  high 
prevalence of dermatological issues (Dudex et al 2005, Lyon et al 2000) were 
found in young, active patients. An increase in activity can therefore increase 
the likelihood of skin complications associated with the stump socket interface.    
 
Pressure to the anatomy of the soft tissue surrounding the stump can impact 
on the vascular and lymphatic flow, further compromising the stumps health 
(Levy, 1980). If the skin becomes compromised by a dermatological disorder, 
however  trivial,  limb  disuse  is  inevitable.  Small  lesions  to  the  cutaneous 
portion of the stump can develop into an extensive disorder. Treatment of 
these  problems,  such  as  relieving t h e  pressure  on  the  soft  tissues  means 
protracted  period  of  limb  disuse.  This  not  only  impacts  on  the  amputee’s 
locomotive ability but also more broadly on work, social and psychological 
status (Levy, 1956).    
 
A further challenge is one of alignment and subsequent fitting between stump 
and  socket  component.  Continual  changes  in  size  and  shape  around  the 
stump cause fitting issues for trans-tibial amputees. It has be reported that 	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users  require  new  sockets  for  their  prosthetic  devices  every  4-years  to 
account for these changes in soft tissue volume (Portnoy, 2009).  
 
New prosthetic users can experience tissue re-modelling as a result of un-
natural  pressures.  Biopsies  of  soft  tissue  from  lower  extremity  amputee’s 
stumps  had  increased  formation  of  fibrotic  tissue  (Levy, 1 9 5 6 ) .  This  can 
detrimentally affect the biology of the soft tissues leading to breakdown and 
tissue remodelling (Le Gros Clark, 1946).  Poor fitting of the socket around the 
stump  may  lead  to  strangulation  of  the  soft  tissues,  starving  the  skin  of  a 
blood supply (Levy, 1956), leading to skin surface Infections, which can be 
common  around  the  stump.  The  closed  environment  becomes  warm  and 
humid,  conducive  for  bacterial  proliferation  and  this  unnatural  environment 
can disrupt the normal bacterial flora (Kohler et al 1989). 
 
The anatomy of the residual limb is not that of a specialised joint. Dissipated 
forces that result from load bearing functions adversely affect the health of the 
stump (Pendegrass et al 2006). Furthermore, all citations make reference to 
the social, economic and psychological implications of medical complications 
associated with conventional treatment for amputations (DesGroseilliers et al 
1978, Dudek et al 2005, Koc et al 2008 and Lyon et al 2000). These may 
present  in  something  as  apparently  simple  as  the  every  day  problems  of 
fastening  or  removing  prosthesis  (Kang  et  al  2010)  or  referred  pain  in 
contralateral limbs, joints or lower backs during or as a result of ambulation 
(Pohjolainen et al 1990). These difficulties can translate into significant energy 
consumption  requirement  (25-65%-  depending  on  level  of  lower  limb 
amputation) compared with non-amputees whilst ambulating (Schmalz et al 
2002). If a miss-match in alignment exists at the stump-socket interface exists, 
muscular correction further increases energy consumption, which, intensifies 
if cadence changes (Schmalz et al 2002).    
 
Top athletes overcome these issues by frequently changing their prosthetic 
devices to maintain the best possible fit. However, this is not achievable within 
the general population (Webster et al 2001).  
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1.2iv- The Proposed Solution 
 
The  conventional  prosthetic  devices  are  flawed  in  design  because  they  all 
conduct  and  dissipate  forces  through  an  unnatural  load  bearing  structure.  
One author even makes light of the situation, by referencing bionics as the 
solution to the stump-socket issue (DesGroseilliers et al 1978).  
 
It was suggested by Winter (1974) that a skeletally attached prosthesis could 
alleviate these issues observed at stump-socket interface. Several research 
groups  have  clinical  experience  in  using  a  bone  anchored  transcutaneous 
device that provides a platform for prosthetic attachment (Pitkin, 2013). The 
crucial feature of these devices allows the user the transfer load through their 
skeletal system to the prosthesis without undue force on soft tissue of the 
stump.  
  
Intraosseous  Transcutaneous  Amputation  Prosthesis  (ITAP)  is  a  concept 
where  an  implantable  device  anchors  into  a  host’s  bone  and  protrudes 
through the overlaying soft-tissue and skin. If stable fixation is achieved, a 
solid platform allows the transfer of load from the skeletal system through the 
ITAP device to a prosthesis, promoting functionality of load bearing activities 
(Pendegrass et al 2006). Kang et al. (2010) reported clinical usage of ITAP in 
a  two-year  follow  up  study  for  a  trans-humeral  amputee.  Radiographs 
suggested stable bone anchorage in the residual humeral medullary canal of 
the  patient.  Furthermore,  the  patient’s  own  account  was  well  documented. 
The range of motion of the shoulder joint was stated as being comparable to 
near-normal movements, these accounts were supported by Disabilities of the 
Arm, Shoulder and Hand (DASH) scores pre and post surgery. No clinical 
concerns  were  reported.  Fitzpatrick  et  al.  (2011)  reported  further  clinical 
experience with ITAP implanted into distal limb amputation stumps in dogs. 
Loading  bearing  functionality  was  observed  in  4-animal  subjects.  Stable 
integration between the implant and skin appeared to form by 3-weeks, which 
was retrospectively confirmed with histology, post mortem. Authors noted a 
high degree of dermal fibroblasts and epidermal keratinocytes interacting with 
the implant, suggesting biological integration. 	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Branemark and Albrektsson (1982) were the first to use implantation of skin 
penetrating titanium implants in human subjects. Their results were varied. 
Where  implants  were  allowed  free  movement  with  the  skin,  histological 
analysis  of  the  interface  and  surrounding  tissue  showed  an  active 
inflammatory  response.  Where  implants  were  stabilised  with  connective 
elements  on  the  hypodermis  and  dermis,  no  evidence  of  an  inflammatory 
response  was  observed.  Where  implants  were  anchored  into  the  temporal 
bone on the lateral aspect of the skull, macroscopically there were no obvious 
signs of an inflammatory up to a period of 50-months).  
 
Aschoff et al. (2010) (2011) have 10 years of clinical experience of bone- 
anchored transcutaneous implants.  They refer to these implants as the Exo-
Endo  Prosthesis.  In  their  early  attempts,  development  of  hyper-granulation 
tissue  frequently  occurred.  It  was  attributed  to  a  rough  implant  surface  at 
transcutaneous  portion.  Later  designs  to  the  Exo-Endo  Prosthesis 
incorporated  a  smooth  surface  finish  that  has  been  reported  to  support  a 
stable soft tissue interface.   
 
A study by Sullivan et al. (2003) assessed clinical performance of 11 trans-
femoral amputees who had bone-anchored transcutaneous devices implanted 
for prosthetic attachment. Their findings, 2 years post implantation, suggested 
over 80% of recipients had functional implants.  
 
Lundberg et al. (2011) in a study of bone-anchored transcutaneous devices 
described  the  effects  of  functionality  on  quality  on  life.  Profoundly  positive 
impacts  were  observed  on  physical  activity,  emotional  and  psychological 
relationships. However the authors declined to discuss the complications that 
their patient cohort experienced.  
 
Disrupting  the  naturally  continuous  skin  with  a  transcutaneous  device 
compromises  the  primary  function  of  the  skin  (Von  Recum, 1 9 8 4 ) .  Winter 
(1974)  provided  histological  evidence  of  disruption  to  the  natural  wound 
healing  process  caused  by  transcutaneous  devices.  He  observed  that  re-	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epithelization of a wound could occur if the structures could support an influx 
of  dermal  fibroblast  to  support  wound  healing  through  the  structure o f  t h e  
implant.  Without  such  events,  the  upper  layers  of  the  skin  would  migrate 
downwards.  This  migration  or  marsupilization  is  a  biological  attempt  to 
extrude the device and keep the skin continuous (Von Recum, 1984). Such 
observations  have  been  observed  clinically  with  the  use  of  bone-anchored 
transcutaneous implant devices (Sullivan et al 2003).  
 
1.2v The Anatomy of the Skin  
 
Bone  anchored  transcutaneous  devices,  such  as  ITAP,  do  overcome  the 
issues surrounding conventional treatment of amputees (Kang et al 2010). In 
turn,  their  use  creates  a  new  set  of  biological  complications  principally 
surrounding  the  natural,  dynamic  action  of  the  skin  and  its  response  to  a 
foreign body (Von Recum, 1984). A detailed understanding of the anatomy 
and physiology of the human skin may better direct my experimental research 
in the development of a potential solution to the failure modalities of bone 
anchored transcutaneous devices.   
 
Collections  of  solitary  cells,  similar  in  morphology  are  held  together  in  a 
scaffold, structure known as the extra-cellular matrix (ECM). Soft tissues such 
as the dermis and epidermis are formed by distinct structures known as cell-
cell and cell-matrix junctions. This allows cells to anchor and organise within 
connective  ECM  or  basement  membrane  and  maintain  form  and  function 
(Alberts et al 2002 and Lanza et al 2000).  
  
Human skin is an organ that surrounds the entire body, without interruption. At 
natural openings or orifices it joins seamlessly with mucosal membranes. Skin 
can be separated into distinct layers, comprising of different cells (Fig 1.01).  
 
The  outermost  layer,  the  epidermis,  is  rich  in  epidermal  keratinocytes, 
stratified in layers or strata that anchor to a basement membrane, the basal 
lamina (Fig 1.02). Keratinocytes continually migrate up the strata towards the 
surface. During this time the cells mature and morph into flatter, a-nucleate 	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corneocytes  and  at  the  upper  most  strata  exuviate  from  the  body. 
Keratinocytes deposit keratin, a structural protein that assembles into an ECM. 
This process occurs over a month, maintains structural integrity and provides 
a physical barrier between the body and outside environment. The epidermis 
is  a  stratified  layer  with  distinct  molecular  components  referred  to  as  the 
epithelium.  The  well-ordered  and  organised  nature  of  the  keratinocyte  cell 
layer is evident when observing the function performed by human skin. The 
keratinocytes strata interconnect via cell junctions that physically stabilise the 
tissue, aid and facilitate communication between neighbouring cells and the 
ECM. There are various classes of anchoring cellular junctions that comprise 
of intra and extracellular domains and on interaction form dense molecular 
plaques (Le Gros Clark, 1946, Gardner and Osburn 1973, Hess and Kirsner 
2003, Kanitakis, 2002, Alberts et al 2002 and Lodish et al 2008).  
 
Adherens junctions link neighbouring epidermal keratinocytes on the lateral 
aspect to the actin cytoskeleton. Transmembranous cadherin proteins project 
out  into  the  cytoplasm  and  homodimerise  with  an  adjacent  cadherins. 
Intracellular  components  anchor  each  cadherin  protein  to  the  actin 
cytoskeleton.  A  cadherin/catinin  complex  forms  through  the  physical 
interaction between alpha, beta and gamma catinin and vinculin (Albert et al 
2002 and Niessen, 2007).  
 
Desmosomal  junctions  perform  cell-cell  anchoring  roles  but  to  keratin 
containing  intermediate  filaments  of  the  cytoskeleton  rather  than  actin 
filaments.  Transmembranous  desmosomal  cadherins,  desmocollin  and 
desmoglien, project into the extracellular space from the lateral aspect of the 
cell  and  interact  with  corresponding  projections  on  adjacent  keratinocytes. 
The extra-cellular domains of both desmosomal and cadherin glycoproteins 
are  highly  conserved  regions.  Dense  intracellular  plaques  anchor  cadherin 
components to keratin elements of the cytoskeleton. These anchoring plaques 
consist of gamma-catinin (often referred to as plakaglobin) and desmosplakin. 
The  desmosomal  homophillic  interaction  fluctuates  between  two  adhesive 
states, mediated by Ca
2+ binding in the extra-cellular domain (Albert et al 2002 
and Green and Jones 1996). 	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Below this thin and avascular layer of the skin lies the thicker and fibrous 
dermis, separated via a basement membrane, the dermal-epidermal junction 
(Fig 1.02).  
 
The  dermal-epidermal  junction  compartmentalises  the  two  distinct  layers, 
providing mechanical anchorage and a portal for metabolic communication. In 
skin epithelia, the junction is referred to the basal lamina in which immature 
keratinocytes  anchor  through  cell-matrix  junctions  known  as 
hemidesmosomes. These anchoring cell-matrix junctions link to the keratin 
elements  of  tonofilaments  in  the  cytoskeleton,  in  the  same  manner  as 
desmosomal junctions.  
 
Hemidesmosomal junctions permit the transmission of tensile strength across 
the  extracellular  junction  and  are  thus  similar  in  function  to  desmosomal 
junctions, which distribute forces to neighbouring cells. This helps promote an 
even distribution of trans-cellular tensile force (Alberts et al 2002).  
 
Hemidesmosomes  act  through  a  distinct  class  of  cell  surface  receptors, 
integrins.  Integrins are a distinct group of membrane spanning proteins with 
separate alpha and beta subunits that heterodimerise during ligand binding. 
Cytoplasmic plaques of anchoring proteins link the intracellular portion of the 
beta  subunit  of  the  integrin  protein  receptor  with  the  actin  cytoskeleton 
(Alberts et al 2002). These molecular junctions, project into the extra cellular 
cytoplasm with the same transmembranous desmosomal cadherins that the 
full  desmosome  uses.  The  intracellular  plaque  of  the  hemidesmosome 
involves  protein  associations  between  Plectin  and  Bullous  Pemphigoid 
Antigen  230  (BP230)  to  keratin  elements  of  the  cytoskeleton.  Bullous 
Pemphigoid Antigen 180 (BP180) spans the cellular membrane in conjunction 
with the integrin receptors. This binds Laminin-5, an ECM protein component, 
to which keratinocytes can anchor to the basal lamina (Jones et al 1998).  
 
The dermis differs from epidermal anatomy and is considered a connective 
tissue  rather  than  an  epithelial  tissue.  Dermal  fibroblasts,  the  cellular 	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component  of  the  dermis,  secrete  collagen  and  elastin  proteins  that  form 
structural matrices giving the integrity and flexibility to the dermis. Blood and 
lymphatic vessels are rooted in the soft tissue for protection but also provide 
nutrients and fluid exchange. Hair follicles, sebaceous, eccrine and apocrine 
glands are all embedded within the dermis and regulate protection, sensation, 
thermoregulation,  excretion,  metabolism  and  immunoregulation  (Le  Gros 
Clark,  1946,  Gardner  and  Osburn  1973,  Hess  and  Kirsner, 2 0 0 3  a n d  
Kanitakis, 2002).  
 
 
 
Fig 1.01. Light microscopic section of human skin. A) Subdermal layer, the hypodermis 
consisting mainly of adipose tissue. B) Dermal layer, the dermis consisting mainly of 
connective tissue. C) Epidermal layer, keratized rich strata. Taken from 
http://missinglink.ucsf.edu/lm/dermatologyglossary/img/Dermatology%20Glossary/Glossary%
20Histo%20Images/normal_skin_not_of_a_special_site.jpg. 	 ﾠ 40	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Fig 1.02. Light microscopic section of the upper most layer of human skin. D) Stratum Basale 
E) Stratum Spinosum F) Stratum Granulosum G) Stratum Corneum. Taken from 
http://tissupath.com.au/medical-student-subjects-skin/  
 
Focal Adhesions (FA) establish a bridge between the actin cytoskeleton of 
fibroblasts (Singer et al 1988) and endothelial cell (Fath et al 1988) and the 
underlying substrata through the association of intra and extra cellular protein 
components, clustering, forming dense plaques (Fig.1.03).  
 
Fibronectin  was  first  described  as  an  “exfoliate”  of  chicken  fibroblasts 
(Ruoslahti et al 1973). It was of high molecular weight, separated into two 
distinct subunits and soon after this the presence of the protein was confirmed 
in  human  fibroblasts  (Ruoslahti  et  al 1 9 7 4 ) .  The  protein,  fibronectin,  was 
subject to extensive research and the proteins interaction with fibroblasts and 
extra-cellular  collagen  matrices  has  been  described  (Klebe, 1 9 7 4  a n d  
Ruoslahti, 2003). Fibronectin has a central role in the ECM. In addition to 
binding  to  the  cell  surface,  it  binds  many  other  macromolecules  such  as 
collagens,  fibrin,  heparin  and  actin,  implicating  it  in  cell  attachment,  cell 
motility,  wound  healing  and  cell  morphology.  It  is  ubiquitous  within  many 
tissues including skin and underlying connective tissues (Alberts et al 2002). 
Morphology of attached fibroblasts within an ECM are well spread (Pearlstein, 
1976) with projected cellular processes (Yamada et al 1976) (Fig.1.04).  
 
Anchorage of fibroblasts through fibronectin depends on the affinity of a tri-
peptide binding domain consisting of Arginine-Glycine-Aspartic acid or RGD 	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(Pierschbacher  and  Ruoslahti  1984).  This  small  polypeptide  fragment 
promotes cell attachment by providing anchoring points (Alberts et al 2002). 
Attachment can be inhibited if stable presentation of the RGD-polypeptide is 
not  achieved  (Yamada  and  Kennedy  1984).  The  relationships  of  flanking 
residues  to  the  RGD-polypeptide,  in  native  fibronectin,  take  the  form  of  a 
secondary structure. Hydrogen bonds form within a hexa-peptide fragment, 
which  contains  the  RGD-polypeptide  binding  domain  (Glycine-
ArginineGlycine-Aspartic  acid-Serine-Proline).  Within  fibronectin,  this 
sequence is highly conserved, exhibiting a curved or cyclic structure. Beta-
turns  add  structural  specificity  in  the  native  conformation  in  fibronectin 
compared  with  primary  linear  polypeptides  of  the  same  binding  sequence 
(Reed et al 1988).  
 
Molecular  mechanisms  involved  in  fibroblast  attachment i n v o l v e   a 
complimentary cell surface receptor with specific affinity for fibronectin (Pytela 
et al 1985a). A second cell-surface receptor was soon discovered that also 
had affinity for RGD-polypeptide (Pytela et al 1985b). Both receptors bound 
different  ligands  (fibronectin  and  vitronectin  respectively),  but  each  acted 
through the same basic amino acid sequence, RGD. A family of receptors 
were  soon  established  and  are  known  as  integrins.  They  induced  signal 
recognition system dependent of cell attachment to the ECM (Ruoslahti and 
Pierschbacher  1987).  To  date,  24  combinations  of  various  alpha  and  beta 
subunits make up the integrin family (Alberts et al 2002).     	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Fig 1.03. Schematic representation of the Focal Adhesion complex (Rao and Winter 2009). 
 
Fig 1.04. Schematic representation of fibronectin, 
http://www.zoology.ubc.ca/~alorch/ecm/gallery2.htm 
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1.2vi- Wound Healing 
 
Six  functional  aspects  make  up  the  dynamic  response  to  the  skin  being 
broken,  known  as  the  wound  healing  process,  although  these  are  broadly 
classed into three phases. Platelets migrate, through the vascular system and 
leak into the wound space. Thrombosis and coagulation plugs the space with 
a three-dimensional latticework of ECM components; fibronectin, fibrinogen, 
thrombospondin and platelets. This is part of the inflammatory response and 
primarily serves to maintain integrity and protective properties by sealing the 
wound, blocking the entry of pathogens and preventing blood loss. Infection 
control  begins  with  the  mobilization  of  neutrophils  to  the  wound  site.  The 
wound is debrided of dead cellular material and foreign bodies by monocytes, 
enzymatic  degradation  and  toxic  oxygen  products,  which  also  initiate  the 
anabolic stage by secreting growth factors. In the anabolic stage, fibroblasts 
move  up  into  the  wound  space  from  the  sub-dermis.  The  initiation  of  the 
tissue-repairing phase is thought to result from monocyte metamorphosis to 
wound macrophages, which in turn secrete a variety of growth factors into the 
wound space and stimulate growth. Fibroblasts contract and form granulation 
tissue, synthesize collagen and proteoglycans in an effort build a new ECM 
and  remodel  tissue,  which  is  nutritionally  supported  by  endothelial  cells. 
Endothelial  cells  migrating  form  the  sub-dermis,  re-vascularising  the  area. 
Keratinocytes from the wound edges, spread and migrate downwards, using 
the fibrin latticework to re-epithelise and form an epidermal layer. Fibroblasts 
continue to move through the fibrin network and thicken the dermal cell layer. 
This  process  is  swift  and  fulfills  the  vital  role  of  knitting  the  layers  back 
together. Connective tissue of the sub-dermis often leaves fibrous scars as a 
result of dense collagen bundles being deposited. Fig 1.05. Represents the 
wound-healing cascade on a logarithmic timescale. Secondary homeostatic 
functions of the skin are often lost due to the regenerated skin being unable to 
support structures such hair follicles usually found in normal adult skin. Due 
the skins’ ability to re-generate, skin grafting can be achieved at a superficial 
level because of the stratum germinativums high mitotic proliferative capacity 
(Le Gros Clark, 1946, Grinnel, 1984, Pollack, 1984, Martin, 1997 and Lanza et 
al 2000).    	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Fig1.05. The phases of wound healing cascade represented in a logarithmic timescale. Taken 
from http://www.worldwidewounds.com/2004/august/Enoch/Pathophysiology-Of-Healing.html 
 
1.2vii- Natural Transcutaneous Appendages  
 
At  first  glance  it  may  appear  that  nature  has  many  examples  of 
transcutaneous structures. Fingernails, hair or horns may be seen as such 
examples. Grosse-Siestrup and Affled (1984) make the distinction that such 
structures are in fact “organs of the skin”. A layer of epithelial cells separates 
the  appendages  and  skin  and  therefore  should  not  be  considered  a 
transcutaneous structure, as they do not break skin continuity.  
 
Bone-anchored  transcutaneous  devices,  including  ITAP,  do  disrupt  skin 
continuity. Cellular downgrowth is the critical determinant of the success or 
failure  of  bone-anchored,  skin-penetrating  devices,  such  as  ITAP 
(Pendegrass et al 2006).  
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ITAP devices were modelled on deer antlers, which are a natural analogue to 
a  bone-anchored  transcutaneous  device  (Pendegrass  et  al 2 0 0 6 ) .  Deer 
antlers are of bony protuberances that out-crop from the frontal portion of the 
skull via a permanent bony pedicle. Anatomy of the frontal bones and pedicles 
are the same, both made up of trabecular bone. It is easier to think of the 
pedicle as simply an extension of the frontal bones. The structural architecture 
of the pedicle changes as the deer increases with age, becoming thicker as 
bone is deposited evenly around the structure (Landete-Castillejos et al 2012). 
  
Winter  (1974)  noted  that  the  tooth  created  a  “natural”  and  “permanent” 
disruption  in  the  epithelial  membrane  lining  the  mouth  cavity.  Cellular 
downgrowth of the gingival epithelia can not re-establish continuity because of 
a physical blockade of collagen fibres arranged in a peridontal membrane that 
interact  with  the  bony  socket  and  cementum  of  the  tooth.  Here,  a  natural 
example exists of an interface created when the epithelial layer is disrupted. 
Hemidesmosomes  bridge  the  soft-hard  tissue  interface,  linking  the  gingival 
epithelia with the collagen fibres that interact with the tooth (Grosse-Siestrup 
and Affled 1984). The anatomy structurally stabilises the gingival epithelia to 
the hard tissue of the tooth but critically, minimises the effect of breaking the 
skin seal (Sauberlich et al 1999). Maintenance of a healthy environment is 
sustained by the action of the saliva, washing away cell debris and promoting 
normal flora (Grosse-Siestrup and Affled 1984). No free movement between 
the gingival epithelia and tooth exists, which may play a role in permitting and 
maintaining soft tissue interface formation (Branemark and Albrektsson 1982).        
 
During the developmental stage, antlers are covered by a Velvet- an adapted 
layer  of  skin  that  is  shed  as  and  when  the  bones  grow.  The  Velvet  and 
connective tissue consists of large bundles of collagen fibres and extensive 
vasculature. This epidermis is thicker than that of normal epidermis (Chapman, 
1975). At the point of breaking the transcutaneous continuity collagen fibres, 
or  Sharpey’s  fibres,  bridge  the  soft  hard  tissue  gap  by  anchoring  into  the 
porous  trabecular  bone  with  the  surrounding  connective  tissues.  The 
interaction  of  Sharpey’s  fibre  between  the  bony  pedicle  and  dermal  tissue 
physically  block  marsupilisation  and  create  a  tight  biological  seal.  This 	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supports the development of the epithelium and ties the soft tissue into the 
bone so that there is little movement between the two tissues (Pendegrass et 
al 2006).      
 
Early in vivo development of ITAP saw straight titanium alloy pins skeletally 
anchored  into  a  trans-tibial g o a t  m o d e l  ( Capra  hircus)  for  4-weeks 
(Pendegrass, 2005). The implant shaft provided an opportunity for epithelial 
downgrowth and the formation a dead space between the implant and skin 
interface. Dermal and epidermal cellular attachment was limited (Pendegrass, 
2005 and Pendegrass et al 2006). In an attempt to increase the surface area 
for dermal tissue to attach to, novel engineering structures were incorporated 
in  later  ITAP  designs  based  on  deer  antler  histology,  however,  epithelial 
downgrowth was not fully eradicated (Pendegrass et al 2006 and Pendegrass 
et al 2006). 
 
1.2viii- Implant Biomaterials  
Materials  that  are  used  to  aid  or  restore  natural  function  of  tissue  are 
described as biomaterials. Biomaterials have to satisfy two aspects and as 
suggested by Black (1992), requirements for implantable biomaterials should 
not  be  absolute  but  should  be  seen  to  have  a  “minimum  requirement”  of 
biocompatibility.  He  also  suggested  that  given  the  body’s  dynamic 
environment,  performance  of  an  implant  biomaterial  should  be  classed  in 
terms of the host response and a greater understanding of the host responses 
is  key  in  the  development  of  successful  biomaterials.  Some  of  the  most 
obvious successes of the implant biomaterial can be seen in the hard tissue 
replacement  area,  with  vast  numbers  of  joint  replacement  arthroplasty 
surgeries being performed each year alone (Liu et al 2000). The challenge is 
clear; a non-living, foreign material must interface with a living material on a 
long-term basis (Van Noort,1987).  
 
Commercially  pure  titanium  (cp.Ti)  was  first  described  as  “tolerated”  in 
reference to direct contact between native bone and implant surface by Bothe 
et al. (1940). Cp.Ti does not invoke an adverse tissue response and due to its 	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material properties lends itself as an ideal material for bony fixation (Leventhal 
and Gottlied 1951). The metal forms a very stable oxide of titanium dioxide 
(TiO2), referred to as a passivation layer, and as a result the material is far 
less likely to corrode in its local environment. The material strength of cp.Ti 
can  be  increased  when  the  metallic  hexagonal  crystalline  structure  is 
stabilised  with  additions  of  aluminium  and  vanadium.  The  desired 
characteristics for orthopaedic applications require a low elastic modulus (so 
the  ratio  of  stiffness  between  implant  and  bone  are  a  close  as  possible), 
mechanical strength (to withstand forces in load-bearing activities) and tissue 
compatibility to resist corrosion. By matching the Young’s modulus to that of 
the anchoring point, the stress shielding effect can be limited and bio-fixation 
can be supported. TiAl6V4 is an alloy of cp.Ti and has increased structural and 
tensile strength, which is important for load-bearing activities, necessary for 
ITAP devices. This makes the metallic alloy a more appropriate material to 
use  for  orthopaedic  implant  device  manufacturing.  A  mismatch  in  Young’s 
modulus still exist between bone and titanium alloy (Wang 1996 and Liu et al 
2004).  
 
Electron beam manufacturing (EBM) is a rapid type of powder metallurgical 
processing  that  fabricates  highly  specific  microstructures  for  medical 
implantation.  It  is  a  layer-by-layer  single  process  that  is  CAD-directed  and 
occurs  under  vacuum.  Atomized  Titanium  alloy  powder  is  homogeneously 
applied layer-by-layer and a directed electron beam fuses the powder to form 
struts, which when the residual powder is removed produces a 3-dimensional 
porous  structures.  The  EBM  process  also  has  a  greater  energy  density 
compared  to  laser  manufacturing  techniques.  High  scanning  speeds  and 
position  accuracy  are  achieved  by  focusing  the  E-beam  through 
electromagnetic lenses, meaning this single step process has shorter build 
times and lower manufacturing costs (Heinl et al 2007, Heinl et al 2008 and 
Parthasarathy et al 2010).  
 
Porous structures can act as a mechanical scaffold to aid cell attachment for 
implant  biomaterials.  Inter-pore  connections  allow  cells t o   grow  through 
implants. This benefits load-bearing implants as bio-fixation and mechanical 	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attachment of osteoblastic cells can be achieved. Current joint replacement 
implants utilize these principles. High volumetric porosity of implants can also 
positively influence biological tissue integration at the soft tissue level. The 
permeability of an open structure can facilitate transport of body fluid through 
the  implant  promoting  in-growth  of  well  vascularised  soft  tissue  in  a  short 
period  of  time.  As  a  result  the  tissue-implant  interface  can  be  integral.  By 
modifying the porosity as a function of pore and strut size the functionality and 
longevity of the implant are increased (Heinl et al 2007, Heinl et al 2008 and 
Parthasarathy et al 2010).  
 
ITAP’s long-term success relies upon dermal attachment to prevent epithelial 
downgrowth. A flange increases the surface area for soft tissue attachment 
and decreases epithelial downgrowth (Pendegrass et al 2006). If the porosity 
of this structure could be increased, soft tissue attachment could be optimized 
to promote a skin seal around ITAP.   
 
Branemark led the cross-disciplinary research from the 1950s with the aim of 
understanding and establishing direct bone-implant interfaces. This principal, 
of establishing bony contact onto a foreign surface, without rejection or fibrous 
encapsulation  was  termed  osseointegration.  (Branemark  et  al  1969)   
Albrektsson  et  al  (1981)  postulate  the  interface  could  be  as  a  result  of 
chemical integration between cell and TiO2 layer as opposed to direct contact 
with the solid metal. In turn, this evidence was seen as the pre-requisite for a 
stable bio-fixation to allow load-bearing activities to be performed.  
 
Titanium alloy’s structural characteristics, in relation to implant materials, have 
been well established (discussed earlier). To better serve the host, implant 
substrates  can  be  functionalised,  adapting  to  the  biology  of  the  host  and 
attempting to develop a biologically stable interface.  
 
Cellular  interactions  with  an  implant  biomaterial  are  challenging,  as  the 
environment is dynamic. Functionalisation can involve the physical structure 
such  as  topographical  changes  to  better  suit  cell  attachment.  Biological 
elements  can  be  incorporated  on  an  implant  substrate  to  aid  cellular 	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attachment  or  hinder  bacterial  colonisation.  Research  has  focused  on 
attempting to meet the demands of an implant’s intended function within a 
specific biological environment thereby increasing longevity in situ and clinical 
success (Kasemo and Gold 1999).  
 
Hall  et  al.  (1975)  suggested  that  a  smooth,  non-textured  surface  of  a 
transcutaneous device, such as a cannula, would increase the opportunity for 
marsupilisation  to  create  a  portal  between  the  skin  and  device.  He  also 
observed the maturation rate of the cells involved in playing a critical roll for 
long-term  transcutaneous  device  to  be  in  situ.  Burnette  et  al.  (1986) 
substantiated implant surface research in vivo (Albrektsson et al 1981 and 
Branemark and Albrektsson 1982), when epithelial cells ordered themselves 
within surface crevices of titanium-coated substrates. Cell projections, such as 
lamella and filopodia, were observed, “bending” over topographical features.  
 
Others argue that increasing the surface roughness decreases the surface 
area  available  for  epithelial  cell  attachment,  spreading  and  proliferation 
leading  to  flattened  cells  and  the  successful  development  of  a  monolayer 
(Elisenbarth et al 1996 and Pendegrass et al 2008).  
 
The  longer-term  effect  of  micro-machined  surfaces  on  transcutaneous 
implants  suggested  an  optimal  surface  topography  could  limit  bacterial 
colonisation and positively aid soft tissue integration (Chehroudi and Brunette 
2002).  Smooth  surfaces  presented  a  7-fold  increase  in  susceptibility  to 
infection compared with porous-coated transcutaneous implant devices in vivo. 
Topographical features of the implant surface aided attachment of cutaneous 
and subcutaneous soft tissues (Isckson et al 2011). 
 
Three different cellular responses occur when a device breaks the skin barrier, 
which induces a cascade of events. Disruption of the well-ordered anatomy of 
the skin changes the mechanical forces between the individual components. 
The introduction of a foreign substrate disrupts normal stresses exerted by 
soluble biological material. This adversely affects the cell matrix assembly and 
links to the cellular cytoskeleton. So called “contaminated air” and the lack of 	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cellular attachment cause a build up of cellular debris and wound exudate.  
Cells migrate along the interface and the skin surrounding the foreign body 
invaginates  in  an  attempt  to  re-establish  the  continuity  of  the  skin  often 
forming pockets or recesses (Grosse-Siestrup and Affled 1984 and Balaban 
et al 2001).   
 
Holgers  et  al.  (1995)  observed  no  physical  interaction  between  extra-oral 
epithelia and cpTi bone anchored dental implant devices. SEM analysis was 
unable to establish hemidesmosome formation or organised collagen bundles 
linking the epidermis to implant surface in implants retrieved from 14 human 
subjects.  
 
Lundborg et al. (1996) insist the critical factor for successful skin penetrating 
devices is stabilising the skin around the implant, this can be achieved by 
pinning  to  the  underlying  bone.  Surface  topography  needs  to  enhance 
epithelial cell attachment in vivo for successful integration between skin and 
implant, and this is the critical determinant for the clinical success of ITAP 
(Kang et al 2010).  
 
Roy  and  Linnehan  (1974)  suggested  that  hydroxyapitite  (HA)  possessed 
potential as an implant material as a result of its native structure. HA, a major 
component  of  hard  tissue  in  humans  was  prepared  using  hydrothermal 
exchange reactions from coral skeletal carbonate samples. The bone implant 
interface could form a strong chemical bond (Jarcho et al 1977). Ducheyne et 
al.  (1980)  compared  HA  functionalised  steel  sintered  fibres  with  uncoated 
controls  in  vivo.  Osseointegration  with  the  HA  functionalised  substrates 
demonstrates  a  strong  stable  interface  as  measured  by  mechanical  tests, 
indicating greater bio-fixation.  
 
HA  soft  tissue  integration  is  also  achievable,  when  porous  HA  blocks 
supported soft tissue infiltration and revascularisation throughout the structure 
within 21 day in vivo (Butts et al 1989). Solid implants, in combination with HA 
coatings are successful as endoprostheses where bony fixation is necessary, 	 ﾠ 51	 ﾠ
however these implants do not promote soft tissue attachment or infiltration 
(Gupta et al 2006).  
 
Biological functionalisation of implant biomaterials are used to better meet the 
functional requirements of the cells involved in the host biological composition 
(Kasemo and Gold 1999). The principle of using native, non-rigid, biological 
materials  bridging  the  interface  between  the  host’s  tissue  and  implant 
biomaterial fits in with Black’s statement referencing a host response to an 
implantable biomaterial (Black, 1992).  
 
Cells must be attached to a substratum in order to function (Stoker et al 1968). 
Components for the ECM and connective tissue are aimed at cell surfaces 
receptors  to  induce  molecular  interaction  between t h e  host  and  implant 
material. Recognition of molecular substrates supports contact guidance, in 
which cells deposit a fibrous layer that acts as a scaffold to promote cellular 
morphogenesis  (Weiss, 1 9 4 5 ) .  ECM  constituents  readily  adsorb  onto 
biomaterial substrates, on entering a biological environment, but exposure to 
such environments is not specific and cannot be regulated to elicit the desired 
cellular interactions (Shin et al 2003). Proteins in aqueous solution, when in 
the  presence  of  a  solid  surface, w i l l  n o n -covalently  interact  with  that  solid 
surface to produce a monolayer. For the desired cellular response (anchorage 
dependent)  this  protein  layer  is  critical  (Wilson  et  al  2005). N o n -covalent 
forces of attraction allow the physical attachment of proteins to titanium alloy 
surfaces.  Functionality  of  the  adsorbed  protein  can  be  maintained  and 
quantifiable increases in anchorage dependent cell growth mechanisms have 
been  well  established  using  ECM  components.  The  performance  of 
fibronectin  has  been  established  within  the  biomaterial  field.  Yang  et  al. 
(2003) showed the use of a simple adsorption method (relying upon surface 
energy of a cp.Ti surface) to bind and present fibronectin as a coating.  This 
fibronectin coating functionalised titanium surfaces and significantly increased 
osteoblast attachment.    
 
Laminin-5 is implicated in hemidesomsome formation (Jones et al 1998). It 
can  be  adsorbed  on  to  titanium  alloy  substrates  and  up-regulate 	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hemidesmosome formation and cell spreading of epidermal keratinocytes (El-
Ghannam et al. 1997). Well-spread, viable and attached gingival fibroblasts 
have been observed (to a significantly greater degree) on collagen coated 
cpTi substrates compared with uncoated substrates in vitro (Nagai et al 2002).  
 
The  dynamic  environment  created  in  vivo  means  physical  and  chemical 
aspects  affect  cellular  attachment  (Hormia  and  Kononen  1994). I m p l a n t  
biomaterials  are  subject  to  blood  and  serum  on  entering  an  in  vivo 
environment. Attachment of specific cells have to compete for the surface with 
an  active  immune  response,  which  involves  protein  adsorption  and  the 
attachment of cells such as macrophages and neutrophils, associated with the 
immune system (Baier and Dutton 1969 and Nygren et al 1997). Chemical 
coupling of a biological molecule to a biomaterial substrate can be engineered 
to control and enhance the subsequent cell and tissue response (Davis et al 
2002). Covalent bonding of a protein to the substrate surface can provide a 
stronger  and  more  stable  immobilization.  Jose  et  al.  (2005)  utilized  the 
reactive oxide layer of titanium to couple antibiotics to self protect their implant 
devices against infection.  
 
Cell attachment functional groups have been explored in the same manner in 
order  to  promote  osseointegration  (Nanci  et  al  1997)  and  soft  tissue 
integration (Middleton et al 2007 and Chimutengwende-Gordon et al 2011). 
 
All the referenced examples above rely on comparable methodologies utilizing 
the  same  intermediary  between  metal  and  protein.  Aminopropylated 
substrates  provide  a  spacer  between  implant  and  protein,  coupling  via 
unpaired electrons (Fig 1.05). An increase in the number of chemical bonds 
between  the  metal  and  protein  mean  greater  distance  amid  the  two 
components,  facilitating  biological  activity  of  the  protein  functionaliseation 
(Jose  et  al  2005,  Nanci  et  al  1997,  Middleton  et  al 2 0 0 7  a n d  
Chimutengwende-Gordon et al 2011).       
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Fig 1.06. Schematic representation of Aminopropylated substrates. 
1) Implant substrates. 2) Coupling of 3-aminopropyl-triethooxysiane (APTES) containing 
saline complex to the substrate. 3) Coupling glutaraldehyde to saline complex. 4) Covalent 
bond formation between a functional group and spacer complex. 	 ﾠ 54	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These  cited  examples  suggest  a  good  rationale  for  the  use  of  biological 
functionalisation for biomaterials. Cellular responses can be influenced and as 
such,  physical  attachment  may  be  increased  by  the  up-regulation  of  the 
formation of contacts points between host and substrate. This can act as the 
prerequisite in the development of a tight biological interface between host 
tissues and implant biomaterial.  
 
In  vitro  studies  are  one-dimensional.  Exposure  to  serum  that  creates a  
competitive  environment  to  the  biologically  functionalised  surfaces i s  o f t e n  
withheld so only specific cellular responses can be observed. The challenge is 
to establish a functionalised substrate and demonstrate that it works in an in 
vivo model. These coatings have been shown to be effective in a number of in 
vivo models (Chimutengwende-Gordon et al 2011, Elmengaard et al 2005 and 
Ferris et al 1997).  
 
Elmengaard  et  al.  (2005)  reports  RGD-polypeptide  functionalised  porous 
coated titanium alloy substrates in vivo. Fibrous tissue formation was reduced 
yet new bone formation in the experimental groups was not as advanced as 
hypothesised.  
 
Bone  thickness  increased  around  rat  femurs  when  RGD-polypeptide 
substrates were implanted in vivo yet results did not significantly increase the 
strength of osseointegration (Ferris et al 1997).    
 
Fibronectin has shown promise as a protein coat both in vitro and in vivo 
(Middleton et al 2007 and Chimutengwende-Gordon et al 2011). Established 
methodologies  show  the  positive  up-regulatory  effect  fibronectin  has  on 
dermal fibroblast attachment and attachment strength on materials used for 
ITAP devices, by fluorescently tagging vinculin within the FA (Middleton et al 
2007 and Pendegrass et al 2008). 
 
Early Immunocytochemistry methodologies for intra-cellular FA components 
demonstrate that these complexes, which are composed partly of vinculin and 
actin, differentiate into a mature form in attached fibroblasts, and appear as 	 ﾠ 55	 ﾠ
intracellular  ‘dashes’  and  ‘dots’  respectively  under  fluorescent  microscopy. 
Vinculin and Actin localisation were observed in both mature and immature 
forms  of  FAs,  with  the  mature  dash  contacts  associated  with  actin 
microfilament bundles (Bershadsky et al 1985). Both Hunter et al. (1994) and 
Middleton et al. (2007) appear not to discriminate between maturity of FAs 
when assessing dermal fibroblast attachment to titanium alloy substrates. 
 
The relationship between vinculin localisation, as a function of cell area and 
the  biophysical  forces  necessary  for  fibroblast  detachment  from  a  metallic 
surface, positively correlate. It is therefore possible to calculate the force of a 
single FA. Cells cultured on fibronectin functionalised titanium alloy surface 
response by producing more FA per unit area without increasing their cell 
area (Pendegrass et al 2009). Morphology characterised under microscopy, 
be  it  at  a  micro  or  nanoscale,  of  attached  fibroblasts  to  titanium  alloy 
substrates appear consistent. Cellular projections extend outwards of the cell 
body creating a stellate shape and morph into a discoid shape, attached to a 
surface (Hunter et al 1994 and Middleton et al 2007).  
 
Earlier work by Truskey and Pirone (1990) used laminar fluid flow through 
parallel  plates  to  theoretically  quantify  detachment  of  murine  fibroblasts 
attached to glass substrates, functionalised with or without Fibronectin.  
 
Well spread fibroblast cells (of human or murine lineage) are less susceptible 
to  laminar  hydrodynamic  forces  coupled  to  a  greater  number  of  physical 
contacts (fibronectin mediated) between cell and substrate results in a greater 
force required to detach the cells (Truskey and Pirone 1990 and Pendegrass 
et al 2009). 
 
I now strive to develop functionalisation techniques for ITAP devices that can 
withstand  in  vivo  implantation  support  a  tight  biological  seal  at  the 
transcutaneous interface and can feasibly be applied in the clinical setting. I 
aim  to  develop  techniques  to  functionalise  titanium  alloy,  which  will u p -
regulate human dermal fibroblast attachment strength. In a previous study the 
number of FAs per unit cell area (termed FA density) has been shown directly 	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to  correlate  with  the  strength  of  attachment  of  fibroblasts  to  substrates 
(Middleton  et  al  2007  and  Pendegrass  et  al  2009).  Hence,  throughout  my 
thesis,  FA  density  will  be  used  as  a  measure  of  human  dermal  fibroblast 
attachment strength.  	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1.3- Thesis Aim      
 
My overall aim is to  develop  techniques  that  will  enhance  dermal  and 
epidermal  cell  and  tissue  attachment,  in  order  to  create  a  seal  and 
prevent  infection  of  implant  biomaterials  used  for  ITAP.  The  general 
hypothesis  for  my  thesis  is  that  soft  tissue  attachment  to  ITAP  will  be 
improved  using  a  protein  coated  porous  implant  compared  with 
surfaces that are currently used for ITAP.  
 
Fig  1.06  illustrates  a  breakdown  of  my  thesis.  It  aims  to  schematically 
represent how the experimental work in this thesis has been dictated by a 
central axis. It starts with the overall aim for the experimental work, followed 
by a brief outline of the problem this research wishes to address. My research 
bifurcates into in vitro (Chapter 2 and 3) and in vivo (Chapter 4) experimental 
chapters,  each  addressing  the  overall  aim  but  by  differing  methods.  Each 
chapter is dictated by a research question, highlighted in red italics in the flow 
diagram. The final experimental chapter, Chapter 5, brings the two branches 
of my thesis together in one final experimental study.     	 ﾠ 58	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Fig 1.07 Schematic representation of the outline of my thesis. Text in red indicate my main 
research questions and are related to experimental chapters of my thesis 
	 ﾠ
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rate of 0.5mm/min using three rectangular speci-
mens with dimensions of 8.2mm610mm636mm at
room temperature. The span length for the three-
point bending test was 28mm.
3 RESULTS AND DISCUSSION
Figure 1 shows an SEM image of the powder. It can
be seen that all the powder is spherical in shape. The
distribution of the particle sizes of the powder is
shown in Fig. 2. All particles can be fully melted
by an electron beam to form dense parts. Figure 3
shows the porous Ti–6Al–4V implants produced by
Arcam’s EBM process. Figure 4 shows the XRD
patterns of the starting Ti–6Al–4V powder and the
fabricated Ti–6Al–4V implant. The XRD peaks of
both diffraction patterns agree well, which indicates
that the EBM process has not changed from the
composition of Ti–6Al–4V. The macrostructure of the
implant with a honeycomb structure was examined
by SEM. It presents a fully interconnected pore
network (Fig. 5). The mean macropore size of the Ti–
6Al–4V implant was around 1060mm. Taking the
theoretical density of solid Ti–6Al–4V as 4.42g/cm
3,
the result of the volume–weight analysis revealed
that the porosity was 60.4¡2.6 per cent for the
mechanical testing samples and 66.5¡3.2 per cent
for the samples with a honeycomb structure. Large
pore and high porosity (60–80 per cent) could
enhance bone ingrowth and osseointegration of the
implant after surgery [14]. The measured Vickers
microhardness of the samples was around 428HV.
Fig. 1 SEM image of Ti–6Al–4V powder
Fig. 2 The distribution of the particle sizes of Ti–6Al–
4V powder
Fig. 3 The fabricated Ti–6Al–4V implants: (a) samples
for mechanical tests; (b) samples with honey-
comb structure
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A highly porous pedicle provides an 
increased  surface  area  for  well 
vascularised  dermal  tissue 
attachment  capable  of  extreme 
loading.  
Chapter 2 
To investigate the effect of synthetic 
RGD  polypeptides  and  fibronectin, 
on  human  dermal  fibroblast  (HDF) 
attachment  to  titanium  alloy 
substrates in vitro. 
 
Chapter 4 
To  determine  the  effect  of 
porous  titanium  alloy 
structures by varying the pore 
and  strut  dimensions  and 
assessing tissue in-growth and 
vascularisation throughout the 
implant in vivo. 
!
Chapter 5 
To  determine  the  effect  of 
functionalising t h e  I T A P  f l a n g e  
with  an  optimised  porous 
structure  and  durable  biological 
coating  on  the  skin  implant 
interface  in  a  long-term  in  vivo 
model.  
!Enhancement of dermal cell and tissue attachment to ITAP 
!
!
Fibronectin  is  central  in  dermal  cell 
attachment  to  the  ECM.  Fibronectin 
functionalised t i t a n i u m  a l l o y  
substrates  significantly  increased 
dermal  cell  attachment  compared  to 
controls in vitro.  
!
Unimpeded  epithelial  downgrowth  can 
provide a direct route for infection as the cell 
sheet  tracks  down  the  shaft  of  the  implant, 
this  can  results  in  device  avulsion  and 
subsequent  failure.  The  deer  antler  is  a 
biological  analogue  for  a  transcutaneous 
implant.   
!
!
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© 2006 The Authors
Journal compilation © 2006 Anatomical Society of Great Britain and Ireland
 
60
 
properties of the antler and the skin–bone interface
of deer antler specimens when, albeit transiently, the
interface exists transcutaneously. We report how the
adaptations to suit a transcutaneous environment in
deer antler have been mimicked to develop a successful
amputation prosthesis design.
During growth antlers are covered with soft hairy
skin (velvet) and are provided with an abundant supply
of blood vessels. Evidence shows that antler growth
involves both endochondral and intramembranous
ossification and is closely linked to circulating testo-
sterone levels (Kierdorf et al. 2003; Price et al. 2005). To
date, the precise molecular pathways responsible for
antler regeneration remain unknown. Once antlers are
fully grown, androgen levels rise and the velvet is shed.
This leaves the external antler bare during the mating
season, and a transcutaneous interface between the
skin and the antler–pedicle junction (Goss, 1985) (Fig. 1).
For the purpose of our study this duration will be referred
to as the ‘transcutaneous phase’.
The pedicle is subcutaneous living bone that becomes
evident around the onset of puberty and grows from
frontal bone cells of the deer skull (Chapman, 1975;
Li & Suttie, 1994). The pedicle bone undergoes con-
tinuous remodelling throughout the antler cycle (Kierdorf
et al. 2003); however, during the transcutaneous phase
the dermal tissues are adhered to the pedicle with
sufficient strength to prevent infection, marsupilization
and ultimate failure of the soft–hard tissue interface
(Banks & Newbrey, 1983). Marsupilization is a phenom-
enon observed around transcutaneous implants as a
result of epithelial cell migration causing downgrowth
around the skin-penetrating obstruction to re-establish
continuity in the skin layers. Downgrowth thus occurs
as a direct result of the normal wound-healing response
to regenerate the protective barrier function of the skin.
In transcutaneous implants, downgrowth commonly
results in implant failure as a result of infection. Nature
has evolved biological mechanisms to protect against
bacterial infection through the mechanical stabilization
of the interface. As a natural structure, antlers represent
an analogue for developing transcutaneous implants
for the musculoskeletal system (Grosse-Siestrup & Affeld,
1984).
 
Materials and methods
 
Statistical analysis
 
All quantitative data were assessed using SPSS for
Windows version 12.0.1 (SPSS, Chicago, IL, USA). The
Kolmogorov–Smirnov test for normality was used to
determine whether the data fit the assumptions required
for parametric testing. Values of 
 
P
 
 < 0.05 were con-
sidered non-normally distributed. Normally and non-
normally distributed data were analysed using a Student’s
 
t
 
-test or a Mann–Whitney 
 
U
 
-test, respectively. Results
were considered significant at the 
 
P
 
 < 0.05 level.
 
Deer antler specimens
 
Twenty-one pairs of deer antlers from Red deer (
 
Cervus
elapus
 
) (24–28 months, 104–178 kg), killed during the
Transcutaneous Phase of the antler cycle for concurrent
research projects, were supplied by the Royal Veterinary
College (North Mymms, Hertfordshire, UK) and the Rayne
Institute. All procedures were carried out in accordance
with the Home Office Animals (Scientific Procedures)
Act 1986.
 
Scanning electron microscopy of deer antler specimens
 
The skin and surrounding fascia were removed from
five of the antler specimens. The antler–pedicle portion
of each specimen was macerated by treatment with
Fig. 1 Antler–pedicle specimen following maceration 
demonstrating the marked difference in morphology at the 
interface between the antler (A) and the pedicle (P) bone. 
The white arrows demarcate the position of epithelial layer 
attachment. Scale bar = 1 cm.
Providing a highly porous structure 
for ITAP may enhance dermal 
tissue attachment?   
Could RGD be immobilized onto 
a titanium alloy substrates and 
aid dermal cell attachment?   
Can I optimise this functionalisation 
technique using RGD-polypeptides in 
preparation for in vivo applications?
   
Chapter 3 
To develop a full understanding of the 
loading and release kinetics of RGD 
polypeptides  on  titanium  alloy 
substrates. 
 
  Soft tissue attachment to ITAP will be improved using a biologically coated porous 
implant compared with surfaces that are currently used for ITAP.  
Can I incorporate the 
functionalisation techniques into 
an ITAP device and enhance soft 
tissue attachment in vivo long-
term?   
!
Collageneous f i b r e s  a n c h o r  d e r m a l  s o f t  
tissue  to  the  bony  deer  antler.  The 
dermal  tissue  physical  impedes  cell 
downgrowth  and  seals  the 
transcutaneous interface from infections. 
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Chapter 2 
2.1-Introduction 
 
Fibronectin is a critical component within the ECM. In addition to binding to 
the cell surface, fibronectin facilitates the binding of many macromolecules 
such as collagens, fibrin, heparin and actin, implicating it in cell attachment, 
cell motility, wound healing and cell morphology. It is ubiquitous within many 
tissues including skin and underlying connective tissues (Alberts et al 2002). 
 
Fibronectin  has  been  shown  to  improve  cell  attachment  to  titanium  alloy 
substrates, with increases in vinculin expression being observed as early as 
1-hour  (Yang  et  al 2 0 0 3  a n d  M i d d l e t o n  et  al  2007).  Functionalisation o f  
titanium alloy using fibronectin increases the FA density per cell area, which 
correlates with an increase in force required to detach dermal cell from the 
substrate (Middleton et al 2007 and Pendegrass et al 2009). For the purpose 
of  the  thesis  functionalisation  techniques  of  titanium  alloy  substrates  are 
aimed at increasing human dermal fibroblast attachment strength.    
 
The  minimum  amino  acid  sequence  in  fibronectin  required  to  initiate  cell 
attachment  via  integrin  binding  is  arginine-glycine-aspartic  acid  (RGD) 
(Pierschbacher and Ruoslahti 1984a).  
 
Independently  of  fibronectin,  the  RGD-polypeptide  can  bind  many  different 
integrin receptors with low affinity (Ruoslahti, 1996). However, high affinity is 
observed with the whole fibronectin molecule, which is only observed to bind 
the alpha5 beta1 integrin receptor (Hautanen et al 1989).  
 
This  native  alpha5  beta1  integrin  binding  may  occur  because  fibronectin 
exposes the RGD-polypeptide in a specific orientation, thus increasing cell 
attachment (Ruoslahti, 1996).  
 
The RGD-polypeptide in fibronectin exists as a looped structure, which is held 
together by hydrogen bonds and forms a beta turn. This creates the specific 
orientation  that  increases  integrin  affinity  (Reed  et  al  1988  and  Main  et  al 	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1992).  In  addition,  there  is  evidence  to  suggest  that  further  regulation  of 
integrin  binding  could  be  achieved  in  native  fibronectin  by  a  second 
synergistic site, remote from the RGD sequence, which may play a role in 
increasing  specific  interaction  between  integrin  receptors  and  the  RGD 
binding domain in fibronectin (Obara et al 1988). 
 
Individual  amino  acids  within  the  RGD-polypeptide  can  also  significantly 
impact on integrin binding affinity. Substituting L-aspartic with D-aspartic acid 
down-regulates integrin binding, and this has been shown to decrease cell 
attachment (Pierschbacher and Ruoslahti, 1987).  
 
In addition, the amino acids that flank the RGD-polypeptide can impact upon 
orientation, and hence integrin binding; therefore cell attachment (Ruoslahti, 
1996). For example, cysteine residues flanking the RGD-polypeptide can form 
di-sulphide bonds causing the polypeptide structure to loop. This can result in 
increased  affinity  to  specific  integrin  receptors  compared  with  linear  RGD-
polypeptide structure (Koivunen et al 1994). If Proline flanks the aspartic acid, 
integrin affinity is completely inhibited (Pierschbacher and Ruoslahti, 1987). 
 
RGD-polypeptides  flanked  by  long  chains  of  amino  acids  show  greater 
integrin  binding  affinity  compared  with  the  RGD  sequence  alone.  Some 
evidence suggests that increasing length stabilizes the RGD binding domain, 
which  holds  the  polypeptide  in  a  formation  that  supports  specific  integrin 
binding. However the precise mechanism has not been determined (Ruoslahti, 
1996). Irrespective of the mechanism by which this occurs, longer chain RGD-
containing polypeptides with specific flanking residues that can induce a cyclic 
structure may confer increased integrin binding affinity compared with linear 
forms,  hence  may  increase  cell  attachment.    There  is  some  evidence  to 
support  this  because  the  cyclic  forms  of  RGD-containing  polypeptides  can 
bind specific integrin receptors with high affinity, which is known to increase 
cell attachment compared with the ubiquitous weaker integrin binding seen 
with linear forms. It may be possible to use lower concentrations of cyclic 
RGD-containing polypeptides. Patel et al (2012) have shown that the same 	 ﾠ 62	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degree of cell attachment can be achieved with significantly less cyclic RGD-
containing polypeptides compared with linear forms. 
 
For ITAP to be successful, it is critical to up-regulate cell attachment at the 
skin-implant interface as early as possible. Biological functionalisation of the 
titanium  alloy  used  in  ITAP  may  achieve  this,  irrespective  of  whether 
fibronectin or an RGD-containing polypeptide is used.  
 
ITAP  is  designed  for  load  bearing  activities  and  osseointegration  must  be 
achieved. Titanium Alloy is the material that is used clinically for ITAP (Kang 
et al 2010). This is because it’s Young’s Modulus is closer to that of bone 
(compared with other implant materials, such as alloys of cobalt) reducing the 
potential  for  stress  shielding,  and  it  is  highly  biocompatible  (discussed  in 
Chapter  1.2).  Titanium’s  material  properties  can  influence  functionalisation 
techniques. Proteins can be absorbed onto the amorphous oxide layer on the 
surface of titanium. Immobilization of the absorbed proteins is achieved via 
electrostatic forces, which hold the proteins in place (Yang et al 2003). RGD-
polypeptides could be immobilized in the same way.  
 
Covalent tethering of fibronectin to titanium alloy using silanization (Chapter 
1.2, Fig 1.05) has been shown to provide a stronger, and more durable bond 
compared  with  adsorption  and  maintains  significant  positive  effects  on  cell 
attachment compared with non-functionalised controls (Middleton et al 2007). 
It therefore may be possible to silanise RGD-containing peptides to titanium 
alloy substrates to up-regulate HDF attachment.  
 
The clinical use of fibronectin is highly regulated because it is sourced from 
humans or animals and hence may induce an inflammatory response due to 
an  immune  reaction.  However,  sterilization  techniques  denature  proteins 
rendering them inactive. RGD may provide a possible solution because it can 
be artificially synthesized avoiding potential regulatory complications and may 
be less susceptible to sterilization damage.   
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Some  studies  have  demonstrated  increasing  cell  attachment-dependent 
processes on RGD-containing polypeptide functionalised material substrates 
(Kantlehner et al 2000 and Kammerer et al 2011). However, there are no 
studies  investigating  cell  attachment  strength  on  RGD-functionalised 
substrates,  comparing  linear  and  cyclic  RGD-containing  polypeptides  with 
fibronectin.  This  chapter  aims  to  develop  a  functionalised t i t a n i u m  a l l o y  
substrates, which act to increase human dermal cell attachment strength to 
titanium alloy substrates.    	 ﾠ 64	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2.2- Aims and Hypotheses 
 
This chapter aims to investigate the effect of synthetic RGD polypeptides 
and  fibronectin,  on  human  dermal  fibroblast  (HDF)  attachment  to 
titanium alloy substrates in vitro. 
 
To achieve this aim, I will determine whether there is a difference in HDF 
attachment  to  functionalised  titanium  alloy  substrates  with  either  linear  or 
cyclic  RGD-polypeptides  compared  with  fibronectin.  In  addition,  I  will 
investigate  whether  silanisation  effects  HDF  attachment  in  vitro  compared 
with  adsorption,  and  whether  attachment  will  be  increased  at  earlier  time 
points on functionalised substrates compared with controls.   
 
This chapter aims to test the following specific hypotheses: 
 
1.  Linear  RGD-polypeptide  functionalised  titanium  alloy  substrates  will 
significantly increase HDF attachment compared with controls. 
2.  There  will  be  no  significant  difference b e t w e e n   HDF  attachment  on 
linear  RGD-,  compared  with  cyclic  RGD-polypeptide  functionalised 
titanium alloy substrates. 
3.  Attachment of HDFs will be RGD-polypeptide concentration dependent.  
4.  Titanium alloy substrates functionalised with Fibronectin or RGD will 
significantly  increase  HDF  attachment  at  1,  4,  24  and  96  hours 
compared with controls.  
5.  There  will  be  no  significant  difference  in  HDF  attachment  between 
silanised and adsorbed fibronectin- or RGD-functionalised substrates. 	 ﾠ 65	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2.3- Materials and Methods 
2.3i- Study Design 
 
This chapter is broken down into individual experiments to address a series of 
questions to test my hypotheses.  
 
Study 1 
 
The first research question was whether titanium alloy adsorbed with RGD-
polypeptides  increases  HDF  attachment?  Secondly,  regarding  optimal 
adsorption duration, linear (A8052, Sigma Aldrich, UK) and cyclic (ANA63785-
1, Cambridge Bioscience, UK) RGD-containing polypeptides were adsorbed 
for  1  and  4  hours  prior  to  assessing  HDF  attachment  to  establish  the 
adsorption duration for HDF attachment protocols for Studies 2-5. Table 2.01 
outlines  the  groups  assessed  (2.41),  their  specific  functionalisations a n d  
details of the experiment performed.   
Table 2.01- Study 1 Description  
Group.   Substrate Functionalisation.   Study details. 
Control.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
0.1mM L RGD 1h.  0.1mM  linear  RGD-polypeptide 
adsorbed for 1-hour to titanium 
alloy substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
0.1mM L RGD 4h.  0.1mM  linear  RGD-polypeptide 
adsorbed for 4-hour to titanium 
alloy substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
0.1mM C RGD 1h.  0.1mM  cyclic  RGD-polypeptide 
adsorbed for 1-hour to titanium 
alloy substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
0.1mM C RGD 4h.  0.1mM  cyclic  RGD-polypeptide 
adsorbed for 4-hour to titanium 
alloy substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
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Study 2 
 
The second research question was to determine whether silanised linear or 
cyclic RGD-polypeptides significantly improved HDF attachment to titanium 
alloy. Cell attachment assays were performed at 24-hours on titanium alloy 
substrates, which were silanised with linear or cyclic RGD-polypeptides and 
compared with controls. Table 2.01 outlines the groups assessed (2.42), their 
specific functionalisations and details of the experiment performed.   
 
Table 2.02- Study 2 Description 
Group.  Substrate Functionalisation.  Study Details. 
Control.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed  at 
24-hours. 
siLinear RGD.  0.1mM linear RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed  at 
24-hours. 
siCyclic RGD.  0.1mM cyclic RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed  at 
24-hours.  
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Study 3 
 
Study 3 was performed using linear RGD-polypeptides only. This was based 
on the results from studies 1 and 2, which demonstrate its significantly greater 
positive effects of HDF attachment (2.41 and 2.42). This study compared the 
effects  of  silanised  and  adsorbed  linear  RGD-polypeptides  with  those  of 
fibronectin (F2006, Sigma Aldrich, UK) on HDF attachment to titanium alloy in 
vitro, a methodology that has been established by Middleton et al. (2007). 
Table  2.03  outlines  the  groups  assessed  (2.43),  their  specific 
functionalisations and details of the experiment performed.   
 
Table 2.03- Study 3 Description 
Group   Substrate Functionalisations  Study Details. 
Control.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours. 
Adsorbed RGD.  0.1mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours. 
Adsorbed fn.  10.0µg/ml Fibronectin adsorbed 
to  titanium  alloy  substrates 
(2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours. 
Silanised RGD.  0.1mM  linear  RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours. 
Silanised fn.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours. 
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Study 4 
 
The  research  question  was  whether  increasing  the  number  of  RGD-
polypeptides  increases  HDF  attachment?  The  aim  was  to  determine  an 
optimal concentration of RGD-polypeptide for HDF attachment at 24-hours. 
Table  2.04  outlines  the  groups  assessed  (2.44),  their  specific 
functionalisations and details of the experiment performed.   
 
Table 2.04- Study 4 Description 
Group   Substrate Functionalisation   Study Details 
Control.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours.  
5mM.  5mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
10mM.  10mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
25mM.  25mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours.  
50mM.  50mM l i n e a r  R G D -polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
100mM.  100mM linear RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay (2.3vii) performed at 
24-hours. 
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Study 5 
 
To determine the degree of HDF attachment over time, functionaliseed RGD-
polypeptides and fibronectin titanium alloy substrates were prepared by both 
adsorption and silanization and HDF attachment assessed at 1, 4, 24 and 96-
hour  time-points.  Table  2.05  outlines  the  groups  assessed  (2.45),  their 
specific functionalisations and details of the experiment performed.   
 
Table 2.05- Study 5 Description 
Group  Substrate Functionalisation  Study Details 
Control 1h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
Control 4h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
Control 24h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
Control 96h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
AdRGD 1h.  5mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
AdRGD 4h.  5mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
AdRGD 24h.  5mM  linear  RGD-polypeptide 
adsorbed t o  t i t a n i u m  a l l o y  
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
AdRGD 96h.  5mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
Adfn 1h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
Adfn 4h.  10.0µg/ml  Fibronectin  adsorbed  n=3  and  cell  attachment 	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to  titanium  alloy  substrates 
(2.3iii). 
assay  (2.3vii)  performed 
at 4-hours.  
Adfn 24h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
Adfn 96h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
SiRGD 1h.   5mM  linear  RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3…)  performed 
at 1-hour.  
SiRGD 4h.   5mM  linear  RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
SiRGD 24h.   5mM  linear  RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
SiRGD 96h.   5mM  linear  RGD-polypeptide 
silanised  to  titanium  alloy 
substrates (2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
Sifn 1h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
Sifn 4h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
Sifn 24h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
Sifn 96h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
 
The following methods were performed for Studies 1-5.  
 
2.3ii- Substrate Preparation 
  
Surgical grade titanium alloy (Ti6V4Al) discs, 10mm in diameter and 2mm thick 
were manufactured. Substrates were prepared by grinding down one surface 	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using  P400,  P800,  P1200  and  P2500  Silicon  Carbide  Abrasive  Papers 
(Buehler, Germany).  Substrates were polished to orthopaedic grade standard 
(surface roughness (Ra) value <0.03) using P4000 Silicon Carbide Grit Paper 
(Buehler,  Germany) f o l l o w e d  b y  polishing  with  a  pad  lubricated  with  AP-A 
Suspension, a 5µm agglomerate α alumina suspension (Struers, Germany). 
Method validation was confirmed by surface profilometry analysis, examples 
of which are published in Appendix 1. 
 
All  substrates  were  cleaned  ultrasonically  with  10%  Decon  90  (Decon 
Laboratories Ltd., UK) for 10-minutes, thoroughly rinsed under running water 
and distilled water for 5-minutes respectively and ultrasonically cleaned using 
acetone for a further 10-minutes. All substrates were autoclaved at 126
0C and 
1.4 bar for 25-minutes (PriorClave Ltd, UK).  
 
2.3iii- Functionalisation via Adsorption  
 
Substrates for peptide or protein coatings were individually placed in a well-
plate  under  aseptic  conditions.  A  50µl  droplet  of  protein  solution  (at  the 
concentrations stated in Tables 2.01-2.05) was placed onto each substrate, 
covering the entire surface, using a Gilson pipette.  This droplet was left for 4-
hours  (unless  otherwise  stated-  2.3i)  at  37
0C  to  adsorb  on  the  surface. 
Substrates were washed with sterile phosphate buffered saline (PBS) 3 times 
to remove any unbound protein.   
 
2.3iv- Functionalisation via silanisation 
 
Substrates for peptide or protein silanisation were individually placed in a 10:1 
solution of acetone and 3-aminopropyltriethooxysilane (APTES, Sigma-Aldrich, 
UK) for 2-hours at room temperature and pressure (RTP). Substrates were 
washed  in  acetone  and  air-dried  overnight  at  37
0C.  Substrates  were 
immersed in 1% glutaraldehyde (Agar Scientific, UK) solution in 0.172M PBS 
for 2-hours at RTP, washed in PBS and air-dried. Proteins were pipetted onto 
the surfaces of the substrates according to the protocol stated in 2.3iii.  	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2.3v- Cell Culture  
 
Human  dermal  fibroblasts  (1BR.3.G  90020507,  Culture  Collections,  Public 
Health England, UK) were sub-cultured in vented flasks at 37
oC and 5% CO2 
using Dulbecco's Modified Eagle's Medium (DMEM) with 4500mg/L glucose, 
supplemented  with  1%  Penicillin/Streptomycin  and  10%  Fetal  Calf  Serum 
(FCS).  Adherent cell populations were trypsinised (10% trypsin in PBS) after 
reaching  80%  confluence.  The  number  of  cells  was  counted  in  a 
haemocytometer  using  a  vital  dye,  Trypan  Blue  (Sigma-Aldrich,  UK). 
Population numbers were calculated by N=M x D x 10
4 V cells, where N is the 
number of cells, M is the average number of cells counted from each of the 
four quadrants in the haemocytometer, D is the dilution factor between cell 
volume  and  Trypan  Blue  dye  and  V  is  the  volume  of  the  original  cell 
population.  Cells  were  re-suspended  in  DMEM  to  give  a  concentration  of 
200,000/ml. 
 
2.3vi- Cell Seeding  
 
Substrates were individually placed in well-plates under aseptic conditions. 
10,000 cells were seeded onto each disc in a 50µl droplet of DMEM, which 
covered the entire substrate surface. The substrates were incubated for 1-
hour at 37
oC and 5% CO2 prior to the wells being flooded with media and 
returned to the incubator for a further study-dependent incubation period (2.3i).  
 
2.3vii- Cell Attachment Assay- Immunocyochemistry   
 
Excess media was removed from the wells and the substrates were washed 3 
times for 5-minutes with PBS. Cells were fixed with 10% formal saline for 5-
minutes,  prior  to  4, 5 -minute  washes  in  PBS.  A  50µl  droplet  of  primary 
antibody (Primary anti-vinculin mouse monoclonal Antibody (v9131, Sigma-
Aldrich, UK), dilution of 1:200 with PBS and 0.0025% Triton X) was used to 
cover the entire surface of each substrate according to the protocol 2.3iii and 
incubated at RTP for 1-hour.  Unbound primary antibody was removed with 3, 	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10-minute PBS washes. The secondary antibody (Alexa Fluor 488 chicken 
anti-mouse IgG antibody (A21200, Invitrogen, UK), dilution 1:1000 with PBS) 
was applied in a 50µl droplet according to protocol 2.3iii and substrates were 
incubated at RTP for 2-hours in the dark.  Unbound secondary antibody was 
removed with 3, 10-minute PBS washes in the dark.  
 
Samples were stored in PBS at 4
0C, analyses were performed within 24 hours 
using a Carl Zeiss photomicroscope (KS300, Zeiss, Germany). Six, randomly 
selected  cells  were  photographed  per  disc.  Cell  area  was  measured,  the 
number of focal adhesion were determined by counting the individual vinculin 
markers within each cell. The FA density (the number of vinculin markers per 
cell) was calculated using digital image processing software (Axiovision Rel 
4.5, Zeiss, Germany).  FA density data were used as a method of assessing 
HDF attachment strength. Cell area, vinculin count and vinculin density were 
measured on attached HDFs and compared between substrates. Previously 
published research has shown that FA density per cell area directly correlates 
with cell attachment strength in HDFs (Pendegrass et al 2009).  
 
2.3viii- Assessment  
Fluorescent Microscopy was used to assess HDF morphology. Cell area and 
the number of vinculin markers and were both measured under fluorescent 
microscopy, with FA density calculated from these figures.   
 
2.3ix- Statistics 
 
Data  are  presented  graphically  in  box  and  whisker  plots  where  the  X-axis 
represents the substrate groups and the Y-axis represents FA Density/per unit 
cell area. Data is presented as median (with 95% confidence intervals) and 
outliers are plotted as individual points outside the box and whiskers. The 
data  did  not  meet  the  assumptions  required  for  parametric  testing.  Non-
parametric statistical analyses were performed. Kruskal-Wallis tests of each 
data set, consisting of one nominal variable and one measurable variable, 
were performed to determine whether multiple groups were from the same 
population distribution. Where data sets were not observed to be in the same 	 ﾠ 74	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population  distribution  (Kruskal-Wallis  p  <  0.05),  pair-wise  Mann-Whitney 
(MWU) tests were used to determine differences between groups on a pair-
wise basis. These tested were performed using SPSS version 19.0 (IMB Inc, 
USA) (McDonald 2008) and significance results were considered significant at 
the 0.05 level. Pair-wise comparisons (MWU) are presented in tables for each 
study. Significant values are highlighted in yellow.  	 ﾠ 75	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2.4- Results 
2.41- Study 1 
  
HDF  attachment  was  observed  on  all  substrates.  A  Kruskal-Wallis  test 
demonstrated that the data were not from the same population distribution (p 
<0.05).  
 
There were no significant differences in HDF attachment with either linear or 
cyclic RGD-polypeptide functionalised titanium alloy substrates compared with 
controls when substrates were prepared with a 1-hour adsorption time (MWU 
p >0.05; Fig 2.01, Table 2.06).  
 
HDF  attachment  significantly  increased  on  RGD-polypeptide  functionalised 
titanium  alloy  substrates  compared  with  controls  when  substrates  were 
prepared with a 4-hour adsorption time (MWU p <0.05; Fig 2.01, Table 2.06).  
 
No difference in HDF attachment was observed with linear or cyclic RGD-
polypeptide functionalised substrates at either 1 or 4-hours (MWU p >0.05; 
Fig 2.01, Table 2.06). 
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Fig 2.01 Box and Whisker plot demonstrating FA Density on adsorbed (green) RGD 
polypeptide functionalised titanium alloy substrates compared with controls (red) at 24 hours. 
 
Table 2.06- Pair-wise MWU comparisons 
   Control   0.1mM L 
RGD 1h. 
0.1mM L 
RGD 4h. 
0.1mM C 
RGD 1h. 
0.1mM C 
RGD 4h. 
Control    0.515  0.000  0.069  0.000 
0.1mM L RGD 
1h. 
    0.000  0.261   
0.1mM L RGD 
4h. 
        0.322 
0.1mM C RGD 
1h. 
        0.000 
 
 2.4ii- Study 2 
 
Statistical  analysis  using  Kruskal-Wallis  test  suggested  data  were n o t  
normally distributed (p <0.05). 
 
HDF attachment was highest on titanium alloy substrates functionalised with 
silanised linear RGD-polypeptides, median value 0.0439 (CI 0.0363-0.0476). 
These data were significantly higher compared with controls (MWU p <0.05; 
Fig 2.02, Table 2.08) and substrates functionalised with silanised cyclic RGD-
polypeptide (MWU p <0.05; Fig 2.02, Table 2.07).  
 
No significant difference was observed in HDF attachment between cyclic 
RGD-polypeptide functionalised titanium alloy substrates and controls (MWU 
p >0.05; Fig 2.02, Table 2.07).  
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Fig 2.02 Box and Whisker plot demonstrating FA Density on silanised Linear (dark green) and 
silanised Cyclic (light green) RGD functionalised titanium alloy substrates compared with 
controls (red) at 24 hours. 
 
 
 
Table 2.07- Pair-Wise MWU Comparisons 
   Control    siLinear RGD  siCyclic RGD 
 Control    0.007  0.411 
 siLinear RGD      0.007 
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2.4iii- Study 3 
 
A Kruskal-Wallis test of normality demonstrated that the data were not from 
the same population distribution (p <0.05). 
 
All  functionalised  substrates,  whether  with  fibronectin  or  RGD  polypeptide, 
prepared  through  adsorption  or  silanization,  significantly  increased  HDF 
attachment  when  compared  with  controls  (MWU  p  <0.05;  Fig  2.03,  Table 
2.08).  
 
Attachment of HDF peaked on silanised fibronectin substrates with a median 
value of 0.0428 (CI 0.0357-0.0454). These data were significantly higher than 
HDF attachment on substrates functionalised with silanised RGD polypeptides 
(MWU p <0.05; Fig 2.03, Table 2.08). 
 
There was no significant difference in HDF attachment between the adsorbed 
and  silanised  fibronectin  functionalised  titanium  alloy  substrates  (MWU  p 
>0.05; Fig 2.03, Table 2.08).  
 
There was no significant difference in HDF attachment between the adsorbed 
and silanised RGD-polypeptide functionalised titanium alloy substrates (MWU 
p  >0.05;  Fig  2.03,  Table  2.09),  nor  when  comparing  RGD  with  fibronectin 
functionalised  substrates,  using  the  adsorbed  protocol  (MWU  p  >0.05;  Fig 
2.03, Table 2.08). 
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Fig 2.03 Box and Whisker plot demonstrating FA Density on adsorbed (green) and silanised 
(yellow) RGD functionalised titanium alloy substrates, adsorbed (blue) and silanised (purple) 
fibronectin functionalised titanium alloy substrates compared with controls (red) at 24 hours. 
 
 
Table 2.08- Pair-wise MWU Comparisons 
  Control  AdRGD  Adfn  SiRGD  Sifn 
Control    0.000  0.000  0.000  0.000 
AdRGD      0.591  0.164   
Adfn           
SiRGD          0.002 
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2.4iv- Study 4  
 
Data in Study 4 were not normally distributed as demonstrated by Kruskal-
Wallis test (p <0.05). 
 
HDF  attachment  was  significantly  increased  on  all  RGD-polypeptide 
functionalised  titanium  alloy  substrates  compared  with  controls  (MWU  p 
<0.05; Fig 2.04, Table 2.09).  
 
HDF  attachment  was  highest  on  10mM  RGD-polypeptide  functionalised 
titanium alloy substrates (median value: 0.0344, CI 0.0286-0.0389). However 
this  was  not  significantly  higher  than  HDF  attachment  observed  on  either 
5mM  but  significantly  higher  than 2 5 m M  R G D -polypeptide  functionalised 
substrates (MWU p >0.05; Fig 2.04, Table 2.09).  
 
5mM  RGD-polypeptide  functionalised  titanium  alloy  substrates  significantly 
increased  HDF  attachment  compared  with  all  other  RGD-polypeptide 
functionalised titanium alloy substrates (MWU p <0.05; Fig 2.04, Table 2.09).  
 
HDF  attachment  was  significantly  increased  on  25mM  RGD-polypeptide 
functionalised  titanium  alloy  substrates  compared  with  50mM  substrates 
(MWU p <0.05; Fig 2.04, Table 2.09).   
 
There  was  no  significant  difference  observed  in  HDF  attachment  between 
50mM and 100mM RGD-polypeptide functionalised substrates (MWU p >0.05; 
Fig 2.04, Table 2.09).   
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Fig 2.04 Box and Whisker plot demonstrating HDF attachment on adsorbed RGD 
functionalised titanium alloy substrates (green) compared with controls (red) at 24 hours. 
 
 
Table 2.09- Pair-wise MWU Comparisons  
   Control  5mM  10mM  25mM  50mM   100mM 
Control    0.000  0.000  0.000  0.008  0.000 
5mM      0.728  0.021  0.000  0.001 
10mM        0.054  0.000  0.006 
25mM          0.004  0.155 
50mM             0.112 
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2.4v- Study 5  
 
Analysis using the Kruskal-Wallis test showed that data in this study were not 
normally distributed  (p <0.05). 
  
HDF attachment was significantly increased on all functionalised titanium alloy 
substrates compared with controls at 1-hour (MWU p <0.05; Fig 2.05, Table 
2.11),  with  the  exception  of  silanised  RGD-polypeptide  functionalised 
substrates (MWU p >0.05; Fig 2.05, Table 2.10).  
 
HDF  attachment  was  highest  on  adsorbed  RGD-polypeptide  functionalised 
titanium alloy substrates with a median value of 0.0195 (CI 0.0174-0.021). 
This HDF attachment was significantly higher compared with silanised RGD-
polypeptide functionalised substrates (MWU p <0.05; Fig 2.05, Table 2.10).  
 
No  significant  difference  in  HDF  attachment  was  observed  between  RGD-
polypeptide  and  fibronectin  functionalised  titanium  alloy  substrates,  when 
compared with either adsorbed or silanised fibronectin (MWU p >0.05; Fig 
2.05, Table 2.10).   
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Fig 2.05 Box and Whisker plot demonstrating HFD attachment on adsorbed (green) and 
silanised (yellow) RGD functionalised surfaces, adsorbed (blue) and silanised (purple) 
fibronectin functionalised titanium alloy substrates compared with controls (red) at 1-hour. 
 
 
Table 2.10- Pair-wise MWU Comparisons 
  Control   AdRGD 1h  Adfn 1h  siRGD 1h  Sifn 1h 
Control    0.000  0.000  0.161  0.016 
AdRGD 1h      0.395  0.049   
Adfn 1h          0.496 
siRGD 1h          0.188 	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HDF  attachment  was  significantly  increased  on  adsorbed  RGD-polypeptide 
functionalised  titanium  alloy  substrates  compared  with  controls  at  4-hours 
(MWU  p  <0.05;  Fig  4.06,  Table  2.11).  The  highest  HDF  attachment  was 
observed on this substrate at this time point with a median value of 0.0285 (CI 
0.0238-0.0329). (Fig 4.06, Table 2.11) 
 
No  significant  difference  existed  between  functionalised t i t a n i u m  a l l o y  
substrates adsorbed with RGD-polypeptides and absorbed fibronectin (MWU 
p >0.05; Fig 4.06, Table 2.11). 
 
There  was  a  significant  increase  in  HDF  attachment  on  silanised  RGD-
polypeptide  functionalised  substrates  compared  with  silanised  fibronectin 
functionalised substrates (MWU p <0.05; Fig 4.06, Table 2.11).  
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Fig 2.06 Box and Whisker plot demonstrating HDF attachment on adsorbed (green) and 
silanised (yellow) RGD functionalised titanium alloy substrates, adsorbed (blue) and silanised 
(purple) fibronectin functionalised titanium alloy substrates compared with controls (red) at 4-
hours. 
 
Table 2.11- Pair-wise MWU Comparisons 
  Control   AdRGD 4h  Adfn 4h  siRGD 4h  Sifn 4h 
Control    0.013  0.057  0.342  0.572 
AdRGD 4h      0.430  0.018   
Adfn 4h          0.001 
siRGD 4h          0.039 
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HDF attachment was significantly increased in all functionalised titanium alloy 
substrates compared with controls at 24-hours (MWU p <0.05; Fig 2.07, Table 
2.12) 
 
Highest  levels  of  HDF  attachment  were  observed  on  adsorbed  RGD-
polypeptide functionalised titanium alloy substrates; with a median value of 
0.0333  (CI  0.0303-0.0391) a n d  silanised  RGD-polypeptide  functionalised 
titanium  alloy  substrates,  (median  value  0.0325; C I  0 . 0 2 9 2 -0.0421).  There 
was no significant difference in HDF attachment between these functionalised 
substrates (MWU p >0.05; Fig 2.07, Table 2.12). 
 
No  significant  difference  in  HDF  attachment  was  observed  when  a 
comparison  was  made  between  adsorbed  and  silanised  fibronectin 
functionalised substrates (MWU p >0.05; Fig 2.07, Table 2.12). 
 
RGD-polypeptide  functionalised  titanium  alloy  substrates  significantly 
increased HDF attachment compared with fibronectin functionalised titanium 
alloy substrates, when either adsorbed or silanised (MWU p <0.05; Fig 2.07, 
Table 2.12).  
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Fig 2.07 Box and Whisker plot demonstrating HDF attachment on adsorbed (green) and 
silanised (yellow) RGD functionalised titanium alloy substrates, adsorbed (blue) and silanised 
(purple) fibronectin functionalised titanium alloy substrates compared with controls (red) at 
24-hours. 
 
 
Table 2.12- Pair-wise MWU Comparisons 
  Control   AdRGD 24h  Adfn 24h  siRGD 24h  Sifn 24h 
Control    0.000  0.007  0.000  0.044 
AdRGD 24h      0.002  0.933   
Adfn 24h          0.885 
siRGD 24h          0.010 
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HDF attachment was significantly increased in all functionalised titanium alloy 
substrates compared with controls at 96-hours (MWU p <0.05; Fig 2.08, Table 
2.13).  
 
Highest  levels  of  HDF  attachment  were  observed  on  adsorbed  RGD 
polypeptide functionalised titanium alloy substrates (median value 0.0734; CI 
0.0668-0.0785).  HDF  attachment  was  significantly  higher  than  those  on 
adsorbed fibronectin functionalised substrates (MWU p <0.05; Fig 2.08,Table 
2.13) and silanised RGD-polypeptide functionalised titanium alloy substrates, 
(MWU p <0.05; Fig 2.08,Table 2.13).  
 
No  significant  difference  in  HDF  attachment  existed  between  fibronectin 
functionalised  titanium  alloy  substrates  when  either  adsorbed  or  silanised 
(MW p >0.05; Fig 2.08, Table 2.13).  
 
No  significant  difference  in  HDF  attachment  existed  between  silanised 
fibronectin  and  silanised  RGD-polypeptide  functionalised t i t a n i u m  a l l o y  
substrates (MWU p >0.05; Fig 2.08, Table 2.13).  
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Fig 2.08 Box and Whisker plot demonstrating HDF attachment on adsorbed (green) and 
silanised (yellow) RGD functionalised titanium alloy substrates, adsorbed (blue) and silanised 
(purple) fibronectin functionalised titanium alloy substrates compared with controls (red) at 
96-hours 
 
Table 2.13- Pair-wise MWU Comparisons 
  Control   AdRGD 96h  Adfn 96h  siRGD 96h  Sifn 96h 
Control    0.000  0.000  0.000  0.000 
AdRGD 96h      0.002  0.000   
Adfn 96h          0.626 
siRGD 96h          0.204 
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2.4vi-Qualitative Assessment  
 
At 1-hour, HDF morphology on control substrates were rounded and compact 
with no cellular processes evident. Vinculin markers were few and appeared 
as small dots at the periphery of the cell. HDF morphology was consistent on 
functionalised titanium alloy substrates. However more vinculin markers were 
observed at the cell periphery and also more spicule shaped markers were 
observed on these substrates.  
 
At 4-hours HDF morphology on control substrates appeared to be the same 
as  their  appearance  at  1-hour.  However  there  was  evidence  of  bi-polar 
elongation of  the  vinculin markers at the cell periphery as HDF processes 
began  to  emanate  from  the  cell  body.  HDF  morphology  on  functionalised 
titanium  alloy  substrates  exhibited  polygonal  spreading  with  multiple 
processes emanating from the HDF body (Fig 2.09). 
 
At  24-hours  HDF  morphology  on  control  substrates e x h i b i t e d  b i -polar 
elongation from the cell body. HDFs were less round and more spread out 
with an increase in vinculin markers, distinct as dashes at the cell periphery 
compared  with  earlier  time-points  (Fig  2.09).  HDF  morphology  on 
functionalised titanium alloy substrates also exhibited increased spreading at 
this time-point. However, cells were more symmetrical and exhibited a discoid 
shape,  as  spreading  appeared  to  occur  in  multiple  directions.  Vinculin 
markers were also clearly evident at the cell periphery and throughout the cell 
(Fig 2.10).  
 
At 96-hours HDF morphology on controls were well spread and elongation 
could  be  observed  in  multiple  directions.  HDFs  were  often  observed  in  a 
stellate  shape  compared  with  discoid  morphologies  observed  on 
functionalised  titanium  alloy  substrates.  Vinculin  markers  were  evident, 
concentrated  in  the  periphery  in  HDFs  on  control  substrates.  A  greater 
number of vinculin markers were observed in HDFs on functionalised titanium 
alloy  substrates.  These  were  evident  throughout  the  attached  HDFs,  with 
clusters  still  observed  in  leading  edges.  Observations  at  96-hours  using  a 	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lower  magnification  suggested  functionalised  titanium  alloy  substrates 
appeared  to  have  an  increased  number  of  attached  cells  compared  with 
control substrates (Fig 2.11).      	 ﾠ 93	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Fig 2.09. Immunolocalisation of vinculin in HDFs attached to titanium alloy substrates at 4-
hours; A) image: control, B) functionalised with adsorbed RGD-polypeptide. 
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Fig 2.10. Immunolocalisation of vinculin in HDFs attached to titanium alloy substrates at 24-
hours; A) image: control, B) functionalised with adsorbed RGD-polypeptide. 
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Fig 2.11. Immunolocalisation of vinculin in HDFs attached to titanium alloy substrates at 96-
hours; A) image: control, B) functionalised with adsorbed RGD-polypeptide. 
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2.5- Discussion 
Study 1 
 
Adsorption for 1 hour with either linear or cyclic RGD-polypeptides, had no 
positive  influence  on  cell  attachment  compared  with  controls.  To  positively 
influence cell attachment the polypeptide would need to be immobilized onto 
the  substrate  and  remain  biologically  active.  At  4  hours,  the  polypeptides 
demonstrated bioactivity by significantly increasing cell attachment. At 1-hour 
RGD-polypeptides had no significant effect on HDF attachment. Adsorption of 
biological  material  to  a  metallic  substrate  relies  on  the  formation  of 
electrostatic bonds between the two (Wilson et al 2005). RGD-polypeptides 
would need to form electrostatic bonds, such as dipole-dipole or Hydrogen 
bonds, with the titanium alloy substrate. I propose an insufficient number of 
bonds  had  formed  between  the  RGD-polypeptides  (irrespective  of  the 
structure) and the titanium oxide layer had 1-hour. Immobilization of RGD-
polypeptides  was  not  achieved  and  as  a  consequence,  they  were  able  to 
dissociate  from  the  substrate  during  the  washing  phase  of  the  protocol. 
Passivation of my titanium alloy substrates may have induced an amorphous 
oxide  layer  to  form  and  therefore  increased  the  formation  of  electrostatics 
bonds  between  RGD-polypeptides  and  the  substrates.  However,  this 
technique can detrimentally affect the structural properties of titanium alloy, 
which  in  turn  may  compromise  its’  performance  in  load  bearing  situations, 
such as ITAP devices in vivo (Chimutengwende-Gordon et al 2011). Yang et 
al.  (2003)  demonstrated  fibronectin  adsorption  to  titanium  substrates  was 
dependent on time, with significant increases in protein adsorption between 
15-minutes and 3-hours. 
      
No  significant  difference  in  HDF  attachment  existed  between  substrates 
functionalised with linear and cyclic RGD-polypeptides I suggest that linear 
RGD-polypeptide functionalised titanium alloy substrates, in my study, were 
able to bind a greater variety of integrin receptors, which has counterbalanced 
the  added  preferential  affinity  of  the  cyclic  polypeptide  to  the  alphaVbeta3 
integrin  receptor,  accounting  for  the  lack  of  significant  difference  in  HDF 
attachment observed.  	 ﾠ 97	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The  primary  amino-acid  sequence  RGD,  can  bind  many  integrin  receptors 
with  low  affinity  compared  with  the  high  affinity  to  integrin  alphavbeta3 
possessed by cyclic RGD-polypeptides. (Ruoslahti, 1996) 
 
The  linear  polypeptide  in  this  study  is  zwitterionic,  meaning  the  opposing 
charges on Arginine (positive) and Aspartic Acid (negative) counterbalance 
each  other.  This  small,  linear  polypeptide  sequence  can  be  flexible  in  an 
aqueous  environment  as  the  polar  water  molecules  can  interact  with  the 
charged  arginine  and  aspartic  acid  residues.    Immobilized  on  a  substrate 
surface,  this  flexibility  may  provide  a  greater  degree  of  freedom  to  bind 
integrin receptors, as there is less emphasis on a highly conserved secondary 
structure and precise orientation (Reed et al 1988 and Chen et al 2009).  
 
The  cyclic  polypeptide  structure  is  more  rigid  due  to  the  presence  of 
stabilising  Beta  turns  (Reed  et  al  1988).  If  immobilized  onto  a  substrate 
surface the structure must be presented to the specific integrin alphavbeta3 in 
order to bind. With less flex in the structure, free movement is limited which 
may  decrease  receptor  affinity.    Kammerer  et  al.  (2009)  and  Patel  et  al. 
(2012) both observed significant differences between linear and cyclic RGD-
polypeptides on functionalised titanium and PMMA substrates respectively.   
 
Study 2 
 
Silanised  linear  RGD-polypeptides  significantly  increased  HDF  attachment 
compared with controls. The RGD-polypeptide increased HDF attachment by 
binding integin receptors on the cell surface. Silanization of biological coatings 
uses  an  APTES/Glutaraldhyde  complex  to  act  as  a  spacer  between  the 
metallic substrate and, in this case, RGD-polypeptides. This adds rigidity and 
stability to the coating (Wilson et al 2005) allowing stable presentation of the 
binding domain to the cell surface receptors.  
 
Davis et al. (2002) confirmed immobilisation of RGD-polypeptides with X-ray 
Photoelectron  Spectroscopy  elemental  analysis  (XPS)  before  observing 	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biological activity on his substrates.  Myocardial fibroblasts were observed to 
significantly  increase,  in  number,  when  cultured  on  silanised  RGDC-
polypeptides functionalised silicone substrates compared silicone controls. 
 
No significant difference was observed in HDF attachment when cyclic RGD-
polypeptides  were  silanised  to  titanium  alloy  substrates  compared  with 
controls. I have already discussed the orientation requirements of the cyclic 
structure;  and  these  may  have  contributed  to  non-significant  differences  in 
HDF attachment with the linear structure, when coatings were adsorbed. 
  
Covalent  bonding  may  reduce  the  flex  of  the  cyclic  structure  even  more, 
rendering the polypeptide less able to interact with specific integrins, required 
hence further effecting HDF attachment. Porte-Durrieu et al. (2004) showed 
successful  silanization  with  both  linear  and  cyclic  RGD-polypeptides  to 
titanium alloy substrates. Moreover, osteoprogenitor cell attachment on both 
linear  and  cyclic  RGD-polypeptide  functionalised  substrates  dramatically 
improved at 3 and 24-hours time-points compared with titanium alloy controls. 
Their  observed  cell  attachment  results,  on  the  cyclic  RGD-polypeptide 
functionalised  substrates,  do  not  support  the  findings  of  this  experiment, 
although no statistical evidence was presented.  
 
Kammerer et al. (2011) also observed significant increases in endothelial cell, 
attachment-dependent processes at 24-hours on titanium substrates silanised 
with linear RGD-polypeptides. Cyclic RGD-polypeptide functionalised titanium 
did not have an effect at this time-point, in accordance with my study.  
 
At  72-hours,  cyclic  RGD-polypeptide  functionalised  titanium  substrates 
significantly  increased  endothelial  cell  proliferation  compared  with  both 
controls and linear RGD-functionalised substrates (Kammerer et al 2011).  
 
It  is  possible  that  HDF  attachment  could  be  significantly  increased  by 
silanised cyclic RGD-polypeptides at later time points. However, as soft tissue 
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 ﾠ 99	 ﾠ
I have chosen to perform research that looks for a functionalisation strategy to 
optimise attachment at this time point.    
 
Study 3 
 
Functionalised  titanium  alloy  substrates  either  with  fibronectin  or  RGD-
polypeptide and prepared through adsorption or silanisation, saw a significant 
up-regulation in HDF attachment compared with controls.  
 
HDF  attachment  on  substrates  functionalised  with  fibronectin  was  not 
significantly  different,  irrespective  of  coating  methodology.  This  is  in 
accordance with Middleton et al (2007), who demonstrated both adsorbed and 
silanised fibronectin could significantly enhance HDF attachment. 
 
Adsorbing  RGD-polypeptides  had  no  significant  effect  on  HDF  attachment 
compared  with  silanisation.  This  suggests  the  additional  surface  chemistry 
associated with silanization does not detrimentally affect the presentation of 
linear  RGD-polypeptides  to  integrin  receptors.  Furthermore  silanization 
provides a more favourable functionalisation technique for in vivo applications 
due to the formation of a more durable coating (Middleton et al 2007).  In this 
study, and in opposition to Middleton et al (2007), the silanisation of titanium 
alloy substrates was performed without a passivation stage. The result of this 
study  supports  earlier  work  performed  by  Chimutengwende-Gordon  et  al 
(2011), who demonstrated enhanced dermal fibroblast attachment to titanium 
alloy  substrates  in  vitro a n d  in  vivo  without  this  harsh  substrate  treatment 
preceding silanisation.   
 
No significant difference in HDF attachment was observed on either absorbed 
RGD-polypeptide  or  fibronectin,  however  silanisation  of  fibronectin 
significantly increased attachment compared with RGD-polypeptides.  
 
A  true  comparison  between  RGD-polypeptides  and  fibronectin  is  difficult, 
because  the  numbers  of  binding  domains  can  never  be  controlled  for. 	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However the overall aim for ITAP is to develop a functionalised substrate that 
up-regulates HDF attachment to the greatest degree.  
 
Obara  et  al.  (1988)  suggest  that  differences  in  fibronectin-mediated 
attachment  and  RGD-mediated  attachment  may  be  due  to  a  loss  of  a 
synergistic  site  when  immobilising  the  RGD-polypeptide  as  a  biological 
coating.  Results  from  site-directed  mutagenesis  experiments  suggest  the 
plausibility of fibronectin’s mode to encompass positive allosteric modulation 
through the interaction of a second domain, which may interact with integrin 
subunits  (Obara  and  Yoshizato  1995).  Fibronectin’s  proposed  allosteric 
modulation  of  cell  attachment  compared  with  increasing  the  number  of 
bindings  domains  using  RGD-polypeptide  functionalisations m a y  
counterbalance one other.  
 
Based  on  a  substantially  larger  relative  molecular  mass,  fibronectin  has  a 
superior adsorption capacity compared with RGD-polypeptides, (Yang et al 
2003) which, may be more readily removed from the substrates during the 
preparatory phases of the experiment. However, as no significant difference 
was observed in HDF attachment between the coatings, it is possible that the 
number  of  increased  number  of  binding  domains  on  the  RGD-polypeptide 
compensated for the reduced amount retained on the surface.  
 
RGD-polypeptides in aqueous solution may begin to fold or bend as hydrogen 
bonds form between flanking residues, therefore decreasing the likelihood of 
successful  receptor  affinity  as  presentation  of  the  binding  domain  is 
obstructed compared with fibronectin. However, the linear RGD-polypeptide 
has  the  ability  to  bind  various  integrin  receptors  compared  with  specific 
integrin affinity associated with binding domain of fibronectin.  
 
Holland  et  al.  (1996)  demonstrated  a  significant  increase  in  percentage  of 
endothelial  cell  attachment  using  both  fibronectin  and  RGD-containing 
polypeptide coated polystyrene substrates compared with control substrates 
at 1-hour.  
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Despite these possible differences, functionalisation with RGD-polypeptides 
or fibronectin is favourable for ITAP as they both significantly up-regulate HDF 
attachment compared with controls.    
 
Study 4 
 
RGD-polypeptide functionalisation significantly increased HDF attachment in 
a concentration dependent manner compared with controls.  
 
5mM  and  10mM  RGD-polypeptide  significantly  increased  HDF  attachment 
compared  with  all  other  concentrations.  Increasing  the  number  of  binding 
domains  with  25,  50  and  100mM  of  RGD-polypeptides  may  result  in 
polypeptide  aggregation,  inhibiting  presentation  and  subsequent  binding  to 
integrin  receptors,  and  resulting  in  the  decrease  in  HDF  attachment.    The 
addition of more binding domains may have promoted a non-uniform surface 
topography and inhibited HDF attachment compared to lower concentrations 
of RGD-polypeptide. Holland et al. (1996) suggests a uniform surface of RGD-
containing  polypeptide  functionalised  polystyrene  substrates  significantly 
increases endothelial cell attachment-dependent processes.  Integrin receptor 
clustering in response to the RGD-polypeptides would support the significant 
increased in HDF attachment observed in substrates functionalised with 5mM 
and 10mM (Irvine et al 2002). 
 
Maheshwari et al. (2000) demonstrated that increasing the number of RGD-
polypeptides covalently bound to glass substrates increased murine fibroblast 
attachment.  However  their  results  suggested  receptor  saturation  at  high 
ligand densities, which may account for my results with concentrations above 
10mM of RGD-polypeptides.  
 
Holland  et  al.  (1996)  showed  significant  increases  in  endothelial  cell 
attachment with RGD-containing polypeptide functionalisation. However, the 
data  did  not  indicate  whether  a  concentration  dependent  increase  in  cell 
attachment was observed.  
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In my study a concentration dependent increase was observed up to 10mM 
and despite a larger number of RGD-polypeptides being made available to the 
HDF with 25, 50 and 100mM concentrations of RGD polypeptides, failure to 
see a continued increase in HDF attachment may be due to the cells reaching 
a maximum level of integrin expression.  
 
This  study  has  shown  that  HDF  attachment  to  RGD-polypeptides  is  a 
concentration  dependent  process  up  to  10mM.  Further  investigation  to 
optimise RGD concentration for HDF attachment is required.  
 
Study 5 
 
Adsorbed  RGD-polypeptide  functionalisation  significantly  increased  HDF 
attachment compared with controls at 1, 4, 24 and 96-hours.  Middleton et al. 
(2007) demonstrated similar findings in HDF attachment with silanised and 
adsorbed  fibronectin.  In  my  study,  at  some  time  points,  5mM  RGD-
polypeptides  significantly  increased  HDF  attachment  compared  with 
fibronectin. This pattern was not observed at 24 hours in Study 3 at 24 hours, 
where  there  was  no  significant  difference  in  HDF  attachment  on  RGD-
polypeptide or fibronectin functionalised substrates. This may be due to the 
decreased  concentration  on  0.1mM  in  Study  3,  which  was  insufficient  to 
observe  a  significant  difference.  The  inconsistency  between  the  studies 
necessitates further investigation, which is the subject of Chapter 3.  
 
The  cell  density  appeared  to  be  greater  under  FM,  on  RGD-functionalised 
substrates compared with controls, which would indicate higher proliferative 
capacity of cells on these surfaces. This was not quantified, however it is a 
finding that is in agreement with Middleton et al. (2007), who, demonstrated a 
significant increase in dermal cell metabolism with fibronectin functionalised 
titanium  alloy  substrates  compared  with  controls.  My  observations, i n  
conjunction with these data, suggest that coating a titanium substrate with a 
functional  ligand  (such  as  RGD-polypeptide  or  fibronectin)  may  positively 
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cell proliferation, ECM formation and cell differentiation. However, further work 
would be needed to investigate this.       
 
2.6- Conclusion 
 
The aim of this chapter was to investigate  the  effect  of  synthetic  RGD-
polypeptides  and  fibronectin,  on  human  dermal  fibroblast  (HDF) 
attachment to titanium alloy substrates in vitro.  
 
My experiments have shown that linear RGD-polypeptides can up-regulate 
HDF attachment to substrates and may be used for ITAP devices to enhance 
early  cell  attachment.  Such  techniques  have  functionalised t i t a n i u m  a l l o y  
substrates as demonstrated by increased HDF attachment strength data. It is 
critical for soft tissues to attach to ITAP devices within the first 24-hours of 
implantation  in  vivo.  In  vitro  HDF  attachment  increases  with  increasing 
concentration of linear RGD-polypeptides, up to 10mM, provided they have 
had  sufficient  time  to  adsorb  onto  the  substrate  surface  or  have  been 
covalently tethered to it using silanization.  
 
If  functionalisation w i t h  R G D -polypeptides  is  to  be  considered  for  in  vivo 
applications  the  durability  of  the  coating  must  be  tested.  Silanisation  may 
confer a more beneficial method for functionalising ITAP devices in vivo but 
the use of RGD-polypeptides with this method requires further experimental 
study to observe whether the functionalised titanium alloy substrates remain 
functionalised in vivo, as demonstrated in this chapter in vitro. 
 
Sterilization  process  combined  with  regulatory  requirements  may  limit  the 
clinical  use  of  fibronectin  as  a  functionalisation  technique.  My  experiments 
have  shown  the  adsorption  or  silanization  of  RGD-polypeptides  can  up-
regulate HDF attachment to a similar degree to that of fibronectin. This may 
provide  an  opportunity  to  use  RGD-polypeptides  clinically.  Linear  RGD-
polypeptides can be synthesized from non-human or animal sources and may 
be  less  susceptible  to  harsh  sterilization  techniques  that  can  denature 
quaternary structured proteins, such as fibronectin.     	 ﾠ 104	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A full understanding of the loading and release kinetics for the preparation of 
a functionalised titanium alloy substrate with RGD-polypeptides is required. I 
conclude that the RGD biomimetic functionalisation technique in this chapter 
shows promise for a possible substrate for ITAP but the preparation protocol 
must be optimized first in vitro.  	 ﾠ 105	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Chapter 3- Understanding of the Loading and Release Kinetics of 
Biological Functionalisation to Titanium Alloy Substrates, in vitro 
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Chapter 3 
3.1- Introduction  
 
Functionality  of  ITAP  devices  in  vivo  rely  upon  a  tight  skin  seal  at  the 
transcutaneous interface forming as early after implantation as possible.  
 
In  Chapter  2,  I  demonstrated  that  RGD-polypeptide  functionalised t i t a n i u m  
alloy substrates can up-regulate HDF attachment compared with controls. My 
results  suggested  HDF  attachment  on  adsorbed  and  silanised  RGD-
polypeptide functionalised substrates was concentration dependent. However, 
the  amount  of  RGD-polypeptide  coupled  to  the  titanium  alloy  substrates 
needs  to  be  quantified  so  cell  attachment  can  be  optimised  and  be  more 
strongly attached to titanium alloy substrate.  
 
In the development of other biological functionalisation techniques, fibronectin 
and laminin have been successfully iodinated to quantify loading and release 
kinetics to titanium alloy substrates (Middleton et al 2007 and Gordon et al 
2009). These techniques rely on the coupling of the ligand with a gamma-
emitting Iodine
125 (I
125) isotope.  
 
Others have successfully iodinated RGD-containing polypeptides by the same 
method and maintained integrin affinity (Jin et al 2010). However, successful 
RGD-polypeptide  iodination  required  the  addition  of  a  Y  residue  (Tyrosine 
amino  acid)  to  support  isotope  coupling.  This  can  be  achieved  by  the 
established  Chloroamine-T  method  (Jin  et  al  2010  and  advice  from 
PerkinElmer).  
 
The  Chloroamine-T  method  of  coupling  is  rapid  and  efficient;  it  minimizes 
structural  changes  to  the  polypeptide  and  decreasing  changes  related  to 
bioactivity  (Hunter,1962).    The  reaction  utilizes  an  enzyme  to  increase  the 
power  of  oxidation  and  therefore  lower  the  concentration  of  potential 
damaging oxidizing agents (Marchalonis, 1969).  
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This  technique  should  allow  the  successful  quantification  of  RGD-
polypeptides in order to develop an optimal functionalisation protocol.   
 
Flanking  residues  adjacent  to  RGD  can  influence  integrin  affinity 
(Pierschbacher and Ruoslahti, 1987). Tyrosine is a neutral amino acid with a 
polar  hydroxyl  side  group  (Alberts  et  al  2002).  Its  addition  and  possible 
influence  on  HDF  attachment  to  titanium  alloy  substrates  will  need  to  be 
observed before further study to the protocol is undertaken.   
 
As outlined in Chapter 1.2viii, aminopropylated substrates can functionalise 
implant surfaces by covalently bonding ligands that remain biologically active. 
This functionalisation technique has been referred to as silanisation (Davis et 
al 2002, Chimutengwende-Gordon et al 2011, Jose et al 2005, Middleton et al 
2007, Nanci et al 1997 and Puleo, 1995). A schematic representation of the 
silanisation reaction is presented below (Fig 3.01), which has been adapted 
from  others  (Puleo,  1995  and  Middleton  et  al  2007).  The  silane  complex 
provides a ductile spacer arm that covalently bonds to oxygen provided by 
free surface hydroxyl groups on the substrate (Jose et al 2005), in my case 
titanium alloy. The ductility of the silane complex may provide the mechanical 
properties to better withstand the physical stresses associated with receptor 
interaction during cell attachment (Hersel et al 2003). Hydroxyl groups form 
on the surface of titanium alloy substrates in an amorphous layer. This layer 
can  be  experimentally  induced  by  passivation  (Davis  et  al  2002, 
Chimutengwende-Gordon et al 2011, Jose et al 2005, Middleton et al 2007, 
Nanci  et  al  1997)  however,  as  previously  indicated,  it  compromises t h e  
structural  properties  of  titanium  alloy,  which  is  critical  for  ITAP  in  vivo 
(Chimutengwende-Gordon  et  al  2011).  Substrate  analysis o n  silanised 
implants has been used to demonstrate the covalent reaction has taken place 
(Davis et al 2002, Jose et al 2005, Nanci et al 1997 and Puleo, 1995) and 
functional analysis has been used to confirm the biological activity of tethered 
ligands (Davis et al 2002, Chimutengwende-Gordon et al 2011, Jose et al 
2005, Middleton et al 2007, Nanci et al 1997 and Puleo, 1995). 
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Fig 3.01 Schematic representation of the silanisation reaction in the biological 
functionalisation of titanium alloy substrates using RGD-polypeptides. Taken from 
http://www.intechopen.com/books/nanowires-implementations-and-applications/organic-
surface-modification-of-silicon-nanowire-based-sensor-devices   
 
RGD-polypeptides  (or  other  ligands)  used  to  functionalise  implant  surfaces 
must remain immobilized to the substrate in dynamic environments to have a 
positive effect. It has been hypothesized that adsorbed proteins are displaced 
in vivo (Middleton et al 2007), so a durable covalent bond between RGD-
polypeptides and titanium alloy must be developed. Functionalisation of the 
bone implant interface using RGD-polypeptides has been established in vivo 
(Ferris et al 2005, Elmengaard et al 2005 and Kroese-Deutman et al 2005), 
whilst  silanisation,  rather  than  adsorption,  of  fibronectin  to  titanium  alloy 
implants  has  been  shown  to  increase  soft  tissue  attachment  in  vivo 
(Chimutengwende-Gordon et al 2011). However, the environment in vivo is far 
removed from that of in vitro experiments.  
 
Other methods of covalently coupling biological ligands to material substrates 
exist. 2,2,2-trifluoroethanesulfonyl chloride (Tresyl chloride) has been used to 
hydroxylate titanium and covalently bond fibronectin to the substrate.   This 
method,  which  does  not  require  a  solvent,  has  not  been  validated  by 
functionally testing the biological activity of the tethered fibronectin (Hayakawa 
et  al  2003).    Nylon  functionalisation  has  been  achieved  with  the  covalent 
attachment  of  oligodeoxynucleotides.  Substrates  were  coated  with 
poly(ethyleneimine)  and  2,4,6-trichloro-1,3,5-triazine  (cyanuric  chloride), 	 ﾠ 109	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which  allowed  the  covalent  attachment  of  biologically  functional 
oligodeoxynucleotide ligands (Van Ness et al 1991).  
 
Despite  the  variety  of  published  methodologies  describing  the  covalent 
attachment  of  functional  ligands  to  substrates  (Hersel  et  al  2003), I  h a v e  
decided to use silanisation because significant increases in HDF attachment 
strength to titanium alloy substrates were observed in Chapter 2 using this 
particular method. To build upon those initial results, it is important to optimize 
the methodology in preparation for the in vivo development of functionalised 
ITAP  substrates.  To  achieve  this  I  will  use  methodologies  established  by 
Middleton et al. (2007), in which functionalised substrates were exposed to a 
competitive environment, mimicking that observed in vivo, using protein rich 
serum and measuring the amount of fibronectin remaining bound over time. 
The steps taken to optimize this RGD-polypeptide functionalisation technique 
must  positively  influence  HDF  attachment  in  vitro.  If  my  protocol  can  be 
optimised I may be able to develop a functionalised ITAP substrate for in vivo 
use.  
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3.2- Aims and Hypotheses 
 
This  chapter  aims  to  develop  a  full  understanding  of  the  loading  and 
release kinetics of linear RGD polypeptides on titanium alloy substrates, 
through  adsorption  and  silanisation,  and  to  compare  their  effects  on 
HDF attachment in vitro with those of fibronectin. 
 
To  achieve  this,  I  have  devised  more  specific  experimental  aims.  First, 
because the addition of a Y residue to the RGD polypeptide is necessary, my 
initial aim is to establish the effect of YRGD-polypeptide functionalisation on 
HDF  attachment.  Secondly,  to  determine  the  maximum  amount  of  RGD-
polypeptide  and  fibronectin,  that  can  be  adsorbed  or  silanised,  to  titanium 
alloy, and observe how much remains immobilized over time. Thirdly, I aim to 
assess  the  durability  of  my  functionalisation  techniques  by  measuring  how 
much  RGD-polypeptides  and  fibronectin  remains  bound  to  the  substrates 
when they are exposed to competitive environments which a more realistic in 
terms  of  the  in  vivo  application.  Finally,  I  will  use  my  optimised 
functionalisation protocol, which will be determined in these experiments, and 
assess the outcome of this on HDF attachment in vitro.    
 
This Chapter will test the following hypotheses: 
 
1.  The Y addition to RGD-polypeptides will have no effect on its ability to 
up-regulate HDF attachment on titanium alloy surfaces.  
2.  Silanisation o f  R G D -polypeptide  or  fibronectin  will  create  a  more 
durable coating compared with substrates functionalised by adsorption 
protocols.  
3.  HDF attachment at 1, 4, 24 and 96 hours will be significantly greater on 
RGD and fibronectin functionalised substrates compared with controls.  
  
  	 ﾠ 111	 ﾠ
3.3- Material and Methods 
3.3i- Study Design 
 
Each  study  was  directed  by  a  specific  research  question  to  test  my 
hypotheses, outlined previously.  
 
Study 1 
 
The first research question was whether the addition of a Y residue would 
alter the effects of the RGD-polypeptide on HDF attachment? Substrates were 
prepared  by  adsorption  of  either  RGD-polypeptides  or  YRGD-polypeptides 
(HQ809608,  AltaBioscience,  UK  and  outlined  in  3.3iii).  HDF  attachment 
assays  were  subsequently  performed.  Table  3.01  outlines  the  groups 
assessed (3.41), their specific functionalisations and details of the experiment 
performed.    
 
 Table 3.01- Study 1 Description 
Group.  Substrate Functionalisation.  Study Details. 
Control.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed  at 
24-hours. 
5mM adYRGD.  5mM linear YRGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed  at 
24-hours. 
5mM adRGD.  5mM R G D -polypeptide 
adsorbed t o  t i t a n i u m  a l l o y  
substrates (2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed  at 
24-hours.  
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Study 2 
 
This study asked whether there were any errors in the iodination of either 
ligand, relating to half life or radiolysis. A concentration gradient was set up for 
I
-125YRGD-polypetides and I
-125fibronectin respectively and calibration curves 
were  generated.  I
-125YRGD-polypetides  ranged  from  1-10mM  and  I
-
125fibronectin ranged 0.02µg/mL-20µg/mL, ligands were always dissolved in 
50µL droplet of PBS. Assays were repeated three times and the radioactivity 
was analysed for beta radiation in counts per minute (CPM) using a Tricarb 
2900  TR  Liquid  Scintillation  Analyser  (PerkinElmer  LAS  (UK)  Ltd),  a  full 
methodology is discussed in 3.3iv.     
 
Study 3 
 
The first aspect of understanding the loading and release kinetics of YRGD 
was to determine the maximal amount of YRGD polypeptide that could be 
adsorbed  and  silanised  to  titanium  alloy  substrates.  I
-125YRGD-polypetides 
substrates were prepared by adsorption (2.3iii) or silanisation (2.3iv) protocols 
using a range of concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10mM in 50µL 
PBS solutions. I
-125fibronectin substrates were prepared by silanisation using 
a range of concentrations, namely 0.2, 2, 5, 10, 15, 20, 40 and 60, 80 and 
100µg/mL. These equated to weights of 10, 100, 250, 500, 750, 1000, 2000, 
3000, 4000, 5000ng per 50µL droplet of PBS. Radioactivity levels of each 
substrate were read (3.3iv) and plotted against the original concentrations or 
weights.  
 
Study 4 
 
This  study  was  performed  to  determine  the  time  required  to  couple  either 
YRGD  or  fibronectin  to  titanium  alloy  substrates.  Functionalised  substrates 
were prepared through adsorption or silanisation with I
-125YRGD-polypetides 
and  I
-125fibronectin.  Initial  concentrations  of  I
-125YRGD-polypetides  were 
increased to 7mM, based on results from Study 3. Ligands were allowed to 	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couple  to  substrates  for  5-min,  2-hour,  20-hour  and  140-hour  time-points 
before being washed with PBS. Radioactivity levels of the substrates were 
read to evidence the amount of ligand remaining bound to the substrates.  
     
Study 5 
 
The aim of this study was to determine the durability of coatings. I
-125YRGD-
polypetides  and  I
-125fibronectin  substrates  were  prepared.  Adsorption  and 
silanisation  protocols  were  amended  on  the  basis  of  the  previous  Study’s 
results and the coupling time during silanisation of I
-125YRGD-polypetides was 
increased  to  20-hours.  In  order  to  measure  the  durability  of  adsorbed  or 
silanised proteins substrates were soaked in either PBS or FCS for 5-mins, 2-
hours, 20-hours and 140-hours. At each time interval substrates were washed 
in  PBS  three  times  and  analysed  for  radioactivity  levels.  Assays  were 
repeated three times.  
 
Study 6 
 
To determine the degree of HDF attachment over time, functionalised RGD-
polypeptides and fibronectin substrates were prepared by both adsorption and 
silanisation and HDF attachment assessed at 1, 4, 24 and 96-hour time-points. 
Protocols  used  in  the  preparation  of  functionalised  substrates  were  based 
upon 2.3iii and 2.3iv but specific alterations were made based on the findings 
of  Studies  2  and  3  of  this  chapter  (3.4).  Table  2.05  outlines  the  groups 
assessed (2.45), their specific functionalisations and details of the experiment.   
 
Table 3.02- Study 6 Description 
Group  Substrate Functionalisations  Study Details 
Control 1h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
Control 4h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
Control 24h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 	 ﾠ 114	 ﾠ
assay  (2.3vii)  performed 
at 24-hours.  
Control 96h.  Polished titanium alloy (2.3ii).  n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
AdYRGD 1h.  7mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (Based on 2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
AdYRGD 4h.  7mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (Based on 2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
AdRGD 24h.  7mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (Based on 2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
AdRGD 96h.  7mM  linear  RGD-polypeptide 
adsorbed  to  titanium  alloy 
substrates (Based on 2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
Adfn 1h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(Based on 2.3iii) 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
Adfn 4h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(Based on 2.3iii) 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
Adfn 24h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(Based on 2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
Adfn 96h.  10.0µg/ml  Fibronectin  adsorbed 
to  titanium  alloy  substrates 
(Based on 2.3iii). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
SiYRGD 1h.   7mM  linear  YRGD-polypeptide 
silanised,  left  to  couple  to 
substrate  for  20-hours, t o  
titanium alloy substrates (Based 
on 2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3…)  performed 
at 1-hour.  
SiYRGD 4h.   7mM  linear  YRGD-polypeptide 
silanised,  left  to  couple  to 
substrate  for  20-hours, t o  
titanium alloy substrates (Based 
on 2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  	 ﾠ 115	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SiYRGD 24h.   7mM  linear  YRGD-polypeptide 
silanised,  left  to  couple  to 
substrate  for  20-hours, t o  
titanium alloy substrates (Based 
on 2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
SiYRGD 96h.   7mM  linear  YRGD-polypeptide 
silanised,  left  to  couple  to 
substrate  for  20-hours, t o  
titanium alloy substrates (Based 
on 2.3.iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
Sifn 1h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 1-hour.  
Sifn 4h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 4-hours.  
Sifn 24h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 24-hours.  
Sifn 96h.  10.0µg/ml  Fibronectin  silanised 
to  titanium  alloy  substrates 
(2.3iv). 
n=3  and  cell  attachment 
assay  (2.3vii)  performed 
at 96-hours.  
 
The following methods were performed for Studies 1-6.  
 
3.3ii- Substrate Preparation 
 
Surgical grade titanium alloy (Ti6V4Al) discs were prepared in accordance with 
the methodology described in Chapter 2.3ii. 
 
3.3iii- Polypeptide Synthesis 
 
YRGD-polypeptide synthesis was outsourced to AltaBiosciences (Birmingham, 
UK). Peptide synthesis was achieved by solid phase synthesis from the C-
terminal to the N-terminal. High Performance Liquid chromatography (HPLC) 
and Mass Spectroscopy data confirmed purity. Full spectra data is published 
in Appendix 2.  	 ﾠ 116	 ﾠ
 
3.3iv- Radio-labeling of Ligands 
 
YRGD-polypeptides  and  fibronectin  were  radiolabeled  by  Perkin  Elmer 
(PerkinElmer LAS (UK) Ltd). Iodination of YRGD was performed with oxidizing 
agent Chloroamine-T. Fibronectin was iodinated by Lactoperoxidase method. 
Radioactive purity was determined by chromatography before use and was 
>95% in both instances. (Appendix 2) 
 
Experimental work described from this point was completed in accordance 
with  University  College  London’s  Rules  for  the  Uses  of  Ionizing  Radiation 
(http://www.ucl.ac.uk/estates/safetynet/guidance/radiation/ionising/index.htm).  
 
3.3v- Assessment of Radioactivity   
 
Functionalised substrates were individually placed into 5ml tubes along with 
4ml of Ultima Gold XR scintillant (PerkinElmer LAS (UK) Ltd) and analysed for 
beta radiation in counts per minute (CPM) using a Tricarb 2900 TR Liquid 
Scintillation  Analyser  (PerkinElmer  LAS  (UK)  Ltd).  Three  readings  were 
performed each time. In the case of Study 2, where no substrate was present, 
a 50ul droplet of dissolved ligand of was pipetted directly into 5ml tubes and 
follows the same protocol.    
 
3.3vi- Functionalisation via Adsorption  
 
Functionalised  substrates  were  prepared  by  adsorption  of  radio-labeled 
ligands according to 2.3iii, unless otherwise stated. 
 
3.3vii- Functionalisation via Silanisation  
 
Silanisation protocols were performed using radio-labeled ligands, according 
to 2.3iv unless otherwise stated.  
 
3.3viii- Cell Attachment Assessment- Immunocyochemistry. 	 ﾠ 117	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The cell attachment assay outlined in 2.3v-2.3vii was performed. In brief, the 
cell  area  and  the  number  of  vinculin  markers  immuno-localised  with  anti-
vinculin and quantified to calculate FA density, which was used as a measure 
of HDF attachment.   
 
3.3ix- Statistics 
 
Statistical  analyses  were  performed  according  to  Chapter  2.3x  however;  I 
have adjusted the p-value to account for the number of pair-wise comparisons 
being performed in this Chapter. Significance was now considered at 0.005 
level, calculated by performing a Bonferroni correction thereby decreasing the 
probability of incorrectly rejecting the null hypothesis (Sedgwick, 2012).  	 ﾠ 118	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3.4- Results 
Study 1 
 
In this section I investigated whether the addition of a Y residue would alter 
the effect of the RGD-polypeptide on HDF attachment.  HDF attachment was 
observed on all substrates. A Kruskal-Wallis test demonstrated that the data 
for FA density were not from the same population distribution (p <0.05; Fig 
3.02) and therefore pair-wise statistical analysis (MWU) was used to compare 
the means between treatments.    
 
HDF  attachment  was  highest  on  adsorbed R G D -polypeptide  functionalised 
titanium alloy substrates, and significantly greater than controls (MWU p<0.05; 
Fig  3.02,  Table  3.03.  Adsorbed  YRGD-polypeptide  functionalised  titanium 
alloy  substrates  significantly  increased  HDF  attachment  compared  with 
controls (MWU p <0.05; Fig 3.01, Table 3.03).   
There was no significant difference was observed in HDF attachment between 
either  RGD  or  YRGD-polypeptide  functionalised t i t a n i u m  a l l o y  substrates 
(MWU p >0.05; Fig 3.02, Table 3.03) and so this indicates that incorporating 
the Y residue into RGD-polypeptide had no effect on the attachment of cells to 
functionalised surfaces.     
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Fig 3.02 Box and Whisker plot demonstrating FA Density on adsorbed Linear (green) RGD 
functionalised titanium alloy substrates compared with controls (red) at 24 hours. 
 
 
 
Table 3.03 Pair-wise (MWU) Compaisons 
  Control   5mM adYRGD  5mM adRGD 
Control    0.000  0.000 
5mM adYRGD      0.975 	 ﾠ 120	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Study 2 
 
To avoid any errors pertaining to changes in half-life of I
-125 a calibration of 
radio-activity,  for  both  I
-125YRGD-polypetides  and  I
-125fibronectin  was 
performed. Each radio-labelled ligand is presented in scatter plot were the Y-
axis is defined by CMP and the X-axis is defined by concentration (Fig 3.03 
and Fig 3.04). The radiochemical concentration of I
-125YRGD-polypetides was 
4.5µCi/µg, with straight-line equation of Y=156326118X  + 37970283.87 (Fig 
3.03).  The  radiochemical  concentration  of 
125fibronectin  was  given  at 
4.30µCi/µg, with a straight-line equation of Y=91092X (Fig 3.04).  
 
Calibration for each radio-labelled ligand demonstrated no errors relating to 
half-life or radiolysis and therefore subsequent experiments continued.  
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Fig 3.03. Calibration curve for I
125YRGD in Counts per Million (CPM) 
 
Fig 3.04. Calibration curve for I
125fibronectin in Counts per Million (CPM) 
y = 156326118x + 37970283.87 
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Study 3 
Adsorbed YRGD 
 
The data were not from the same population distribution (p <0.05). I
-125YRGD-
polypetides were found to be present on all substrates (Fig 3.05).  
 
For  all  adsorbed  values  of  I
-125YRGD-polypetides,  a  lower  concentration 
remained  bound  after  the  application  phase.    These  values  significantly 
increased as the initial concentration increased, up to 7mM (MWU p <0.005; 
Fig 3.05, Table 3.04). There were no significant differences in the amounts of 
adsorbed  I
-125YRGD-polypetides  remaining  immobilized  on  the  substrates 
between 7mM and 8mM (MWU p <0.005) and from 9mM and 10mM (MWU p 
>0.005). A significant difference in adsorbed I
-125YRGD-polypetides remaining 
immobilized on titanium alloy substrates was observed between from 8mM 
and 9mM (MWU p <0.005; Fig 3.05, Table 3.04). 
 
Silanised YRGD 
 
The  data  were  not  from  the  same  population  distribution  (p  <0.05)  and 
silanised I
-125YRGD-polypetides were present on all substrates (Fig 3.06).  For 
all initial amounts of I
-125YRGD-polypetides silanised, a lower concentration 
remained  bound  after  the  application  phase.  These  values  significantly 
increased  with  initial  concentration,  up  to  7mM  (MWU  p  <0.005;  Fig  3.06, 
Table 3.05). There were no further significant differences observed thereafter 
(all p values > 0.005). 7mM was designated the point of substrate saturation, 
for  silanised  I
-125YRGD-polypetides,  this  represented  approximately  60%  of 
the original amount silanised onto the substrates (Fig 3.06, Table 3.05). 
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Fibronectin 
 
The  data  were  not  from  the  same  population  distribution  (p  <0.05).  I
-
125fibronectin was present on all substrates (Fig 3.07).  
 
For all concentrations of I
-125fibronectin used in the silanisation procedure, a 
lower  amount  remained  bound  after  the  application  phase.    These  values 
significantly  increased  as  the  concentration  increased,  up  until  80µg/mL  I
-
125fibronectin, which equates to 4000ng in weight (MWU p <0.005; Fig 3.07, 
Table 3.06).  
 
There  was  no  significant  difference  observed  thereafter.  80µg/mL  initially 
silanised,  resulted  in  946.9ng,  approximately  23%  of  the  original  amount 
remaining  on  the  substrates.  This  was  designated  the  substrate  saturation 
point (Fig 3.07, Table 3.06).   
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Fig 3.05. Box and Whisker plot of changes in concentration of I
125YRGD-polypetptides 
remaining adsorbed to titanium alloy substrates with increasing concentrations of I
125YRGD-
polypeptides. 
 
 
 
Table3.04 Pair-wise MWU comparisons  
Initial Concentration of adsorbed I
-
125YRGD-polypetides  
MWU 
1mM-2mM  0.000 
2mM-3mM  0.000 
3mM-4mM  0.000 
4mM-5mM  0.002 
5mM-6mM  0.000 
6mM-7mM  0.002 
7mM-8mM  0.024 
8mM-9mM  0.000 
9-mM10mM  0.024 
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Fig 3.06. Box and Whisker plot of changes in concentration of I
125YRGD-polypeptides 
remaining silanised to titanium alloy substrates with increasing concentrations of I
125YRGD-
polypeptides. 
 
 
Table3.05 Pair-wise MWU comparisons 
Initial Concentration of silanised I
-
125YRGD-polypetides  
MWU 
1-2  0.005 
2-3  0.000 
3-4  0.000 
4-5  0.005 
5-6  0.000 
6-7  0.002 
7-8  0.171 
8-9  0.009 
9-10  0.145 
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Fig 3.07. Box and Whisker plot of changes in amount of I
125fibronectin remaining silanised to 
titanium alloy substrates with increasing amounts of I
125fibronectin. 
 
 
 
Table 3.06 Pair-wise MWU comparisons 
Initial Concentration of silanised I
-
125fibronectin 
MWU 
10-100  0.000 
100-250  0.000 
25-500  0.000 
500-750  0.000 
750-1000  0.001 
1000-2000  0.000 
2000-3000  0.000 
3000-4000  0.000 
4000-5000  0.012 
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Study 4 
 
The concentration of silanised I
-125YRGD-polypetides significantly increased 
over time up to 20-hours (MWN p <0.005), after which there were no further 
statistical differences (MWU p >0.005; Fig 3.08, Table 3.07). The amount of 
adsorbed I
-125YRGD-polypetides significantly increased between 5-mins and 
2-hours (MWU p <0.005). No significant difference was observed in adsorbed 
I
-125YRGD-polypetides  between  2-hours  and  20-hours  (MWU  p  >0.005).  A 
significant decrease in adsorbed I
-125YRGD-polypetides between 20-hours to 
140-hours was observed (MWU p <0.005; Fig 3.08, Table 3.07). 
 
Comparisons  made  between  functionalisation  techniques  showed  that 
silanisation  results  in  significantly  more  I
-125YRGD-polypetides  coupled  to 
titanium alloy over time compared with adsorption (MWU p <0.005), with the 
exception  of  5-mins,  were  no  statistical  difference  was  observed  (MWU  p 
>0.005); Fig 3.08, Table 3.07).  
 
The amount of silanised I
-125fibronectin significantly increased between 5-mins 
and 2-hours (MWN p <0.005), however, no further statistical differences were 
observed after that time (MWU p >0.005; Fig 3.09, Table 3.08). The amount of 
adsorbed  I
-125fibronectin  significantly  increased  at  all  time-points  (MWU  p 
<0.005;  Fig  3.08,  Table  3.08).  Comparison  of  the  silanised  data  with 
functionalised I
-125fibronectin  showed  significantly  more  silanised  protein 
bound  at  all  time-points  compared  with  adsorbed  I
-125fibronectin  substrates 
(MWU p <0.005; Fig 3.09, Table 3.08). 
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Fig 3.08 Box and Whisker plot of changes in concentration of silanised (yellow) and adsorbed 
(green) I
125YRGD functionalised titanium alloy substrates when washed in PBS after 5mins, 2, 
20 and 140 hours. 
 
 
 
Table 3.07 Pair-wise MWU Comparisons 
 
  siYRG
D 
5mins 
siYRG
D 2hrs 
siYRG
D 
20hrs 
siYRG
D 
140hrs 
adYRG
D 
5mins 
adYRG
D 2hrs 
adYRG
D 20hrs 
adYRG
D 
140hrs 
siYRGD 
5mins 
  0.000      0.171       
siYRGD 
2hrs 
    0.000      0.009     
siYRGD 
20hrs 
      0.102      0.000   
siYRGD 
140hrs 
              0.000 
adYRG
D 
5mins 
          0.000     
adYRG
D 2hrs 
            0.171   
adYRG
D 20hrs 
              0.000 
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Fig 3.09. Box and Whisker plot of changes in concentration of silanised (purple) and 
adsorbed (blue) I
125fibronectin functionalised titanium alloy substrates were washed in PBS 
after 5mins, 2, 20 and 140 hours. 
 
Table 3.08 Pair-wise MWU Comparisons 
 
  Sifn 
5mins 
Sifn 
2hrs 
Sifn 
20hrs 
Sifn 
140hrs 
Adfn 
5mins 
Adfn 
2hrs 
Adfn 
20hrs 
Adfn 
140hrs 
Sifn 5 
mins 
   0.000      0.000       
Sifn 
2hrs 
    0.691      0.000     
Sifn 
20hrs 
      0.085      0.000   
Sifn 
140hrs 
              0.000 
Adfn 
5mins 
         
0.000     
Adfn 
2hrs 
         
  0.000   
Adfn 
20hrs 
         
    0.000 	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Study 5 
 
There  was  no  significant  decrease  in  silanised  I
-125YRGD-polypetides 
between  5-mins  and  2-hours  soaked  in  FCS  (MWU  p  >0.005).  Thereafter 
significant decreases were observed (both MWU values p <0.005; Fig 3.10, 
Table 3.09). A significant reduction in absorbed I
-125YRGD-polypeptides was 
observed at all time-points (all MWU values p <0.005; Fig 3.10, Table 3.09).   
 
Comparisons  between  silanised  and  adsorbed  I
-125YRGD-polypetides 
substrates  showed  silanised  I
-125YRGD-polypetides  were  significantly  more 
durable compared with adsorbed functionalised substrates at all time-points 
(all MWU values p <0.005) with the exception of 5-min time-point, were no 
difference was observed (MWU p >0.005; Fig 3.10, Table 3.09). 
 
There was a significant reduction in the amount of protein attached to the 
titanium  alloy  substrate  between  5-mins  and  2-hours  for  silanised  I
-
125fibronectin (MWU p <0.005), thereafter there were no significant differences 
(both MWU values p >0.005; Fig 3.11, Table 3.10). 
 
For adsorbed I
-125fibronectin there was a significant reduction in the amount of 
attached  protein  after  each  time  point.  Values  at  each  chronological  point 
were  significantly  lower  than  the  preceding  time-point  (all  MWU  values  p 
<0.005; Fig 3.11, Table 3.10). 
 
Comparisons  between  the  functionalised I
-125fibronectin  show  silanisation 
produced a significantly more durable coating compared with adsorption at all 
time-points (all MWU values p <0.005; Fig 3.11,Table 3.10). 
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Fig 3.10. Box and Whisker plot of changes in concentration of silanised (yellow) and 
adsorbed (green) I
125YRGD functionalised titanium alloy substrates when soaked in FCS for 
5mins, 2, 20 and 140-hours. 
 
 
Table 3.09 Pair-wise MWU Comparisons 
  siYRG
D 
5mins 
siYRG
D 2hrs 
siYRG
D 
20hrs 
siYRG
D 
140hrs 
adYRG
D 
5mins 
adYRG
D 2hrs 
adYRG
D 20hrs 
adYRG
D 
140hrs 
siYRGD 
5mins 
  0.047      0.012       
siYRGD 
2hrs 
    0.000      0.000     
siYRGD 
20hrs 
      0.000      0.000   
siYRGD 
140hrs 
              0.000 
adYRG
D 
5mins 
          0.000     
adYRG
D 2hrs 
            0.000   
adYRG
D 20hrs 
              0.000 
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Fig 3.11. Box and Whisker plot of changes in concentration of silanised (purple) and 
adsorbed (blue) I
125fibronectin functionalised titanium alloy substrates when soaked in FCS 
for 5mins, 2, 20 and 140-hours. 
 
 
Table 3.10 Pair-wise MWU Comparisions 
 
  Sifn 
5min 
Sifn 
2hr 
Sifn 
20hr 
Sifn 
140hr 
Adfn 
5min 
Adfn 
2hr 
Adfn 
20hr 
Adfn 
140hr 
Sifn 
5min 
  0.004      0.001       
Sifn 2hr      0.024      0.000     
Sifn 20hr        0.171      0.000   
Sifn 
140hr 
              0.000 
Adfn 
5min 
         
0.000     
Adfn 2hr           
  0.001   
Adfn 
20hr 
         
    0.000 	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PBS Soak 
 
 
The amount of silanised I
-125YRGD-polypetides decreased over time with PBS 
soaking. There was a significant decease in silanised I
-125YRGD-polypetides 
between 5-mins and 2-hours and 2-hours and 20-hours (both MWU values p 
<0.005), there was no significant decease thereafter (MWU p >0.005; Fig 3.12, 
Table 3.11).  
 
Significant decreases in absorbed I
-125YRGD-polypeptides were observed at 
all time-points (all MWU values p <0.005; Fig 3.12, Table 3.11). 
 
Comparison of the functionalisation techniques demonstrated that significantly 
more I
-125YRGD-polypetides remained bound with silanisation compared with 
adsorption at all time points (all MWU values p <0.005; Fig 3.12, Table 3.11). 
 
There was a significant decrease observed between 5-mins and 2 hours for 
silanised I
-125fibronectin (MWU p <0.005), however, no significant differences 
were observed thereafter (both MWU values p >0.005; Fig 3.13, Table 3.12). 
 
Significant decreases in absorbed I
-125fibronectin were observed at all time-
points (all MWU values p <0.005; Fig 3.13,Table 3.12). 
 
Comparisons  between  the  functionalisation  techniques  showed  that 
silanisation of I
-125fibronectin produced a more durable coating compared with 
adsorption at all time-points (MWU p <0.005), with the exception at the 2-hour 
time-point, where no significant difference was observed (MWU p >0.005; Fig 
3.12, Table 3.11). 
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Fig 3.12 Box and Whisker plot of changes in concentration of silanised (yellow) and adsorbed 
(green) I
125YRGD functionalised titanium alloy substrates when soaked in PBS for 5mins, 2, 
20 and 140-hours. 
 
 
Table 3.11 Pair-wise MWU Comparisons  
 
  siYRG
D 
5mins 
siYRG
D 2hrs 
siYRG
D 
20hrs 
siYRG
D 
140hrs 
adYRG
D 
5mins 
adYRG
D 2hrs 
adYRG
D 20hrs 
adYRG
D 
140hrs 
siYRGD 
5mins 
  0.000      0.000       
siYRGD 
2hrs 
    0.000      0.004     
siYRGD 
20hrs 
      0.387      0.000   
siYRGD 
140hrs 
              0.000 
adYRG
D 
5mins 
          0.000     
adYRG
D 2hrs 
            0.004   
adYRG
D 20hrs 
              0.000 
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Fig 3.13. Box and Whisker plot of changes in concentration of silanised (purple) and 
adsorbed (blue) I
125fibronectin functionalised titanium alloy substrates when soaked in PBS 
for 5mins, 2, 20 and 140-hours. 
 
 
Table 3.12 Pair-wise MWU Comparisons  
 
 
 
Sifn 
5mins 
Sifn 
2hrs 
Sifn 
20hrs 
Sifn 
140hrs 
Adfn 
5mins 
Adfn 
2hrs 
Adfn 
20hrs 
Adfn 
140hrs 
Sifn 5 
mins 
  0.004      0.001       
Sifn 
2hrs 
    0.522      0.045     
Sifn 
20hrs 
      0.006      0.002   
Sifn 
140hrs 
              0.001 
Adfn 
5mins 
         
0.002     
Adfn 
2hrs 
         
  0.005   
Adfn 
20hrs 
         
    0.000 	 ﾠ 136	 ﾠ
Study 6 
 
HDF  attachment  was  observed  on  all  substrates,  and  the  data  were  not 
parametrically distributed  (p <0.05). 
 
HDF  attachment  significantly  increased  on  adsorbed  fibronectin  compared 
with  controls  at  1-hour  (MWU  p  <0.005).  There  were  no  other  significant 
differences in HDF attachment with other functionalised substrates compared 
with  controls  at  this  time-point  (all  MWU  values  p  >0.005;  Fig  3.14,  Table 
3.13). 
 
At 4-hours, both adsorbed and silanised fibronectin significantly increase HDF 
attachment  compared  with  controls  (all  MWU  values  p  <0.005).  HDF 
attachment  on  controls  was  significantly  greater  compared  with  YRGD-
polypeptide functionalised titanium alloy substrates at this time-point (MWU p 
<0.005; Fig 3.14, Table 3.13). HDF attachment was significantly greater on all 
functionalised substrates compared with controls at 24-hours (MWU p <0.005; 
Fig 3.14, Table 3.13). 
 
At  96-hours,  HDF  attachment  was  significantly  greater  on  adsorbed  and 
silanised fibronectin functionalised substrates compared with controls (MWU p 
<0.005).  Adsorption  of  YRGD-polypeptides  did  not  significantly  alter  HDF 
attachment  compared  with  controls  (MWU  p  >0.005).  However,  silanised 
YRGD-polypeptides did significantly increase HDF attachment compared with 
controls (MWU p <0.005; Fig 3.14, Table 3.13). 
 
At  1  and  4-hours,  HDF  attachment  significantly  increased  on  adsorbed 
fibronectin substrates compared with adsorbed YRGD-polypeptide substrates 
(both  MWU  values  p  <0.005).  However  no  significant  differences  were 
observed in HDF attachment between these functionalised substrates at 24 
and 96-hours (both MWU values p >0.005; Fig 2.14, Table 2.13).   
 
At 1, 24 and 96-hours, HDF attachment on silanised fibronectin and RGD-
polypeptide functionalised substrates was not significantly different (all MWU 	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values  p  >0.005).  However  HDF  attachment  significantly  increased  on 
silanised fibronectin substrates compared with silanised RGD-polypeptides at 
4-hours (MWU p <0.005; Fig 3.14, Table 3.13).    
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Fig 3.14. Box and Whisker plot demonstrating HDF attachment on adsorbed (green) and 
silanised (yellow) RGD functionalised titanium alloy substrates, adsorbed (blue) and silanised 
(purple) fibronectin functionalised titanium alloy substrates compared with controls (red) at 1, 
4, 24 and 96-hours. 
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Table 3.13- Pair-wise MWU comparisons  
  adYRGD 1hr  adYRGD 4hr  adYRGD 24hr  adYRGD 96hr 
Control 1hr  0.669       
Control 4hr    <0.001     
Control 24hr      <0.001   
Control 96hr        0.01 
 
  Adfn 1hr  Adfn 4hr  Adfn 24hr  Adfn 96hr 
Control 1hr  <0.001       
Control 4hr    0.003     
Control 24hr      0.003   
Control 96hr        <0.001 
 
  Adfn 1hr  Adfn 4hr  Adfn 24hr  Adfn 96hr 
adYRGD 1hr  0.000       
adYRGD 4hr    0.000     
adYRGD 24hr      0.269   
adYRGD 96hr        0.425 
 
  siYRGD 1hr  siYRGD 4hr  siYRGD 24hr  siYRGD 96hr 
Control 1hr  0.225       
Control 4hr    <0.001     
Control 24hr      <0.001   
Control 96hr        <0.001 
 
  sifn 1hr  sifn 4hr  Adfn 24hr  Adfn 96hr 
Control 1hr  0.806       
Control 4hr    0.000     
Control 24hr      0.000   
Control 96hr        0.000 
 
  sifn 1hr  sifn 4hr  sifn 24hr  sifn 96hr 
siYRGD 1hr  0.024       
siYRGD 4hr    0.000     
siYRGD 24hr      0.273   
siYRGD 96hr        0.200 
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3.5- Discussion 
 
In  study  2  I  demonstrated  a  linear  relationship  between  the  level  of 
radioactivity and the concentration of either fibronectin or YRGD suggesting a 
stable coupling of the isotope had taken place and no radiolysis.   
 
The  first  study  in  this  chapter  demonstrated  that  there  was  no  detrimental 
effect on HDF attachment associated with the addition Y residue to the RGD-
polypeptide and integrin affinity is maintained. Pierschbacher and Ruoslahti 
(1987) show flanking residues can influence integrin affinity but the uncharged, 
polar  Y  residue  may  stabilise  the  polypeptide  within  its  local  environment, 
aiding presentation to integrin cellular receptors.  This work supports my first 
hypothesis. In a similar study, Jin et al. (2010) flanked their RGD-containing 
polypeptide  with  a  Y  residue.  Integrin  affinity  for  their  RGD-containing 
polypeptides  was  achieved,  albeit  concentration  dependent  and  not  in  an 
application  with  a  metallic  substrate.    HDF  attachment  was  significantly 
increased  on  RGD-polypeptide  functionalised t i t a n i u m  alloy  compared  with 
controls. This is accordance with the findings of Chapter 2.  
 
Study 3 demonstrated that there was a concentration of RGD or fibronectin, 
which resulted in the saturation of the titanium alloy substrate. Increasing the 
concentration beyond this level did not effectively increase the level of bound 
fibronectin or YRGD. Silanisation of 7mM of YRGD-polypeptide saturated the 
substrates surface with 60% (4.2mM) remaining covalently tether. Adsorbing 
the same ligand saturates the substrate surface at 7mM. However, a larger 
fraction  of  YRGD-polypeptide  remained  bound  (5.0mM)  compared  with 
silanised  substrates.  This  may  be  because  of  the  additional  chemistry 
associated with silanisation and the APTES/Glutaraldehyde complex spatial 
distribution.     
 
Silanizing 4000ng of fibronectin to titanium alloy substrates yielded 946.9ng 
remaining covalently tether, approximately 23% of the original amount. This 
calculated  coupling  efficiency  is  less  than  Middleton e t  a l   (2007),  who 
demonstrated  30%  efficiency  with  4000ng  yielding  1218.40ng  of  silanised 	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fibronectin to titanium alloy substrates. Coupling efficiency is linked to bond 
formation  between  spacer  (APTES/Glutaraldehyde  complex)  and  ligand 
fibronectin  or  YRGD-polypeptides).  It  has  been  suggested  that  in  the 
presence of increased number of ligands decreases the coupling efficiency. 
Increased ligands increases reaction products, which in turn inhibits the bond 
formation  of  a  derivatised  substrate  (Gordon  et  al  2010).  It  is  therefore 
important to understand the loading kinetic in the formation of a derivastised 
substrate, to make it as efficient as possible and have the most beneficial 
effect, in this case, on HDF attachment.     
 
In  study  4,  I  showed  that  YRGD-polypeptides  required  20-hours  to  form 
covalent bonds the APTES/Glutaraldehyde complex linker on titanium alloy 
substrates.  In  contrast  Davis  et  al.  (2002)  performed  covalent  coupling  to 
APTES  linkers  for  2-hours  however  in  this  study  regular  sonication  was 
performed, presumably to lower the activation energy of the chemical reaction. 
This may account for differences in reaction time used in the methodologies.  
 
The use of radio-labelled ligands accurately quantified the presence of YRGD-
polypeptides.  I  postulate  that  YRGD-polypeptides  are  successfully 
immobilized on the substrate surface.  Unbound YRGD-polypeptides would be 
removed  from  the  substrate  surface  by  washing  in  PBS  prior  to  radiation 
assessment  and  therefore  the  level  of  radiation  would  directly  relate  to 
immobilised ligands on the substrate surface.  Davis et al. (2002) confirmed 
immobilisation of RGD-polypeptides with X-ray Photoelectron Spectroscopy 
elemental analysis (XPS). In short, relative changes in elemental composition 
of their substrates were attributed to covalent bond formation.  
 
Based on my experimental findings in this study, the subsequent silanisation 
protocol was adapted to account for the time required for YRGD-polypeptide 
to couple to the APTES/Glutaraldehyde titanium alloy substrate. The time was 
increased from 4-hours to 20-hours. On the other hand fibronectin required 
only  a m i n i m u m  o f  2 -hours  to  covalently  couple  to  APTES/Glutaraldehyde 
complexes  on  substrates  whilst  is  a  similar  study,  Gordon  et  al.  (2010), 
demonstrated  that  laminin  required  4-hours  to  silanised  to  titanium  alloy 	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substrates,  with  no  significant  increase  seen  at  24-hours  of  reaction  time. 
Middleton et al. (2007) observed 4-hours as the critical time for silanisation of 
fibronectin to titanium alloy substrates.  So it appears that a difference exists 
in  the  time  required  for  YRGD-polypeptides  and  fibronectin  to  couple  to 
substrates. I suggest this may involve the number of reactions required to 
silanise  YRGD-polypeptides,  based  upon  the  number  of  binding  domains 
presented to the substrate surface.  Furthermore, there may have been more 
free  amine  side  chains  (-NH3)  available  in  the  each  fibronectin  protein 
compared  with  individual  binding  domains,  increasing  the  opportunity  for 
covalent  bond  formation  between  the  aldehyde  groups  (-CHO) a n d  
subsequently reducing the time required to couple to the substrates.      
 
In  Study  5  I  showed  that  silanised  YRGD-polypeptides  and  fibronectin 
coatings are more durable compared with adsorbed substrates when soaked 
in PBS or FCS.  Adsorption of biological material, be it polypeptides or large 
globular proteins such as fibronectin, will electrostatically bond to the surface 
of  a  substrate  that  possesses  an  amorphous  oxide  layer.  (Discussed  in 
Chapter 1.2 and 2.1) PBS is a buffered solution, which may interact with the 
electro-static  surface  bonds  responsible  for  immobilization,  irrespective  to 
whether YRGD-polypeptides or fibronectin are adsorbed. The covalent bond 
formed  during  silanisation  appears  less  susceptible  to  degradation  from  a 
buffered environment.  
 
Soaking  functionalised  substrates  in  FCS  creates  an  environment  more 
representative  of  an  in  vivo  environment.  Serum  proteins  are  expected  to 
compete for the substrate surface in vivo and displace biological coatings.  
The electrostatic bonds associated with adsorbed substrates are insufficient 
to  immobilise  YRGD-polypeptide  or  fibronectin  to  the  substrates.  Larger 
serum proteins in the FCS may have replaced the coatings, as first described 
by  Vroman  et  al  (1980).  However,  further  work  would  be  needed  to 
demonstrate this. By comparison, the covalent bonds created with silanisation 
can withstand surface competition from serum proteins in the FCS. This has 
been  reflected  in  my  results  as  significantly  more  YRGD-polypeptides  and 
fibronectin remained immobilised on the silanised substrates, at all time points. 	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This may be beneficial for in vivo applications providing the coating remains 
biologically active.     
 
These data support my hypothesis and are in accordance with others, who 
have also demonstrated the increased durability based on covalent tethering 
between metallic substrates and biological functionalisations within a PBS and 
FCS environment (Middleton et al 2007 and Gordon et al 2010). 
 
The  silanisation  of  YRGD-polypeptides  significantly  increased  HDF 
attachment  at 2 4  a n d  9 6 -hours.  These  significant  increases i n  H D F  
attachment to silanised YRGD-polypeptide substrates occur at the same time-
points  compared  with  Chapter  2,  Study  5.  No  detrimental  effects  on  HDF 
attachment were observed as a result of the changes to protocol between 
Chapter 2 Study 5 and Chapter 3 Study 6.     
 
Silanisation  of  either  YRGD-polypeptides  or  fibronectin  show  no  significant 
difference  on  HDF  attachment  when  compared  to  each  other.  Significant 
differences were observed in the comparison on HDF attachment on silanised 
RGD-polypeptides  and  fibronectin  functionalised  substrates  in  Chapter  2, 
Study 5. Amendments to the silanisation protocol in this chapter, based on the 
loading  and  released  kinetics,  may  have  created  a  more  efficient,  robust 
coating that aids HDF attachment. As a result, no significant difference was 
observed in HDF attachment when comparing silanised YRGD-polypeptides 
and fibronectin substrates.  
 
Silanised fibronectin has increased soft tissue attachment to titanium alloy in 
vivo  (Chimutengwende-Gordon  et  al  2011),  yet  its  clinical  use  may  be 
restricted  due  to  regulatory  issues  and  harsh  sterilization  techniques 
rendering it inactive. YRGD-polypeptides may provide an alternative solution 
to overcome these issues, particularly if this functionaliseation technique can 
functionalize the titanium alloy substrate.  
 
It is possible that the silanisation techniques I have used do not result in the 
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alloy  substrates.  Given  the  chemical  structure  of  the  APTES  used,  it  is 
possible t h a t  i t   polymerises  over  the  substrate  surface,  increasing  the 
electrostatic forces of attraction, resulting in a more durable coating in the 
absence  of  the  formation  of  covalent  bonds.  Puleo  (1995)  quantified t h e  
presence o f  -NH2  groups  using  2,  4,  6-trinitrobenzenesulfonic  acid  (TNBS) 
with the aim of demonstrating successfully derivatised metal substrates. Such 
a technique was used to quantify the presence of -NH2 groups however; this 
does  not  conclusively  show  the  formation  of  a  covalently  bonded  APTES 
spacer  to  a  metal  substrate.  Jose  et  al.  (2007)  performed  a  2,2-
Dihydroxyindane-1,3-dione (ninhydrin) assay to demonstrate the presence of -
NH2 groups on their titanium substrates, again, in an attempt to demonstrate a 
successfully derivatised metal substrate. These authors further demonstrated 
the presence of the chosen ligand (vancomycin) on titanium substrates by 
immunologically  staining  vancomycin  with  a  fluorescence  tag.  Both 
techniques demonstrated the presence of silanised titanium substrates and 
localization of the ligands under fluorescent microscopy. In addition to using a 
biochemical  method,  and  as  discussed  earlier,  XPS  has  been  used  in  an 
effort to confirm derivatised glass substrate with APTES (Davis et al 2002). 
Attenuated Total Reflection Fourier Transform Infrared Spectroscopy (ATR-
FTIR) has also been used to demonstrate the formation of ligand bonding to 
polyurethane  substrates  (Lin  et  a  2001).  None  of  these  studies  have 
conclusively demonstrated the formation of covalent bonds between ligands 
and their substrates however these methods have been used to demonstrate 
the formation of a durable, bioactive coating.  
 
With regard to ITAP, a durable coating that could increase cell attachment 
strength for longer time periods of time would be ideal, however dermal cell 
attachment is the most critical in the first 24 hours, for successful ITAP device 
functioning  in  vivo.  Despite  the  fact  that  covalent  coupling  of  the  RGD-
polypeptides  has  not  been  unequivocally  demonstrated  here,  the  coatings 
have  been  shown  to  be  more  durable  over  140  hours  compared  with 
adsorbed coatings, and moreover increased cell attachment strength to the 
substrates in the first 24 hours.  
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Conclusion  
 
The aims of this chapter in my thesis was to develop an understanding of 
the  loading  and  release  kinetics  of  linear  RGD-polypeptides a n d  
fibronectin  to  titanium  alloy  substrates,  through  adsorption  and 
silanisation, and to compare their effects on HDF attachment in vitro.  
Silanisation  of  YRGD-polypeptides  has  been  shown  to  produce  robust 
coatings  that  withstand  binding  competition  from  serum  proteins,  and 
significantly increase HDF attachment between 24 and 96 hours.  
 
The ITAP flange is design to provide an increased surface area for dermal cell 
and  tissue  attachment.  Silanizing  RGD-polypeptides  to  it  may  encourage 
earlier cell attachment to the ITAP flange, thus functionalising it. If achieved, a 
stable  dermal  seal  will  form  and  may  help  reduce  downgrowth  of  the 
epithelium. 	 ﾠ 146	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Chapter 4- Optimal Structure of Porous Implants for Soft Tissue 
Integration into ITAP. 
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Chapter 4 
4.1- Introduction  
 
“The critical part of the design of ITAP is a porous, subcutaneous flange that 
mimics  the  surface  of  the  deer  antler  at  the  transcutaneous  interface” 
(Quotation  taken  from  Kang  et  al  2010)  Perforating  a  flange  with  700µm-
diameter holes, and positioning it under the epidermal tissue layer has been 
shown to increase dermal soft tissue attachment, which acts as a physical 
barrier to limit epithelial downgrowth around ITAP. This implant design was 
based on the morphology of the bone at the skin-pedicle interface of deer 
antlers,  which  achieves  an  infection-resistant,  and  stable  transcutaneous 
juncture without any evidence of downgrowth (Pendegrass et al 2006). When 
this is achieved clinically, it produced an effective seal preventing downgrowth 
and subsequent infection around transcutaneous implants (Kang et al 2010).   
 
Loaded  orthopaedic  implants  requiring  bone  fixation,  such  as  massive 
endoprotheses,  can  be  structurally  adapted  to  selectively  improve 
biocompatibility (Liu et al 2004). The mismatch in Young’s Modulus between 
the metal implant and the bone can be reduced by manufacturing devices 
from metals and alloys with Young’s Moduli closer to that of bone, for example 
titanium  alloy  (Ti6Al4V)  compared  with  Cobalt  Chrome,  thus  limiting  stress 
shielding (Chapter 1.2). Bony fixation can be achieved by the in-growth and 
integration  of  osteoblasts  forming  bone  tissue  within  and  onto  the  implant 
structure. This is referred to as osseointegration. The surface structure of the 
implant  effects  the  early  cellular  reaction,  which  leads  to  osseointegration 
(Simmons et al 1999). 
 
Early  porous  coatings  were  manufactured  using  plasma  spraying  and 
sintering  techniques.  Plasma  spraying  involves  introduction  of  powdered 
metal  usually  titanium  or  hydroxyapatite  particle  into  a  plasma  flame.  The 
particles are heated and accelerated onto the surface of the implant where 
they fuse to form a layer, which can be porous. This creates an efficient and 
low  cost  method  of  implant  fabrication  to  create  a  biocompatible  surface 
capable of being osseointegrated (Liu et al 2004). Sintering can also form 	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porous coatings and structures. Metal powders or beads can be heated and 
fused to each other and to a solid structure to create a porous surface in a 
process that is called sintering.  Simmons et al. (1999) demonstrated that an 
interconnecting  porous  structure,  achieved  by  sintering  titanium  alloy  to 
titanium ally bulk implants, integrated into bone sites earlier and to a more 
stable  degree.  However,  functionaliseation  of  bulk  implant  by  sintering  or 
plasma  often  creates  non-uniform  geometries  layered  onto  a  bulk  implant, 
which  makes  defining  the  tissue  infiltration  with  respect  to  the  internal 
geometries difficult.  
 
EBM  was  discussed,  in  brief,  in  Chapter  1.  It  is  a  rapid  type  of  powder 
metallurical processing that fabricates highly specific microstructures, such as 
open-celled titanium alloy components (Heinl et al 2007). This technology was 
utilised  by  the  aerospace  industry  in  the  fabrication  of  light-weight 
components.  It  is  now  being  utilised  in  the  orthopaedic  implant  market. 
(http://www.arcam.com/)   It is thought that an open structure can act as a 
scaffold for the influx of new cells, supported by fluid and vascular delivery of 
nutrients (Heinl et al 2008).  
 
Harnessed  kinetic  energy  from  an  electron  beam  is  transferred  to  thermal 
energy  from  a  Tungsten  filament  (Parthasarathy  et  al  2010).  Powdered 
titanium alloy is homogeneously applied layer-by-layer to form 3-dimensional 
porous structures. The EBM process has a greater energy density compared 
with  laser  manufacturing  techniques.  High  scanning  speeds  and  position 
accuracy  can  be  achieved  by  focusing  the  electron  beam  through 
electromagnetic lenses, meaning this single step process has shorter build 
times  and  low  manufacturing  costs.  Traditional  manufacturing  processes, 
such as those utilised in our laboratory can lower the purity of the metallic 
implant through adsorption of atmospheric gases, thus degrading the metal 
alloy. EBM maintains purity as the process occurs under vacuum (Heinl et al 
2007, Heinl et al 2008 and Parthasarathy et al 2010).  
 
Porous implant structures have been subject to much research, driven by the 
aim of developing biological fixation of load-bearing prosthesis in hard tissues. 	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Aspects from structure dimensions, through to biological response have all 
been  investigated  to  ascertain  optimal  specifications  (Black,  1992).  The 
porosity of an open or cellular implant facilitates the influx of body fluid in vivo, 
supporting cellular attachment and ultimately tissue implant integration (Wen 
et al 2002).  
 
The EBM process enables the fabrication of precise porous structures. The 
optimal porous structure for bone in-growth is yet to be defined (Ryan et al 
2006). Internal geometries can be designed to support the Young’s Modulus 
of the anchoring point (Li et al 2009), in an attempt to limit stress shielding. 
(Chapter 1.2) The flange, which is utilised for soft tissue in-growth, may be 
enhanced not only by functionaliseation using covalently bound proteins and 
peptides, which I have previously shown enhances cell attachment, but also 
by increasing the porosity, which would allow greater soft tissue in-growth.  So 
for the subject of this thesis and the overall aim for ITAP devices, the effect of 
porous structures on soft tissue in-growth must be considered.  
 
Porous structures aim to limit fibrous encapsulation of implant by providing a 
3-D network in which host cells and tissue can invade, attach and integrate. If 
achieved,  this  can  limit  infection  compared  with  bulk  implants  (Merrit  et  al 
1979). 
 
Neovascularisation throughout a porous structure impacts on connective soft 
tissue  development,  supporting  collagen  deposition  and  protecting  against 
necrotic changes, based on the permeability of a porous implant. Capillary 
formation required larger pore diameter (250-488µm) compared with 18-62µm 
range (Taylor and Smith, 1972). Avascular tissue will impact on the long-term 
health and metabolism of that tissue.  
 
It has been proposed that the internal architecture of a 3-D porous implant will 
allow  soft  connective  tissue  to  infiltrate  through  a  structure,  increasing  the 
attachment strength between tissue and implant interface. However porosity 
in these implants were created by sintering cobalt alloy beads to stainless 
steel bulk implants, meaning the surface was uneven with no well defined 	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pore  dimension  rather  a  range  of  50-200µm  which  has  been  specified  to 
enhance tissue in-growth (Bobyn et al 1982).  
 
In contrast, however, La Berge et al. (1990) observed encapsulation, and no 
fibrous  tissue  infiltration  with  pore  dimensions  of  300µm  (+/-15µm).  Well 
vascularised fibrous tissue infiltration required pore dimensions of 900µm (+/-
24µm). The manufacturing technique in their study produced a single-layer 
porous coating of cobalt-chrome alloy beads to bulk implant and the authors 
postulated  that  further  infiltration  could  be  achieved  with  a  3-D  porous 
structure.  In  contrast  titanium  prostheses  used  for  tendon  re-attachment 
exhibited  well-vascularised,  fibrocartilage  infiltration  in  porous  structures  of 
400µm (Gottsauner-Wolf et al 1994).   
 
Densely ordered, collagen rich, soft tissues have been observed at 4 weeks in 
vivo  throughout  interconnected  and  continuous  porous  tantalum  structures. 
No  specific  details  were  offered  in  reference  to  pore  dimensions,  however 
SEM images suggested diameters of ∼300µm (Hacking et al 2000).  
 
The  dental  implant  arena  has  also  experimented  with  pore  structure  in  an 
attempted to interface soft tissues with metal implants. Schroeder et al. (1981) 
describes  the  effect  of  a  sintered  titanium  alloy  porous  coating  on  sub-
epithelial  (fibro-connective)  soft  tissue  attachment  in  vivo.  Internal  pore 
geometries ranged between 25-100µm and facilitated dense collagen fibres at 
90
0 anchoring to the implant without inflammation.  
 
ITAP  devices  have  been  developed  based  on  information  obtained  from 
studying the deer antler pedicle. These naturally occurring structures support 
a soft-hard tissue interface due to pores, which the soft tissues of the dermis 
and  epidermis  infiltrate  and  attach  to.  Interface  characterisation,  by 
Pendegrass  et  al.  (2006),  suggests  a  mean  pore  diameter  of  217µm  (+/-
19.07µm).  
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The preceding paragraphs indicate that research on soft issue integration with 
metallic  alloy  implants  has  focused  on  discovering  the  optimal  pores  size. 
EBM technology allows me to design implants with a range of pore and strut 
sizes, to assess which is most beneficial for soft tissue integration. Soft tissue 
integration  will  be  assessed  subcutaneously  in  the  belly  of  the  para-spinal 
muscle in an ovine model. If successful, the findings will be applied to the 
ITAP flange to support dermal tissue integration.   
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4.2- Aims and Hypotheses 
 
This chapter aims to determine the effect of varying pore sizes of EBM 
porous titanium alloy on soft tissue in-filtration and re-vascularisation in 
vivo. 
 
This chapter aims to test the following hypotheses: 
 
1.  Subcutaneous  fibrous  soft  tissue  will  infiltrate  all  porous  implant 
structures, but the larger pore sizes will facilitate significantly greater of 
infiltration compared with small pore sizes, in vivo.  
2.  Larger pores sizes will facilitate a significantly greater influx of cells and 
exhibit  advanced  vascularisation  throughout  the  structure  compared 
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4.3- Material and Methods 
4.3i- Study Design 
 
Cylindrical, surgical grade titanium alloy (Ti6V4Al) implants, 20mm in height 
and 10mm in diameter, were manufactured using EBM techniques (Discussed 
in  5.2)  by  Stanmore  Implants  WorldWide  (Stanmore  Implants  Worldwide, 
Elstree, UK). 9-implant groups were tested using various combinations of pore 
and strut sizes (Fig 4.01, Table 4.01), surgically implanted para-spinally into 
the soft tissue of an ovine model for 4-weeks. Implants were a 3-dimensional 
structure of circular pores (of constant diameter) and interconnecting struts, 
also of constant diameter.    
   
 
 
Fig 4.01 Example of Group 5 porous titanium 
alloy implant.  
 
 
Table 4.01- Implant Dimensions  
Group (n=6)  Pore size/ µm
  Strut size/ µm 
1  1000  400 
2  1000  200 
3  700  400 
4  700  300 
5  700  200 
6  500  400 
7  500  300 
8  500  200 
9  250  300 
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4.3ii- Implant Preparation 
 
Implants were degreased in Decon 90 in an ultra-sonicator for 2-hours, rinsed 
extensively in dH20 and cleaned in alcohol in an ultra-sonicator for 4-hours 
with hourly changes in alcohol.      
 
4.3iii- Surgery 
 
All  surgery  was  carried  out  in  accordance  with  the  Animal  (Scientific 
Procedures)  Act  1986  (https://www.gov.uk/government/publications/animals-
scientific-procedures-act-1986-amendment-regulations)  and  in  conjunction 
with  University  College  London’s  Statement  of  the  Uses  of  Animals  in 
Research (http://www.ucl.ac.uk/slms/research/animal-use).    
  
Ovine adult, female Mules (breed) sheep were used for the in vivo study. 
 
Premedication  of  0.2mg/kg  Xylazine,  Rompun  2%  (Bayer  Healthcare,  UK) 
was  administered  to  each  animal.  Ketamine  Hydrochloride  (Ketaset,  Fort 
Dodge  Animal  Health  Ltd.,  UK)  induced  anesthesia  at  2mg  with  2.5mg  of 
Midazolam  Hypnovel  (Roche  Products  Ltd.,  UK),  both  administered 
intravenously.  Animal  subjects  were  intubated,  5ml  of  Cefalexin  Ceporex 
(Schering-Plough Animal Health, UK) was administered to achieve antibiotic 
prophylacsis and anesthesia was maintained by inhalation of Isofluorane at 
2%.  
 
Anesthetised animals were positioned in the ventral recumbencey and shaved 
centrally over the spinal region between T12 vertebrae and the Pelvic region 
in a 15cm
2 area. The shaved area was washed and cleaned with Betadine-
Povidine  Surgical  Scrub  (Dynarex,  Quick  Medical,  Washington,  USA) a n d  
iodine solution (Dynarex, Quick Medical, Washington, USA), transferred into 
the  operating  theatre,  draped  and  the  prepared  area  treated  with 
Chlorhexidine (Cardinal Health, Ohio, USA). All procedures were carried out 
using aseptic techniques.  On the right side of the spine a proximal incision, of 
5cm, 2cm below the T12 vertebrae was made in the longitudinal direction, 	 ﾠ 155	 ﾠ
through  the  skin  and  fascia,  exposing  the  para-spinal  muscle.  A  smaller 
longitudinal incision was made into the muscle, and implants were pushed 
into the belly of the muscle above and below the incision. Implants sat in the 
saggital plane. The muscle and overlaying fascia were closed and sutured 
with  absorbable 2 -0  Vicryl  (Ethicon  Inc.,  New  Jersey,  USA)  and  the  skin 
incision was closed using subcutaneous sutures of 1-0 Vicryl (Ethicon Inc., 
New  Jersey,  USA).  A  second  skin  incision  was  made,  distally  to  the  first. 
Implants were inserted by the same method, such that four implants were 
positioned  in  the  right  side  of  the  para-spinal  muscle.  Each  incision  was 
sprayed  with  Opsite  (Smith  and  Nephew  plc,  London,  UK)  dressing.    The 
procedure was repeated on the left side of the spine.   
 
4.3iv- Implant Retrieval and Histological Processing  
 
Four  weeks  post  implantation;  animals  were  euthanized  by  intravenous 
injection  of  0.7mg/kg  IV  Sodium  Pentobarbitone  (Pharmasol  Ltd.,  Andover 
UK) into the jugular vein. All implants were surgically dissected out en bloc 
and placed in 10% formal saline, for 1-week. Then, over a 5-week period, all 
samples were serially dehydrated with IMS and defatted in Chloroform (full 
processing data is presented in Appendix 3).  
 
Hard Grade Acrylic Resin (London Resin Company Ltd., London, UK) was 
given time to penetrate each sample, under vacuum and on a rotator over 2-
weeks, with two resin changes.  
 
Samples were cast in cold resin. Flexible casting moulds were lubricated with 
LR White Accelerator (London Resin Company Ltd, London, UK). Samples 
were placed in individual moulds and cold resin was mixed with accelerator 
(100:1). The moulds were filled with resin so the samples were covered and 
left to polymerise for a minimum of 4-hours in the freezer.  
 
Sections were made, transversely, at the mid-point of each implant using an 
Exakt E310 diamond edged band saw (Mederex, Frame, UK). Sections were 
ground evenly using Exakt-Micro-Grinding System (Mederex, Frame, UK) to a 	 ﾠ 156	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thickness of 100µm with ascending abrasive papers from P400 to P4000 and 
polished with a pad lubricated with AP-A Suspension, a 5µm agglomerate α 
alumina suspension (Struers Ltd., Solihull, UK). All sections were stained with 
Toluidine Blue, photographed with Carl Zeiss photomicroscope (KS300, Carl 
Zeiss,  Oberkochen,  Germany)  and  digital  image  processing  software 
(Axiovision Rel 4.5, Carl Zeiss, Oberkochen, Germany).    
 
4.3vi- Histological Analysis and Data Collection 
 
Light Microscopy (Carl Zeiss photomicroscope (KS300, Zeiss, Germany)) was 
used  to  assess  soft  tissue  morphology.  Quantitative  analysis,  semi-
quantitative analysis and qualitative analysis was carried out. The implants 
cross-section was divided in 3 Zones, both outer edges (Zones 1 and 2) and 
the central region (Zone 3), to ensure data was collected across the entire 
implant (Fig 4.02). Each outer Zone had data collected from 2 separate points 
with the average taken. 1 data collection point was taken in the central zone. 
A semi-quantitative percentage was assigned at each data collection point to 
represent the quality and maturity of the tissue infiltration within the pores. 
The  percentage  determined  by  comparison  with  healthy  soft  tissues 
surrounding the implant. A score of 100% would be assigned to a pore totally 
infiltrated  with  dense,  well-ordered  fibrous-connective  tissue  that  was  in 
intimate contact with the pore edge. 0% would indicate a pore devoid of soft 
tissue. Fig 4.03 represents typical histological sections that were scored by 
three, blinded independent assessors. These data were substantiated with a 
cell nuclei count within a measured area of each Zone to quantitatively assess 
the tissue maturation and viability, and a count of blood vessels to assess the 
extent of revascularization of the same area. These data were presented as a 
density per square millimeter.    
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Fig  4.02.  Implant  cross-section  for  data 
collection;  1)  Zone  1  First  outer  zone,  2) 
Zone  2  Second  outer  zone  and  3)  Zone  3 
Central zone.    
 
 
 
Fig 4.03. Typical examples of histological semi-quantitative scoring system used to calculate 
percentage of soft-tissue infiltration. A) 100% soft-tissue infiltration score. B) 50% soft-tissue 
infiltration score.  
 
4.3vii- Statistics 
 
Data are presented graphically in box and whisker plots for each Zone, where 
the  X-axis  represents  the  substrate  groups  (Table  4.01)  and  the  Y-axis 
represents  data  collection  made  (Tissue  infiltration,  Cell  Nuclei  Density  or 	 ﾠ 158	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Blood Vessel Density). Data is presented as median (with 95% confidence 
intervals)  and  outliers  are  plotted  as  individual  points  outside  the  box  and 
whiskers.  Statistical  analysis  was  performed  in  the  same  manner  as 
discussed in Chapter 2.3x. Significance was considered at the 0.05 level.  
 
 	 ﾠ 159	 ﾠ
4.4- Results 
 
Data collection was not possible from Group 9 implants. No tissue was visible 
throughout the implant structure due to debris and artefacts infiltrating pores. 
These  implants  were  therefore  not  represented  in  the  result  section  but 
possible reasons for this are discussed in Section 4.5- Discussion. 
 
Tissue Infiltration Zone 1    
 
A  Kruskal-Wallis  test  demonstrated  that  the  data  were  not  from  the  same 
population distribution (p <0.05).  Statistical analysis shows that the greatest 
soft tissue infiltration occurred in Groups 1, 2 and 4 as all values were scored 
at 100% by each assessor. Significantly higher levels of tissue infiltration were 
observed in Group 1 compared with Group 3, Group 4 compared with Group 3 
and Group 7 (MWU p <0.05) yet no difference was observed between Group 
1 and Group 2 (MWU p >0.05; Fig 4.04, Table 4.02).  
 
Group 3 and 6 showed the lowest levels of tissue infiltration at Zone 1, with 
median values of 40% and 27.5% respectively, yet, there were no significant 
differences  between  these  groups  (MWU  p  >0.05).  Tissue  infiltration  was 
significantly lower in Group 3 compared with Group 5 (MWU p <0.05; Fig 4.04, 
Table 4.02). 
 
Group  5  exhibited  high  levels  of  soft  tissue  in-filtration,  median  88%.  No 
significant  difference  existed  between  this  group  and  Group  2  or  Group  4 
(MWU p >0.05; Fig 4.04, Table 4.02). 
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Fig 4.04. Box plot demonstrating the percentage of tissue infiltration of each porous implant 
group from the outer most zone, Zone 1. 
 
 
Table 4.02- Pair-wise (MWU) Comparisons 
  Group 
1 
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.355  0.004      0.003     
Group 2          0.051      0.001 
Group 3        0.011  0.032  0.539     
Group 4          0.111    0.004   
Group 5                0.038 
Group 6              0.073  0.220 
Group 7                0.653 
Group 8                 	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Tissue Infiltration Zone 2    
 
Statistical analysis, using the Kruskal Wallis method, suggested that tissue 
infiltration  data  from  Zone  2  was  not  from  the  same  population  (p  <0.05). 
Results suggest that in this zone the more mature and denser soft tissue were 
seen in the implants with the larger pores sizes. This is similar to those results 
from Zone 1 but the variation of the data was greater, particularly for Groups 
1,2 4 and 5.  A description of the statistical differences follows.  
 
Groups 1, 2 and 4 all exhibited median values of 98.5%, 100% and 95% soft 
tissue  infiltration  at  Zone  2  respectively.  Group  1  had  significantly  higher 
tissue infiltration compared with Group 3 and 6 (MWU p <0.05). Group 2 had 
significantly higher tissue infiltration compared with Group 8 (MWU p <0.05; 
Fig 4.04, Table 4.03). Group 5 exhibited a median value of 87.5% soft tissue 
infiltration, which was significantly higher than Group 3 (MWU p <0.05); Fig 
4.05, Table 4.03). Group 3 and 6 exhibited the lowest levels of tissue in Zone 
2, median value of 35% and 22.5% respectively. (Fig 4.05, Table 4.03) There 
were no other significant differences observed between Groups in this zone 
(MWU p >0.05; Fig 4.05,Table 4.03) 
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Fig 4.05. Box plot demonstrating the percentage of tissue infiltration of each porous implant 
group from Zone 2. 
 
 
 
Table 4.03- Pair-wise (MWU) Comparisons 
  Group 
1 
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.682  0.009      0.006     
Group 2          0.102      0.001 
Group 3        0.140  0.014  0.712     
Group 4          0.779    0.086   
Group 5                0.052 
Group 6              0.251  0.085 
Group 7                0.368 
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Tissue infiltration Zone 3 
 
Statistical  analysis  of  this  data  set,  using  the  Kruskal  Wallis  method,  was 
significant (p <0.05).  Group’s 1, 2 and 4 all facilitated significantly high levels 
of tissue infiltration in Zone 3, as represented median values, all of 100%.  
Significantly higher tissue infiltration was observed in Group 1 compared with 
Group’s  3  and  6  (MWU  p  <0.05).  Group  2  had  significantly  higher  tissue 
infiltration compared with Group 8 (MWU p <0.05). Significantly higher levels 
of tissue infiltration were observed in Group 4 compared with Group’s 3 and 7 
(MWU p <0.05; Fig 4.06, Table 4.04). Group 5 facilitated high levels of tissue 
infiltration, median value 90%, which was significantly higher compared with 
Group 3 (MWU p <0.05; Fig 4.06, Table 4.04). The lowest levels of tissue 
infiltration in Zone 3 were observed in Group 6, median value 10% and Group 
3, median value 25. (Fig 4.06, Table 4.04). There were no other significant 
differences observed in any other pair-wise comparisons between Groups in 
this Zone 3 (MWU p >0.05; Fig 4.06, Table 4.04).  
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Fig 4.06. Box plot demonstrating the percentage of tissue infiltration of each porous implant 
group from inner most zone, Zone 3. 
 
 
 
   
Table 4.04- Pair-wise (MWU) Comparisons 
  Group 
1 
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.431  0.006      0.004     
Group 2          0.392      0.002 
Group 3        0.010  0.016  0.901     
Group 4          0.205    0.004   
Group 5                0.083 
Group 6              0.459  0.163 
Group 7                0.476 
Group 8                 
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Cell Nuclei Density Zone 1 
 
Statistical  analysis  of  this  data  set,  using  the  Kruskal  Wallis  method,  was 
significant (p <0.05). Unlike the semi- quantitative analysis of the percentage 
of soft tissue infiltration, a significant difference in the cell nuclei density could 
be  detected  between  Groups  1  and  2.  The  median  value  for  Group  2 
(5059CN/mm
2), was significantly greater compared with Groups 1, 5 and 8 
(MWU p <0.05; Fig 4.07, Table 4.05). Group 1 also had a high cell nuclei 
density  (median  value  3440.5CN/mm
2),  which  was  significantly  higher 
compared with Group 6 (MWU p <0.05; Fig 4.07, Table 4.05). There was no 
significant  difference  between  Groups  3,  4  and  7  with  median  cell  nuclei 
densities  of  1190,  1389  and  1390CN/mm
2  respectively.  Group  4  was 
significantly  higher  compared  with  Group  5  and  Group  7  was  significantly 
higher compared with Group 6 (MWU p <0.05; Fig 4.07, Table 4.05). There 
were no other significant differences observed in cell nuclei density in Zone 1 
(MWU p >0.05: Fig 4.07, Table 4.05). 	 ﾠ 166	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Fig 4.07 Box plot demonstrating the cell nuclei density/mm
2 of each porous implant group 
from the outer most zone, Zone 1. 
 
Table 4.05- Pair-wise (MWU) Comparisons 
  Group 
1 
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 
1 
  0.046  0.088      0.019     
Group 
2 
        0.003      0.009 
Group 
3 
      0.327  0.670  0.245     
Group 
4 
        0.045    0.570   
Group 
5 
              0.775 
Group 
6 
            0.023  0.058 
Group 
7 
              0.225 
Group 
8 
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Cell Nuclei Density Zone 2  
 
A  significant  difference  was  observed  within  this  data  population  as 
demonstrated  by  the  Kruskal  Wallis  method  (p  <0.05).    Group  2  exhibited 
significantly  higher  cell  nuclei  density,  (median  value  4527CN/mm
2), 
compared with Groups 5 and 8 (MWU p <0.05; Fig 4.09, Table 4.06). Group 1 
(median  value  2846CN/mm
2)  had  a  significantly  greater  cell  nuclei  density 
compared  with  Group  6  (MWU  p  <0.05),  which  had  the  lowest  cell  nuclei 
density (median value 268.5CN/mm
2) of all the Groups (Fig 4.08, Table 4.06).  
Group  4  did  elicit  a  significantly  higher  cell  nuclei  density  compared  with 
Group 5 (MWU p <0.05; Fig 4.08, Table 4.06). No other significant differences 
presented themselves on a pair-wise basis (MWU p >0.05; Fig 4.08, Table 
4.06). 
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Fig 4.08. Box plot demonstrating the number of cell nuclei density/mm
2 of each porous 
implant group from Zone 2. 
 
 
Table 4.06- Pair-wise (MWU) Comparisons 
 
 
Group 
1  
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 
1 
  0.116  0.088      0.032     
Group 
2 
        0.003      0.004 
Group 
3 
      0.221  1.000  0.245     
Group 
4 
        0.006    0.291   
Group 
5 
              1.000 
Group 
6 
            0.073  0.130 
Group 
7 
              0.482 
Group 
8 
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Cell Nuclei Density Zone 3 
 
Statistical analysis of this data set in Zone 3, using the Kruskal Wallis method, 
was significant, p<0.05.  Groups 1, 2 and 4 facilitated the highest cell nuclei 
density;  with  median  values  were  3586.5,  5000  and  1306  CN/mm
2 
respectively.  (Fig  4.09,  Table  4.07).  Group  2  implants  demonstrated 
significantly greater cell nuclei density compared with Groups 5 and 8 (MWU 
p <0.05; Fig 4.09, Table 4.07). Cell nuclei density of Group 1 was significantly 
increased  compared  with  Group  6  (MWU  p  <0.05),  the  lowest  observed 
median  value,  251CN/mm
2  (Fig  4.09,  Table  4.07).  Significantly  higher  cell 
nuclei densities were observed in Group 4 compared with Group’s 3 and 5 
(MWU p <0.05; Fig 4.09, Table 4.07). Pair-wise statistical analysis saw no 
other significant differences (MWU p >0.05; Fig 4.09, Table 4.07).  
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Fig 4.09. Box plot demonstrating the number of cell nuclei density/mm
2 of each porous 
implant group from inner most zone, Zone 3. 
 
 
Table 4.07- Pair-wise (MWU) Comparisons 
  Grou
p 1 
Group 2  Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.063  0.055      0.032     
Group 2          0.004      0.003 
Group 3        0.014  0.831  0.561     
Group 4          0.028    0.123   
Group 5                0.086 
Group 6              0.088  0.088 
Group 7                0.848 
Group 8                 
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Blood Vessel Density   
 
The pore volume and the strut thickness influenced the blood vessel in-growth.  
As expected the overall highest blood vessel density was seen in Zone 1 and 
the lowest in Zone 3 this was also related to an increase in the variability in 
the measurement, which increased towards the inner porous structure.       
 
Zone 1 
 
A Kruskal-Wallis test demonstrated that the data from Zone 1 were not from 
the  same  population  distribution  (p  <0.05).  The  pattern  for  the  number  of 
blood vessels within the porous structures also showed differences that were 
not discernable with semi quantitative analysis of percentage tissue infiltration. 
The Highest blood vessel density in Zone 1 was observed in Group 4, median 
value 15BV/mm
2, which was significantly higher compared with Group’s 3 and 
5 (MWU p <0.05; Fig 4.10, Table 4.08). Group 6 had the lowest blood vessel 
density, 0BV/mm
2, of all other implant groups. This was significantly lower 
compared to Groups 1, 7 and 8 (MWU p >0.05; Fig 4.10, Table 4.08). There 
were no significant differences apparent by pair-wise comparison of the data 
set (MWU p >0.05; Fig 4.010, Table 4.08).  
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Fig 4.10. Box plot demonstrating the blood vessels density/mm
2 of each porous implant group 
from outer most zone, Zone 1. 
 
 
Table 4.08 Pair-wise (MWU) Comparisons  
  Grou
p 1 
Group 2  Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.286  0.461      0.017     
Group 2          0.221      0.897 
Group 3        0.019  0.829  0.091     
Group 4          0.017    0.223   
Group 5                0.223 
Group 6              0.026  0.026 
Group 7                0.522 
Group 8                 	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Blood Vessel Density Zone 2  
 
Statistical  analysis  of  the  data  set  from  Zone  2,  using  the  Kruskal  Wallis 
method,  was  significant,  p<0.05.The  highest  blood  vessel  density  was 
observed in Group 2, median value 10BV/mm
2, which was significantly higher 
compared with Group 5 only  (MWU p <0.05; Fig 4.11, Table 4.09). Group 4 
had high blood vessel density, median value 6BV/mm
2, this was significantly 
higher compared with Groups 3, 5 and 7 (MWU p <0.05; Fig 4.11, Table 4.09). 
Group 6 facilitated the lowest blood vessel density, median value 0BV/mm
2, 
which was significantly lower compared with Group 1 and 8 (MWU p<0.05; Fig 
4.11, Table 4.09). Pair-wise statistical comparisons suggested there were no 
other significant differences in the data (MWU p >0.05; Fig 4.11, Table 4.09).    
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Fig 4.11 Box plot demonstrating the blood vessels density/mm
2 of each porous implant group 
from Zone 2. 
 
 
 
 
Table4.09 Pair-wise (MWU) Comparisons 
 
  Grou
p 1 
Group 2  Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.471  0.083      0.009     
Group 2          0.010      0.158 
Group 3        0.045  0.912  0.321     
Group 4          0.013    0.039   
Group 5                0.113 
Group 6              0.179  0.026 
Group 7                0.434 
Group 8                 	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Blood Vessel Density Zone 3  
 
Statistical  analysis  of  this  data  set  from  Zone  3,  using  the  Kruskal  Wallis 
method,  was  significant,  p<0.05.  Highest  median  value  for  blood  vessel 
density was observed in Group 4, 11BV/mm
2, which was significantly higher 
compared  with  Group’s  3,  5  and  7  (MWU  p  <0.05;  Fig  4.12,  Table  4.10).  
Groups 5 had low blood vessel density, medium value 0BV/mm
2.  This was 
significantly lower compared with Group’s 2, 3 and 8 (MWU p <0.05; Fig 4.12, 
Table 4.10). No other significant differences were observed with blood vessel 
density  in  Zone  3  (MWU  p  >0.05;  Fig  4.12,  Table  4.10).  Groups  5  and  7 
demonstrated no vessels within pores in Zone 3.   
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Fig 4.12 Box plot demonstrating the blood vessels density/mm
2 of each porous implant group 
from inner most zone, Zone 3. 
 
 
Table 4.10 Pair-wise (MWU) Comparisons  
  Grou
p 1 
Group 2  Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Group 1    0.197  0.914      0.225     
Group 2          0.002      0.403 
Group 3        0.050  0.018  0.215     
Group 4          0.003    0.005   
Group 5                0.036 
Group 6              0.779  0.215 
Group 7                0.087 
Group 8                 
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Qualitative Assessment  
 
Light  microscopy  provided  evidence  to  support  the  quantitative  data.  (Fig 
4.13- 4.20) with Groups 1, 2 and 4 show dense, well order soft tissues filling 
the entire pore. Extensive infiltration across the entire implant was observed in 
these  groups.  These  characteristics  were  consistent  with  tissue  infiltration 
data  (Fig 4 . 0 4 ,  4 . 0 5  a n d  4 . 0 6 ,  Fig  4.13  and  4.14).  Little  open  space  was 
visible and intimate contact at the tissue implant interface suggested stable 
integration  (Fig  4.15).  Moreover,  preferential  collagen  deposition  appeared 
evident  around  interconnecting  struts  in  these  implants  groups.  No  pro-
inflammatory cells could be indentified (Fig 4.16). Large numbers of individual 
cells  populated  pores  across  the  entire  implant  in  Groups  1,  2  and  4,  in 
support of the quantitative data (Fig 4.07, 4.08 and 4.09) (Fig 4.16).  Blood 
vessels  were  clearly  visible  with  endothelial  nuclei  punctuating  in  a  ring 
creating  a  lumen.  More  of  these  vessels  were  observed  in  more  open 
structures associated with Groups 2 and 4 (4.10, 4.11 and 4,12), suggestive 
of  a  capillary  network  throughout  the  implant.  No  necrotic  tissue  or 
degradation was evidenced (Fig 4.18). 
 
Figs 4.19 and 4.20 show less dense soft tissue. These observations were 
associated  with  implant  groups  with  a  less  open  structure,  which  also 
correspond with lower cell nuclei densities (Fig 4.07, 4.08 and 4.09). Tissue 
integration  within  theses  groups  saw  gaps  with  little  interface  formation 
between  tissue  and  pore  edge.  Neovascularisation  was  not  observed 
throughout  implants  in  Groups  5,  6,  and  7,  supportive  of  the  blood  nuclei 
density data (Fig 4.10, 4.11 and 4.12), (Figs 4.19 and 4.20). 
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Figure 4.13. Light microscopy image sections stained with Toluidine blue of a Group 4 implant 
at Zone 1. High magnification image of dense, well-ordered soft tissue infiltration. 
 
Figure 4.14. Light microscopy image sections stained with Toluidine blue of a Group 4 implant 
at Zone 1. High magnification image of dense, well-ordered soft tissue infiltration. 
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Figure 4.15 Light microscopy image sections stained with Toluidine blue of a Group 1 implant 
at Zone 2. High magnification image of dense, well-ordered soft tissue infiltration with intimate 
contact (arrows) between pore edge and soft tissues. 
 
Figure 4.15 Light microscopy image sections stained with Toluidine blue of a Group 2 implant 
at Zone 3. Low magnification imagine of dense, well-ordered soft tissue preferentially 
depositing collagen around interconnecting struts (arrows). 
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Figure 4.17 Light microscopy image sections stained with Toluidine blue of a Group 3 implant 
at Zone 1. Dense, well-ordered soft tissue, preferentially depositing collagen around 
interconnecting struts (arrows) with distinct cell nuclei populating the implant pore. 
 
Figure 4.18 Light microscopy image sections stained with Toluidine blue of a Group 4 implant 
at Zone 1. High magnification image of dense, well ordered soft tissue with extensive blood 
vessel formation (arrows). 
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Figure 4.19 Light microscopy image sections stained with Toluidine blue of a Group 7 implant 
at Zone 2. High magnification image of less dense soft tissue with poor contact (arrows) 
between pore edge and soft tissues. 
 
Figure 4.20 Light microscopy image sections stained with Toluidine blue of a Group 7 at Zone 
1. Low magnification image of less dense soft tissues with poor contact (arrows) between 
pore edge and soft tissues. 
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4.5- Discussion  
	 ﾠ
Subcutaneous soft tissue infiltrated throughout all porous implant groups after 
4-weeks in vivo except Group 9. It has been hypothesised that the anatomical 
and  physiological  characteristics  associated  with  soft  tissues  will  require  a 
more  open  structure  to  maintain  viable  tissue  compared  with  bone  tissues 
(Hacking et al 2000). Group 9 pore diameter was 250µm and therefore may 
have been too small to allow tissue infiltration. These data are in support of 
LaBerge et al. (1990) who observed fibrous encapsulation of implant with pore 
diameters  of  300µm  rather  than  infiltration.  However  others  dispute  this 
(Taylor  and  Smith  1972,  Bobyn  et  al  1982,  Hacking  et  al  2000)  and,  in 
contrast to my results, have observed soft tissues infiltrating structures with 
such  diameters.    A  contributing  factor  to  these  results  and  my  own  may 
involve  relative  movement  of  the  implant  structures  in  vivo.  Bobyn  et  al. 
(1982) secured implants into the subcutaneous soft tissue by suturing them, 
thereby  decreasing  relative  movement  in  situ  and  allowing  cell  and  tissue 
infiltration into significantly smaller pore dimensions. This was not performed 
in my study, nor by LaBerge et al. (1990), and both of these investigations 
showed little or no soft tissue infiltration with such dimensions.   
  
Alternatively the successful implant groups in my study, when incorporated 
into an ITAP flange, may increase in the degree of dermal tissue infiltration, 
as the bone-anchored stem will limit relative implant movement in vivo.  Pore 
diameters  greater  than  700µm  supported  extensive  tissue  infiltration 
compared  with  less  open  structures.  Groups  1,  2  and  4  all  demonstrated 
superior  tissue  infiltration  compared  with  other  groups  across  their  entire 
structure. The open structure in these implant groups facilitated the flow of 
blood and body fluid into the structure which supports early attachment of 
cells.    
 
Group 3 implant structures appeared not to follow the trend, observing lower 
soft tissue infiltration despite possessing large pore diameter of 700µm. The 
interconnecting  strut  dimension  of  400µm  in  Group  3  implants  may  have 
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The larger diameter of the strut will take up more free space within the 3-
dimensional network of the implant structure, also taking up the free space 
created by the larger pore size. 
 
Hacking  et  al.  (2000)  observed  soft  tissue  infiltration  throughout  porous 
tantalum implants at 4-weeks. They also noted an increase in tissue infiltration 
over time and an associated increase in attachment strength by mechanical 
testing.  If the degree of tissue infiltration is directly linked to tissue attachment 
strength, it could be suggested that the dimensions of Groups 1, 2 and 4 in 
my study support increased soft tissue attachment strength.  
 
An  ITAP  patient  has  reported  near  normal  functionality  as  a  result  of  the 
treatment (Kang et al 2010). This increases the physical demand on the soft 
tissue implant interface and subsequently, a device that supports increased 
tissue attachment strength would be more favourable.  
 
In my study, pore diameter of 500µm or larger was required to observed soft 
tissue  infiltration  as  no  data  could  be  collected  from  implant  Group  9. 
Interestingly bone tissue has been shown to infiltrate into defined pores below 
this diameter (Howe et al 1973), which is possibly associated with movement 
of the implants. For bone in-growth to occur micro-motion has to be minimal, 
however soft tissue implants (particularly those in muscle) will be subjected to 
the large movements associated with contraction of these muscles.  Even if 
the implants were secured within the muscle, motion may be great due to the 
mismatch in modulus, which is so much greater between titanium alloy and 
soft tissues than with bone.      
 
Hacking et al. (2000) suggested that soft tissues require larger area in which 
to  infiltrate  into  and  metabolise.  This  may  account  for  unattainable  results 
from Group 9 implants.  Collagen appeared to preferentially deposit at the 
pore  edges  and  interconnecting  struts,  extensively  in  Groups  1,  2  and  4. 
These  features  are  indicative  of  soft  tissue  integration.  Albrektsson  et  al. 
(1981)  define  tissue  implant  integration  as  the  interaction  of  collagen  and 
metal  oxide.  Howe  et  al.  (1974)  also  noted  these  features  in  collagen 	 ﾠ 184	 ﾠ
deposition around pore edges at the bone implant interface. Pendegrass et al. 
(2006) showed how collagenous Sharpey’s fibres anchor dermal tissue to the 
deer antler pedicle.    
 
It has been suggested that a lower volumetric porosity will take less time to 
infiltrate  with  bone  tissue  compare  to  an  implant  with  a  greater  volumetric 
porosity (Bobyn et al 1980). This trend is not observed in my study as the 
larger pore diameters observed significantly increased soft tissue infiltration. 
Ponder et al. (2009) suggest successful infiltration with bone tissue can be 
achieve with a pore diameter of 450µm, which is significantly smaller to the 
1000µm and 700µm diameter pores successful in this study. By comparison, 
there  are  obvious  differences  in  tissue  type  between  this  study  and  mine. 
However,  they  went  on  to  suggest  that  there  could  be  a  minimum  size 
requirement to facilitate the influx of tissue. A much larger pore diameter may 
support  vascularisation,  allowing  tissue  respiration  and  promoting 
osteogenesis (Ponder et al 2009).  
 
Groups 1 and 2 showed significantly increased cell nuclei density compared 
with other implant groups. Group 4 also exhibited a high level of cell nuclei 
density compared with Group 3 implant, significantly so in Zone 3, despite 
both possessing the same pore dimensions demonstrating the importance of 
the strut size. The cellular component of the many soft tissues, especially the 
subcutaneous tissue in this study, are fibroblasts (Alberts et al 2002) and are 
identifiable  in  the  histological  analysis.  Toluidine  blue  stains  nucleic  acids 
within the cell nuclei, making fibroblasts easily identifiable.  
 
It is my suggestion that the observed increases in cell nuclei density (seen in 
Groups 1 and 2, and to a lesser degree 4) can be linked to the structural 
dimensions possessed by the implant groups. The structural environment may 
support the chemotactic movement of fibroblasts across the entire implant.  
 
Fibroblast migration across porous titanium alloy has been demonstrated, in 
limited fashion, in vitro (Cheung et al 2007) and can be controlled in vivo by 	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decreasing  the  free  space  between  pores  (Vrana  et  al 2 0 1 1 ) .  Cell  nuclei 
densities between Zone 1 and 3 were not significantly different for Groups 1, 2 
or 4. This suggests a uniform movement of cells across the entire implant 
structures. Surface roughness on EBM implants increases, compared to more 
established  fabrication  methods  (Koike  et  al  2011),  which  may  support 
fibroblast  migration  throughout  the  implant  surface.   Contact  guidance  and 
micro-structured  surfaces  may  aid  fibroblast  migration  along  the 
interconnecting strut network (Walboomers et al 1999). The increases in cell 
nuclei  density  may  result  in  an  increase  in  collagen  deposition,  discussed 
earlier, as fibroblasts are well established as a collagen secreting cell type 
(Alberts et al 2002). 
 
Long-term  in  vivo  success  relies  on  the  early  formation  of  an  extensive 
vascular  network  (Nelson  et  al 1 9 8 3 ) .  Undoubtedly  cell  density  will  be 
associated with the invasion of blood vessels. Blood vessels were observed 
across the entire implant structure in Groups 1, 2, 3, 4 and 8. Groups 2 and 4 
saw  the  highest  blood  vessels  densities,  with  no  significant  differences 
between Zones.  The 400µm strut dimension, of Groups 1 and 3, may have 
detrimentally  influenced  the  vascularisation  in  these  implant  groups  by 
lowering the volumetric porosity, taking up free space. The biological impact 
of  re-vascularisation  provides  nutrients  and  facilitates  the  removal  of 
metabolic products, supporting healthy soft tissue (Taylor and Smith, 1972). 
Porous titanium implants with much smaller inter-porous spaces (150µm) fail 
to  support  blood  vessel  formation  (Schultz  et  al  2007).  Hypoxic  conditions 
associated with the lack of blood vessels may have detrimentally affected soft 
tissue  growth  within  less  open  structures,  conversely,  the  more  open 
structures of implant Groups 2 and 4 allow soft tissue to flourish as a well-
oxygenated environment was present.  
 
My study differentiates itself from others in the quantification of soft tissue 
infiltration. I accept that I have not performed any mechanical testing on the 
strength of tissue attachment to the implant, where other studies have (Bobyn 
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attachment positively correlates with pore size (Bobyn et al 1982) and time in 
vivo (LaBerge et al 1990).   I have extensively quantified the tissue within my 
implant structures, I believe the data are robust and can be compared with 
others (Bobyn et al 1982, LaBerge et al 1990, Hacking et al 2000), who have 
suggested strength of attachment and tissue infiltration positively correlate.  
To my knowledge these studies have not quantified tissue infiltration, rather 
qualitatively described it. Therefore I can postulate that in the groups where I 
have  observed  significant  increases  in  soft  tissue  infiltration  and 
vascularisation,  it  is  likely  that  those  structures  would  demonstrate  a 
significantly higher degree of attachment strength.  Should they be implanted 
for  longer  time  periods  (to  potentially  increase  dermal  tissue  integration  to 
ITAP  devices)  can  also  be  suggested  that  mechanical  strength  would 
increase.  Furthermore,  the  EMB  technique  employed  in  my  study  created 
continuous 3-D porous structure compared with single (LaBerge et al 1990) or 
several  (Bobyn  et  al  1982)  layered  porous  coating.  Hacking  et  al.  2000 
demonstrated an increase in mechanical fibrous tissue attachment strength to 
continuous porous tantalum implants compared with these authors.     
 
4.6- Conclusion 
 
Owing  to  my  methods  of  data  collection  I  have  met  the  pre-determined 
hypotheses of this experimental chapter, with the exception of implant group 9.   
The results from my study allow soft tissue infiltration to be optimised as a 
function of pore and strut diameter. These implant dimensions were made 
possible by the EBM process, which would otherwise be unachievable in our 
laboratory.  Group  4  exhibited  significantly  higher  blood  vessel  densities 
across the entire implant structure compared with other implant groups and 
this structure was taken forward in my next chapter where I investigate the in 
vivo soft tissue in-growth.  If successful in this study this structure should also 
be considered for a clinical ITAP flange. The formation of blood vessels, re-
vascularising the soft tissues surrounding the skin implant interface will be 
beneficial in the long-term stability of the skin seal. The incorporation of a 
flange structure to and ITAP device may provide an opportunity to control the 	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soft  tissue  interface  and  in  turn  develop  a  stable,  biological  seal  at  the 
transcutaneous point.  
 
The ultimate goal for ITAP devices is clinical longevity; the use of an EBM 
ITAP  flange  must  be  tested  in  vivo  long-term  to  characterise  the 
transcutaneous implant interface and observe any changes.  	 ﾠ 188	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Chapter 5- An in Vivo Assessment of Functionalised ITAP Flanges in a 
Long-term Amputation Model. 	 ﾠ 189	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Chapter 5 
5.1- Introduction  
 
Soft  tissue  attachment  and  integration  in  vivo  is  critical  for  the  long-term 
success of ITAP devices. Failure modalities are characterised by the upper 
layers of the skin dividing down along the implant shaft in an attempt to re-
establish continuity (discussed in Chapter 1.2). Dermal attachment to ITAP 
devices  physically  hinders  epidermal  downgrowth  and  promotes  clinical 
longevity (Kang et al. 2010).  
 
In vivo implantation of transcutaneous devices, such as ITAP, breaks the skin 
barrier. In doing so, they trigger a wound healing cascade (Chapter 1.2vi) as 
the  skin  reacts  against  the  foreign  body  and  attempts  to  re-establish  skin 
continuity. The initial reaction or early phase acts to plug the wound space, to 
manage homeostasis. This is followed by the cellular phase, where various 
cell  types  migrate  to  the  site  and  act  to  limit  infection,  re-cellularise  and 
remodel the tissue (Lanza et al 2000).  
 
With the failure modalities of transcutaneous devices linked to wound healing 
mechanisms the functionalisation of devices act to aid these mechanisms and 
allow the foreign body to successfully interface with the soft tissues of the skin. 
Chimutengwende-Gordon  et  al.  (2011)  have  shown  silanised  fibronectin  to 
titanium alloy substrates implanted in subcutaneous soft tissue in an ovine 
model had a positive effect at the tissue implant interface. I have developed 
an  in  vitro  functionalisation  technique  using  silanised  RGD-polypeptides, 
which increases HDF attachment strength compared with polished titanium 
alloy substrates. Furthermore, results showed no significant difference in HDF 
attachment compared with substrates functionalised with silanised fibronectin, 
as described by Chimutengwende-Gordon et al. (2011). The implants used in 
this study were not subject to axial load nor were they in a transcutaneous 
setting, both critical features of an ITAP model (Chimutengwende-Gordon et 
al 2011).  
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Sterilization techniques, such as those implicated by the National Institute of 
Health  an  Excellence  (NICE)  including  gamma  irradiation,  will  degrade  the 
quaternary  structure  of  fibronectin  and  render  it  ineffective.  This  will  limit 
fibronectin’s  use  clinically,  despite  the  biological  gains.  Synthetic  RGD-
polypeptides, such as those used in the development of my functionalisation 
technique,  are  not  subject  to  the  same  degree  of  degradation  as  their 
structures  are  in  primary  form.  They,  therefore,  may  be  able  to  overcome 
these issues and have a long-term clinical application. This however has not 
so far, been tested.  
 
Porous implants promote tissue integration as they support the influx of cells 
in vitro and tissue in vivo (Cheung et al. 2007 and Chapter 4). I have shown 
that varying pore and strut dimensions can optimise soft tissue integration. 
Cells can infiltrate across the entire implant allowing intimate tissue contact 
and  revascularisation  of  the  tissue.  A  pore  diameter  of  700µm  and  strut 
diameter  of  300µm  were  observed  in  Chapter  4  to  facilitate  optimal 
subcutaneous  soft  tissue  integration  compared  with  other  larger  and  small 
dimensions  tested.  Porous  titanium  alloy  transcutaneous  implants  support 
skin  integration  in  vivo  with  varying  degrees  of  infiltration  dependent  on 
structure and implantation time. Epidermal downgrowth was still observed in 
this study (Farrell et al 2013). Squier and Collins (1981) observed an inverse 
relationship between epidermal downgrowth and pore size. They defined the 
critical  feature  of  a  transcutaneous  implant  to  be  its  ability  to  support 
connective tissue, which can infiltrate and anchor into pore spaces.     
 
A  combination  of  proteins  with  a  porous  structure  has  previously  been 
investigated.  Keratin  has  been  covalently  coupled  to  a  porous  coated 
transcutaneous  device  with  varied  success.  No  fibrous  capsule  presented 
after  3-months  in  vivo y e t  e p i dermal  downgrowth  was  still  observed 
(Jeyapalina et al. 2013). Laminin-5 has also been used in conjunction with 
porous structures in an attempt to attach the migrating epithelium to dental 
implants. Histological comparisons offered no discernable difference between 
biological  functionalised  porous  implants  and  uncoated  porous  controls 	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(Werner et al 2009). Laminin-5 is present in the hemidesmosome complex 
that attaches the oral epithalium to basal lamina and Keratin is a structural 
protein on the outmost layer of the skin, not present in the dermis (Chapter 
1.2v and Alberts et al 2002).  
 
RGD-polypeptides  are  ubiquitous  in  cell  attachment  mechanisms  in  the 
dermis (Chapter 1.2v and Alberts et al 2002). Attachment of the dermis to 
implant  shafts  increases  longevity  by  way  of  a  physical  blockage  to  the 
migrating  epidermis.  RGD-polypeptides  may  provide  that  opportunity  to 
functionalise  the  ITAP  transcutaneous  portion  to  increase  the  early 
attachment of the dermis and support the formation of a tight biological seal at 
the transcutaneous interface.      
 
The ITAP flange is designed to mimic the transcutaneous interface of the deer 
antler.  A  highly  porous  pedicle  allows  dermal  tissue  infiltration  over  its’ 
increased  surface  area.  This  creates  a  tight  biological  seal  at  the 
transcutaneous interface. The ITAP flange promotes soft tissue integration by 
providing  an  increased  surface  area  for  dermal  soft  tissue  to  attach  and 
significantly reducing epidermal downgrowth. To achieve this, it follows the 
mechanism described above, where connective fibres anchor perpendicular to 
the  porous  pedicle  (Pendegrass  et  al  2006).  Porous  titanium  coatings  on 
flanged  implants  at  the  soft  tissue  interface  have  been  shown  to  reduced 
infection  compared  with  uncoated  controls  in  a  bone-anchored, 
transcutaneous amputation model (Isackson et al 2011 and Jeyaplina et al 
2012), which suggests a tight seal at the transcutaneous interface. HA coating 
of  the  ITAP  flange  further  increases  soft  tissue  integration  by  providing  a 
biocompatible surface in which to allow soft tissue to attach. This has been 
shown to support clinical longevity (Kang et al 2010).  
 
Despite numerous attempts, epidermal downgrowth has yet to be completely 
eradicated in bone-anchored, transcutaneous devices in vivo.  There is no 
study  that  biologically  functionalised  a  totally  porous  flange  with  RGD-
polypeptides,  in  a  long-term  bone-anchored  transcutaneous  in  vivo m o d e l .  	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This chapter aims to combine the techniques developed in my thesis thus far 
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 ﾠ 193	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5.2- Aims and Hypotheses 
 
This  chapter  aims  to  determine  the  effect  of  functionalising  the  ITAP 
flange on the skin implant interface in a long-term in vivo model.  
 
More specifically I aim to compare the effects of a porous EBM flange with the 
current discoid flange perforated with drilled holes on soft tissue integration at 
the transcutaneous interface. I also want to observe the effect of biologically 
functionalising the ITAP flange (either porous or non-porous) with silanised 
RGD-polypeptides  with  the  current  clinical  standard,  a  HA  coated 
transcutaneous portion.  
 
This chapter aims to test the following hypotheses: 
 
An  RGD-polypeptide  functionalised  porous  flange  will  support  dermal 
interface  formation  and  limit  epidermal  downgrowth  compared  with  the  HA 
coated non-porous flange.    
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5.3- Material and Methods 
5.3i- Study Design 
 
Table  5.01  outlines  the  4  experimental  groups  tested  in  this  study.  ITAP 
devices  were  designed  to  incorporate  structural  and  biological 
functionalisations developed in my previous experimental chapters. Implants 
were manufacture from titanium alloy (TiAl6V4), the alloy used throughout my 
thesis.  A  3-D  porous  structure  was  incorporated  into  the  flange.  This  was 
based on the successful dimensions observed in Chapter 4, which were a 
pore  diameter  of  700µm  and  strut  diameter  of  300µm.  A  discoid  collar 
perforated  with  24,  drilled  holes  acted  as  the  control  (detailed  dimensions 
published in Appendix 4). Implants were biological functionalised by silanising 
7mM of RGD-polypeptides, as observed as the optimal concentration for HDF 
attachment in vitro for Chapter 3. HA coated structures were used as controls 
for both porous and non-porous flanges. ITAP devices were implanted trans-
tibially into an ovine model for a period of 5-months.      
Table 5.01 Study Description 
Group (n=6)  Functionalisation    Experimental Details 
Flange Control   Flange perforated with 24 drilled 
holes,  0.7mm  in  diameter.  HA-
coated  (5.3ii).  This  is  the 
current  clinical  standard 
(Kang et al 2010). 
5-months  in  vivo. 
Removed  en  bloc  and 
processed  for  hard-grade 
resin  histology  and 
interface characterisation.   
Flange RGD   Flange perforated with 24 drilled 
holes,  0.7mm  in  diameter.  The 
drilled flange silanised with RGD 
polypeptide (based on results of 
Chapter 3).   
5-months  in  vivo. 
Removed  en  bloc  and 
processed  for  hard-grade 
resin  histology  and 
interface characterisation. 
Porous Control   Porous  Flange  with  pore  and 
strut dimensions of 700 and 300 
respectively. HA-coated (5.3ii).  
5-months  in  vivo. 
Removed  en  bloc  and 
processed  for  hard-grade 
resin  histology  and 
interface characterisation. 	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Porous RGD   Porous  Flange  with  pore  and 
strut dimensions of 700 and 300 
respectively. The Porous flange 
silanised  with  RGD  polypeptide 
(based on results of Chapter 3).  
5-months  in  vivo. 
Removed  en  bloc  and 
processed  for  hard-grade 
resin  histology  and 
interface characterisation. 
 
 
5.3ii- Implant Preparation 
 
Bone-anchored portion of the ITAP implant shaft were all HA-coated (Plasma 
Biotel, Derbyshire, UK), irrespective of their design features. Those implants 
that  acted  as  controls  to  the  biologically  functionalised  implants,  had  the 
flange structure HA-coated in the same manner. Full implant dimensions are 
published in Appendix 4 but in brief, the bone-anchored portion extended over 
29mm and tapered from a diameter of 5mm to the base of 4mm diameter (Fig 
5.01 B and D).  
 
Biological functionalisation of the ITAP flanges was achieved by silanisation of 
RGD-polypeptides  to  the  titanium  alloy  implant  surface.  The  protocol  was 
based upon the results of Chapter 3, as used in Chapter 3 Study 6. 
 
5.3iii- Surgery 
 
All  surgery  was  carried  out  in  accordance  with  the  Animal  (Scientific 
Procedures)  Act  1986  (https://www.gov.uk/government/publications/animals-
scientific-procedures-act-1986-amendment-regulations)  and  in  conjunction 
with  University  College  London’s  Statement  of  the  Uses  of  Animals  in 
Research (http://www.ucl.ac.uk/slms/research/animal-use).    
  
Ovine adult (fully mouthed and skeletally mature), female Mules (breed) were 
used for the in vivo study.  
 
Premedication of 0.2mg/kg xylazine, Rompun 2% (Bayer Healthcare, UK) was 
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procedure. Ketamine hydrochloride (Ketaset, Fort Dodge Animal Health Ltd., 
UK) induced anesthesia at 2mg with 2.5mg of midazolam hypnovel (Roche 
Products  Ltd.,  UK),  both  were  administered  intravenously.  Animal  subjects 
were  intubated,  5ml  of  cefalexin  ceporex  (Schering-Plough  Animal  Health, 
UK) was administered to achieve antibiotic prophylaxis and anesthesia was 
maintained by inhalation with isoflurane at 2%.  
 
During anaesthesia, each animal was positioned in the dorsal recumbency. 
The skin overlaying the medial aspect of the tibia and surrounding area were 
shaved,  bi-laterally,  and  treated  with  betadine-povidine  scrub  solution  and 
iodine aspetic solution (Dynarex, Quick Medical, Washington, USA) followed 
by alcoholic chlorhexidine scrub (Cardinal Health, Ohio, USA) preoperatively. 
 
The tibial tuberosity was palpated through the skin and the first incision was 
made approximately 3cm distally to the tuberosity over the medial aspect of 
the left tibia, this became the proximal position. The soft tissue was dissected 
off the bone to expose it for ease of drilling. A 4mm diameter hole was drilled 
through both tibial cortices and enlarged to 4.8mm at the top end to construct 
a tapered structure. The construct was reamed to accommodate each implant 
individually  and  then  press  fitted  in  such  that  no  micro-movement  was 
apparent and the base of the flange was 3mm from the bone. The dermal 
tissue and fascia was draped over the flange and sutured with absorbable 1-0 
Vicryl (Ethicon Inc., New Jersey, USA). The uppermost layers of the skin were 
also  sutured  with  2-0  Vicryl  (Ethicon  Inc.,  New  Jersey,  USA)  around  the 
uppermost  stem  of  the  ITAP  device  creating  a  transcutaneous  portion. 
Wounds were coated in excess with Opsite (Smith and Nephew plc, London, 
UK)  and  bandaged.  This  process  was  repeated  for  all  4-sites  per  animal. 
Distal sites were created relative to proximal sites in the given tibia, such that 
the original incision was made approximately 3-cm below the first site. Intra-
operative images can be observed in Fig 5.01, A and C.   
 
Table 5.02 in vivo Implant Position 
Animal 6034  Right Leg  Left Leg  
Proximal site   Flange RGD   Porous Control   	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Distal site   Flange Control   Porous RGD 
 
Animal 6064  Right Leg  Left Leg  
Proximal site   Flange Control   Porous Control   
Distal site   Porous RGD  Flange RGD  
 
Animal 6046  Right Leg  Left Leg  
Proximal site  Porous RGD  Porous Control   
Distal site   Flange RGD   Flange Control  
 
Animal 6073  Right Leg  Left Leg  
Proximal site  Flange RGD   Porous Control   
Distal site   Flange Control   Porous RGD 
 
Animal 6059  Right Leg  Left Leg  
Proximal site  Porous RGD  Flange Control  
Distal site   Flange RGD   Porous Control   
 
Animal 6027  Right Leg  Left Leg  
Proximal site   Flange RGD   Porous Control   
Distal site   Porous RGD  Flange Control  
 
5.3iv- Histological Processing  
 
Implants remained in situ for 5-months, at which point animal subjects were 
euthanized by intravenous injection of 0.7mg/kg IV Sodium Pentobarbitone 
(Pharmasol  Ltd.,  Hampshire,  UK)  into  the  jugular  vein.  All  implants  were 
retrieved,  taking  care  to  remove  all  local  tissue  to  the  implant  without 
disruption.  Following  retrieval,  implants  were  immediately  housed  in  10% 
formal saline, for 1-week.  
 
All samples were prepared for hard grade resin histology is the same manner 
outlined in Chapter 4.3iv. A full laboratory log can be observed in Appendix 4. 
Longitudinal  sections  were  cut,  through  the  centre  of  each  implant  and 
associated  tissues,  ground  and  polished  to  a  thickness  of  <  100µm a n d  
stained with Toluidine Blue.   	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A  B  
C  D  
Fig 5.01 Functionaliseed Implant Groups; A) Flange Control, intra-operative, B) Flanged RGD 
pre-silanisation, C) Porous Control intra-operative (Right), Porous RGD intra-operative (Left) 
and D) Porous RGD pre-silanisation. 
 
5.3vi- Histological Analysis and Data Collection 
 
Light Microscopy was used to characterise the soft tissue implant interface. 
To assess the soft tissue implant interface 4 parameters were measured as 
described below. 
1)  Epidermal downgrowth was measured by length, using the intercept 
method, described by Pendegrass et al. (2006)  
2)  The  percentages  of  epidermal  attachment  to  the  implants  were 
calculated,  based  on  measurements  of  epidermis  peri-implant 
(Pendegrass et al 2006). 
3)  The degree of dermal tissue infiltration was measured within central 
pores or drilled holes within the flange structures of each implant by the 
number of cell nuclei as a function of area (µm
2)  
4)  The number of blood vessels within the pores as a function of area 
(µm
2), as described in Chapter 4.3vi, was also measured.   	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Additionally  a  semi-quantitative  percentage  fill  score  was  assigned  to  the 
amount of tissue infiltration with a pore or drilled hole within flange structure, 
also described previously (Chapter 4.3vi).  
 
5.3vii- Statistics 
 
Statistical  analysis  was  performed  in  the  same  manner  as  discussed  in 
Chapter 2.3x with significance considered at the p = <0.05 level.  	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5.4- Results 
Animal 6034 
 
This animal subject showed gross signs of impaired locomotion and appeared 
lame on the back, right leg.  
 
The  right  leg  proximal  implant  site  presented  with  an  excess  of  strong 
smelling exudate. Microbiology analysis of cultures from the wound exudate 
concluded  moderate  severity  of  Escherichia.  coli,  Corynebacterium, 
Peptostreptococcus  spp,  and  Bacteriodes  spp.  Radiographs  suggested  no 
bone trauma. Both investigations are present in Appendix 4. 
 
It was also noted that this animal had sustained weight loss of 10kg from 
initial  implantation  surgery  to  this  point.  Early  euthanasia  was  agreed  and 
achieved by the method discussed in 5.3iv.  
 
This  animal  subject  was  repeated  in  order  to  limit  the  effect  on  statistical 
analysis.   
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Epidermal Downgrowth 
 
Statistical analysis by the Kruskal-Wallis method demonstrated no significant 
differences  between  the  4  implant d e v i ces,  p  >0.05,  Fig  5.02.  Table  5.03 
displays the median downgrowth values and 95% confidence intervals for all 
implant  groups.  Median  downgrowth  lengths  associated  with  RGD-
polypeptide  functionalised i m p l a n t s   were  higher  compared  with  control 
implants, though these differences were not significant (Fig 5.02, Table 5.03). 
 
Table 5.03 Median Downgrowth Figures for ITAP Devices.  
Group  Median/ µm   95% Confidence Intervals 
Flange Control   7185.5  5941.3-7900.87 
Flange RGD  8178.0  6255.14-11299.41 
Porous Control   5359.0  4646.77-10409.23 
Porous RGD  7878  5702.48-9195.52 	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Fig 5.02. Box and Whisker plot demonstrating the length of Downgrowth (µm) for 
functionalised ITAP flanges by drilling (red), drilling and silanised with RGD-polypeptides 
(green), porous (blue) and porous silanised with RGD-polypeptide (yellow). 	 ﾠ 203	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Epidermal Attachment 
 
No significant difference was observed in the epidermal attachment between 
the 4 implant devices, a Kruskal-Wallis test demonstrated p >0.05, Fig 5.03. 
Table 5.04 displays the median percentages for epidermal attachment and 
95% confidence intervals for all implant groups. Median percentage values 
associated  with  RGD-polypeptide  functionalised  implants  were  lower 
compared with control implants, though these differences were not significant 
(Fig 5.03, Table 5.04). 
 
Table 5.04 Median and 95% Confidence Intervals for Percentage Epidermal Attachment.  
Group  Median/ Percentage   95% Confidence Intervals 
Flange Control   50.9  32.47-63.73 
Flange RGD  44.54  17.16-58.67 
Porous Control   39.4  22.0-57.63 
Porous RGD  27.2  21.81-49.02 	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Fig 5.03. Box and Whisker plot demonstrating the percentage of Epidermal Attachment for 
functionalised ITAP flanges by drilling (red), drilling and silanised with RGD-polypeptides 
(green), porous (blue) and porous silanised with RGD-polypeptide (yellow). 	 ﾠ 205	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Blood Vessel Density 
 
A Kruskal Wallis test demonstrates the data were from different populations 
as p <0.05. Highest blood vessel density was observed in soft tissue within 
porous controls. These data were significantly higher compared with flange 
control implants (MWU p <0.05; Fig 5.04, Table 5.05). Significantly increased 
blood  vessel  density  was  also  observed  in  soft  tissue  within  porous  RGD 
implants compared with flange RGD implants (MWU p <0.05; Fig 5.04, Table 
5.05). There was no significant difference in blood vessel density between 
flange controls and flange RGD implant groups or porous controls and porous 
RGD implant groups (both MWU p >0.05; Fig 5.04, Table 5.05). These data 
suggest that the porous structures promote better invasion of blood vessels 
from the surrounding tissues. 
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Fig 5.04. Box and Whisker plot demonstrating the blood vessel density of soft tissue with 
functionalised ITAP flanges by drilling (red), drilling and silanised with RGD-polypeptides 
(green), porous (blue) and porous silanised with RGD-polypeptide (yellow). 
 
 
 
Table 5.05- Pair-Wise (MWU) Comparisons  
  Flange Control   Flange RGD  Porous Control   Porous RGD 
Flange Control   	 ﾠ 0.594  0.001   
Flange RGD  	 ﾠ     0.001 
Porous Control   	 ﾠ     0.854 
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Cell Nuclei Density  
 
These data were from the same population as a Kruskal Wallis test was not 
significant,  p > 0.05.    Table  5.06  displays  the  median  percentages  for  cell 
nuclei density and 95% confidence intervals for all implant groups. All cell 
nuclei densities remained consistent despite functionalisation of the implant 
flanges (Fig 5.05, Table 5.06).  
 
Table 5.06 Median and 95% Confidence Intervals for Cell Nuclei Density.  
Group  Median/ Percentage   95% Confidence Intervals 
Flange Control   0.000585  0.000254 – 0.00152 
Flange RGD  0.000301  0.0000648 – 0.000813 
Porous Control   0.000513  0.000385 – 0.000675 
Porous RGD  0.00054  0.000386 – 0.000735 	 ﾠ 208	 ﾠ
 
 
Fig 5.05. Box and Whisker plot demonstrating cell nuclei density of soft tissue with 
functionalised ITAP flanges by drilling (red), drilling and silanised with RGD-polypeptides 
(green), porous (blue) and porous silanised with RGD-polypeptide (yellow). 
 
 
 
 	 ﾠ 209	 ﾠ
Dermal Tissue Infiltration 
 
Statistical analysis by the Kruskal-Wallis method demonstrated a significant 
difference between the 4 implant devices; p <0.05 Fig 5.06. Percentage of 
dermal tissue infiltration was significantly increased in porous RGD implant 
structures compared with flange RGD, MWU p <0.05. These data were also 
significantly  higher  compared  with  porous  control  implants,  MWU  p  <0.05; 
Table 5.06, Fig 5.06. There were no other significant differences observed in 
percentage of dermal tissue infiltration (Table 5.06, Fig 5.06). Again, these 
data suggest that porous flanges promote better soft tissue integration and 
that  is  increased  further  when  the  alloy  surface  is  enhanced  with  RGD-
polypeptide. 
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Fig 5.06. Box and Whisker plot demonstrating percentage of dermal tissue infiltration with 
functionalised ITAP flanges by drilling (red), drilling and silanised with RGD-polypeptides 
(green), porous (blue) and porous silanised with RGD-polypeptide (yellow). 
 
 
 
Table 5.06- Pair-Wise (MWU) Comparisons  
  Flange Control   Flange RGD  Porous Control   Porous RGD 
Flange Control   	 ﾠ 0.565  0.637   
Flange RGD  	 ﾠ     0.000 
Porous Control   	 ﾠ     0.001 
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Qualitative Assessment  
 
Downgrowth was evident, characterised by the epidermal cell layer tracking 
down  along  the  implant  shaft.  Distinct  gaps  were  observed  under  light 
microscopy between the implant shaft and soft tissue. This in conjunction with 
the  downgrowth  data  suggested  it  was  not  in  response  to  a  specific 
functionalised group. In some instances downgrowth led to defined pockets 
forming (Fig 5.07). Wound debris, such as clots, necrotic tissue and exduates, 
collected  between  implant  and  tissue  at  the  transcutaneous  portion.  This 
presented in a majority of instances, impeding interface formation (Fig 5.08). 
Where epidermal downgrowth was limited, intimate contact between tissue 
and implant shaft suggested a stable transcutaneous interface well above the 
flange  structure  (Fig 5 . 0 9 ).  Wide  ranging  epidermal  attachment  data  was 
collected due to epidermal soft tissue tracking down to the flange (Fig 5.10). 
Artifacts were common observations during the histological analysis resulting 
from histological processing. 
Soft tissue of the dermis integrated well within porous structures, infiltrating 
throughout  the  interconnecting  frameworks  of  titanium  alloy  structures  in 
many  instances  (Fig  5.11).  Ordered  collagen  formation  was  observed  in 
intimate contact with implant structures including natural recesses, created by 
the underside of the flange.  
Soft  tissue  present  within  porous  structures  was  well  vascularised  with 
rounded lumens and individual cells (Fig.12 and Fig 5.13). Where soft dermal 
tissue  infiltration  was  poor,  gaps  at  the  tissue  implant  interface  could  be 
observed (Fig 5.14).   
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Fig 5.07. Light microscopy image of a transcutaneous section stained with Toluidine blue of a 
Group 4 implant at Zone 1. Low magnification image of epidermal downgrowth and sinus 
track formation along the implant shaft (arrows). 
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Fig 5.08. Light microscopy image of a transcutaneous section stained with Toluidine blue of a 
Group 4 implant at Zone 1. Low magnification image of wound debris impeding epidermal 
attachment, forcing the cell sheet underneath the blockage before interfacing with the implant 
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Fig 5.09. Light microscopy image of a transcutaneous section stained with Toluidine blue of a 
Group 3 implant. Low magnification image of epidermal attachment, with limited downgrowth. 
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Fig 5.10. Light microscopy image (split in two) of a transcutaneous section stained with 
Toluidine blue of a Group 1 implant. Low magnification image of epidermal attachment taking 
place at the flange (red arrows).  
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Fig 5.11. Light microscopy image of a transcutaneous section stained with Toluidine blue of a 
Group 4 implant. Low magnification image of dermal tissue infiltration within a porous flange 
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Fig 5.12. Light microscopy image of a Group 3 transcutaneous section stained with Toluidine 
blue. High magnification image of dense, well-ordered dermal tissue with a number of blood 
vessels formed within a pore. 
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Fig 5.13. Light microscopy image of a Group 4 transcutaneous section stained with Toluidine 
blue. High magnification image of dense, well-ordered dermal tissue with a number of blood 
vessels formed within a pore. 	 ﾠ 219	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Fig 5.14. Light microscopy image of a transcutaneous section stained with Toluidine blue of a 
Group 1 implant. Low magnification image of dermal tissue infiltration within a drilled flange, 
poor contact at dermal tissue implant interface (red arrow). 
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5.5- Discussion  
 
Epidermal  Downgrowth  presented  in  all  implanted  groups  after  a  5-month 
period in vivo. No significant reduction in downgrowth could be attributed to 
any of the functionalisation techniques employed in my study. The percentage 
of epidermal attachment also observed no significant difference between the 
various functionalised ITAP flanges.  Despite the lack of significant difference 
between these data, the functionalisation techniques tested in my study had 
no  detrimental  effect  on  the  performance  of  the  transcutaneous  implant 
devices  compared  with  current  clinical  standard  (Kang  et  al  2010). 
Immediately  after  implantation  in  vivo  the  early  phase  of  wound  healing 
begins.  This  is  characterised  by  an  increase  in  bleeding  in  the  local  area, 
delivering clotting factors to plug the wound space. The fibrinogen and fibrin 
rich  clot  acts  to  provide  a  provisional  matrix  to  structurally  support  the 
migration of cells during later wound healing cascades (Lanza et al. 2000). 
 
Wound debris was clearly visible at the transcutaneous interface both macro- 
and microscopically of my retrieved implants. Farrell et al. (2013) describe a 
serocellular  crust  presenting  at  the  epidermal-implant  junction  with  their 
porous transcutaneous implants. 
 
Epidermal cell sheet followed the course of the debris before interfacing with 
the implant shaft or flange. Farrell et al. (2013) observed downgrowth of “a 
few millimeters”- but no specific data was offered in this regard. My study was 
performed over 5-months, which could account for larger measurements of 
epidermal downgrowth compared with these comments. I postulate that this 
presenting debris could have increased the degree of epidermal downgrowth, 
as it physically impeded the epidermal-implant interface.  
 
Epidermal  keratinocytes  do  not  express  integrin  alphaVbeta3  receptors  that 
have affinity for fibrinogen and fibrin within the clot (Kubo et al 2001). Without 
receptor interaction with the fibrinogen/fibrin rich clot, which sits between the 
epidermal-implant  interface,  the  epidermis  will  have  no  way  of  physically 
attaching to it therefore forcing the entire cell sheet to migrate under it. No 	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debris  or  physical  impedance  was  noted  by  Al-Ajam  et  al.  (2013),  which 
allowed  keratinized  epithelium  (epidermal  layer)  to  interface  with  implant, 
stably. To decrease epidermal downgrowth, limiting debris coagulating in the 
wound space is of paramount importance.  Surgical technique is an obvious 
factor that can be controlled, to limit the local trauma to skin and keep the 
wound  space  as  small  as  possible.  This  may  prevent  build  up  of  clots, 
potentially responsible for increasing the degree of epidermal downgrowth. 
 
The  wound  care  of  a  human  ITAP  recipient  contributed  to  stable 
transcutaneous interface, as no obvious evidence of debris, serocellular crust 
or exudates presented 2-years post implantation. The care regime involved 
daily cleaning and re-dressing (Kang et al 2010). The same standards are 
unachievable  within  an  ovine  model,  which  may  have  contributed  to  the 
formation of wound debris that ultimately increased epidermal downgrowth in 
my study, irrespective of the functionalisation techniques employed.  
 
There are obvious differences in skin anatomy of a human compared with an 
ovine  model.  Farrell  et  al.  (2013)  observed  no  significant  difference,  at  6-
weeks, on porous transcutaneous implant performance between haired and 
hairless  in  vivo  models.  Despite  these  data  the  authors  questioned  the 
likelihood of loose hairs collecting between epidermal-implant interface over 
time. This may have been a contributing factor in my study, in the collection of 
debris in such a long-term haired model, a factor that would not influence the 
human recipient to such a degree.   
 
Blood vessel density significantly increased within porous flanges compared 
with  drilled  flanges  with  RGD-polypeptides  appearing  to  have  no  effect  on 
vascularisation  of  the  soft  tissue.  3-D  porous  structures  can  support  the 
formation blood vessels, which in turn, can provide an innervating network for 
healthy soft tissue metabolism as results from Chapter 4 of my thesis showed. 
Extensive blood vessel formation was observed throughout porous structures 
with  the  same  dimensions  as  the  porous  flanges  in  this  chapter.  These 
implants  were  not  functionalised w i t h  R G D -polypeptides  and  still  exhibited 
significantly  increased  blood  vessel  formation.  Vascularisation  relies o n  	 ﾠ 222	 ﾠ
endothelial  cell  migration  and  subsequent  attachment.  Sprouting  blood 
vessels express the integrin alphaVbeta3 receptors as endothelial cells attach 
to form a new lumen (Brooks et al 1994). Feng et al. (1999) demonstrate how 
an  engineered  ECM  structure  can  influence  integrin  alphaVbeta3  receptor 
expression of endothelial cells, thereby regulating blood vessel formation. A 3-
D  fibrin  matrix  significant  increased  mRNA  levels  of  integrin  alphaVbeta3 
receptors over single layer ECM protein coats.  
 
I  postulate  that  the  3-D  porous  flange  may  act  as  the  provisional  matrix 
thereby inducing integrin alphaVbeta3 receptor expression on endothelial cells 
to a greater degree than drilled flange structures, implicating the structural 
environment  created  by  the  porous  flange  rather  than  the  biological 
functionalisation with RGD-polypeptides. The cascades of events that define 
wound healing occur over time. From vascularisation to be possible, biological 
cues  must  be  in  place  first  and  in  theory  will  not  occur  on  day  4,  post 
implantation.  
 
Results  from  Chapter  3  of  my  thesis  suggested  that  silanised  RGD-
polypeptides have the potential to remain immobilised on the implant in vivo 
up to this time-point. However I suggest that RGD-polypeptide cell attachment 
points,  by  this  time  period,  will  have  bound  ligands  during  early  interface 
formation  and  therefore  be  unable  to  directly  influence  blood  vessels 
formation, as observed.  
 
Cell density as determined by counting nuclei saw no significant differences 
across  all  functionalised  structures.  Both  structural  functionalised  flanges 
incorporated a 700µm diameter pore space for tissue to infiltrate. During the 
cellular phase of wound healing an influx of fibroblasts occurs to initiate the 
ECM  formation  by  secreting  collagen.  As  the  wound  becomes  stable  with 
structural  support  by  a  collagen  matrix,  the  requirement  for  fibroblasts 
decreases and wound healing enters the maturation phase. This is known as 
tissue re-modeling, the collagen ECM is maintained and there becomes less 
of a requirement on fibroblasts.   
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Implant retrieval occurred 5-months post implantation in my study, by which 
time the wound healing process must have entered its maturation phase. I 
postulate  that  no  significant  difference  in  cell  nuclei  density  was  observed 
between my functionalised devices was because the tissue had entered the 
maturation  phase.  Equilibrium  had  been  achieved  in  the  number  of  cells 
required to maintain collagen matrix.  
 
Farrell  et  al.  (2013)  saw  significant  differences  in  soft  tissue  infiltration  to 
various porous transcutaneous structures between 3-weeks and 4-6-weeks in 
vivo. However, no significant differences were observed between the various 
porous  structures  at  the  end  time-point  (4-6-weeks).  Sufficient  time  had 
elapsed for cell migration in vivo to even out as wound healing had entered 
the maturation phase, despite the porosity differences.      
 
A combination of RGD-polypeptides and porous flange significantly increased 
soft tissue infiltration compared with all other implant groups.  Early phase of 
wound healing aims to regulate homeostasis in response to skin breakage 
and lay down a basic structural framework in which to support the influx of 
cells  during  the  cellular  phase  of  wound  healing  (Lanza  et  al.  2000).  I 
postulate  that  the  3-D  porous  flange  silanised  with  RGD-polypeptides 
provides a provisional wound matrix to support the cellular phase of wound 
healing, which has translated in a significant increase in soft tissue infiltration 
compared with the other functionalised devices.  
 
The RGD-polypeptides will stimulate migrating fibroblasts to express integrin 
receptors, responsible for attachment. Xu and Clark (1996) demonstrated up-
regulation of integrin alpha3beta1 and alpha5beta1 receptors on fibroblasts in 
vitro. These receptors have a high affinity for the RGD binding domain and 
therefore it is logical to suggest the same up-regulation may occur within the 
3-D porous flange silanised with RGD-polypeptides that observed a significant 
increase in dermal tissue infiltration in this study. Silanised RGD-polypeptide 
substrates enhanced cell attachment in vitro (Chapter 2 and 3) and I expected 
favorable reaction in vivo as they have the potential to remain immobilised to 
the implant (Chapter 3) and support the influx of fibroblasts.  	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I  hypothesized,  at  the  beginning  of  this  chapter,  that  a  combination  of 
silanised RGD-polypeptides with a porous flange would support the formation 
of a stable transcutaneous interface. Jeyapalina et al. (2013) described the 
covalent coupling of keratin to porous titanium transcutaneous implants. They 
observed no impaired wound healing between 3- and 6-months in vivo despite 
the  additional  chemistry  associated  with  the  coating.  Warner  et  al.  (2009) 
suggest to observed differences attributed to the biological functionalisation 
with  Laminin-5  would  require  experiments  that  could  account  for  the  early 
wound healing cascades. I suggest that my data shows that silanised RGD-
polypeptides  had  a  transient  effect  in  vivo.  Significant  increases  were 
observed in dermal tissue infiltration when in combination with a porous flange, 
which support my hypothesis.  
 
This form of analysis assessed early effects to the wound-healing cascade, as 
cells  migrated  into  the  provisional  wound  matrix  post  clotting  events. 
Subsequent  events  were,  therefore,  unable  to  benefit  from  the  potential 
effects of functionalisation with RGD-polypeptides as they were utilised in this 
preceding event.  
 
RGD-polypeptides  have  a  positive  effect  on  early  transcutaneous  interface 
formation.  However  these  positive  effects  were  not  represented  in  all  the 
measurable outcomes. Significant differences in HDF attachment to titanium 
alloy  substrates  functionalised w i t h  R G D -polypeptides  were  observed  in 
Chapter 2, but were concentration dependent. It may be possible to increase 
the apparent transient effect of RGD-polypeptides in vivo so that later wound 
healing events can exploit their presence by altering the concentration. This 
may involve optimising concentrations in vivo.      
 
Porous structures alone did not suffer from loss of activity in this manner and 
were utilised in later wound healing events, such as significant increases in 
blood vessel formation compared with drilled flanged implants.        
 
No  other  significant  increases  were  observed  to  prove  or  dispute  my 
hypothesis.  Moreover,  the  functionalisation  techniques  used  had  no 	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detrimental  effect  and  demonstrated  no  significant  differences  when 
compared to functionalisation techniques currently used in clinical settings.  
 
The functionalisation techniques investigated in this study had no significant 
positive impact of epidermal downgrowth and epidermal attachment. These 
data do not support my hypothesis, in that RGD-polypeptide functionalised 
porous flange will limit epidermal downgrowth compared with the HA coated 
non-porous flange.  
 
However, a significant increase was observed in dermal tissue infiltration and 
the density of blood vessels in infiltrated dermal tissue in RDG-polypeptide 
functionalised porous flanged implants compared with controls. This supports 
my hypothesis. A good blood supply is essential for formation of a healthy 
dermal tissue interface, and it is postulated that this increase in blood vessel 
density will be essential in maintaining the interface long-term. It has been 
demonstrated that the infiltration of highly vascularised dermal tissue at the 
transcutaneous interface of a bony deer antler is the prerequisite to a long-
term stable transcutaneous interface in nature (Pendegrass et al 2006).  
 
Fitzpatrick et al. (2011) noted soft tissue infiltration to possess high numbers 
of  dermal  fibroblasts  and  epidermal  keratinocytes  at  the  interface  of 
functioning  ITAP  devices  in  clinical  veterinary  cases  after  8-,  12- a n d  1 7 -
months. To facilitate this, there must have been good vascular infiltration to 
support tissue and cell viability. Despite the fact that after 5-months there was 
no  significant  difference  in  downgrowth  or  epidermal  attachment  between 
implant  types  in  my  study,  the  results  suggest  that  improved  vascular 
infiltration has occurred in silanised RGD-polypeptide functionalised porous 
titanium alloy flanges. This may be critical to the maintenance of a healthy 
dermal interface over time periods extending beyond 5-months. It should also 
be noted that downgrowth was not eliminated in the veterinary clinical cases 
reported by Fiztpatrick et al. (2011) using a solid flanged device. It is possible 
that  with  RGD-polypeptide  functionalisation  combined  with  porous  implants 
may  eliminate  downgrowth  and  support  vascular  infiltration  capable  of 
supporting a long-term biologically sealed transcutaneous interface.  	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5.6- Conclusion  
 
The aim of this final experimental chapter of my thesis was to determine the 
effect of functionalising the ITAP flange on the skin implant interface in 
a long-term in vivo model. 
 
Functionalisation  techniques  employed  in  this  study  did  not  eradicate  the 
failure modalities of ITAP devices, however they did not detrimentally affect 
the  formation  of  a  stable  transcutaneous  interface  compared  with  current 
clinical standards. Indeed positive and significant effects were observed, with 
the  biological  functionalisation  using  RGD-polypeptides  and  structural 
functionalisation  with  EBM  fabricated  porous  flanges,  on  the  long-term 
stability of the transcutaneous interface.   	 ﾠ 227	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Chapter 6 
Discussion and Future Work   
 
The aim of my thesis was to develop functionalisation techniques that will 
enhance dermal cell and tissue attachment, in order to enhance a seal 
and reduce infection of implant biomaterials used for ITAP.  
 
The  first  chapter  in  my  thesis  reviewed  the  current  literature  surrounding 
bone-anchored transcutaneous implant devices. Based on the understandings 
from this review I formulated a general hypothesis: Soft tissue attachment to 
ITAP will be improved using a protein coated porous implant compared 
with surfaces that are currently used for ITAP. In order to achieve my pre-
determined aim and test my hypothesis, a number of experimental chapters 
were  devised,  each  of  which  were  designed  to  answer  specific  research 
questions relating to the general hypothesis.  
 
The  first  experimental  chapter  of  my  thesis,  Chapter  2,  focused  on  HDF 
attachment in vitro to titanium alloy substrates, the material of choice for ITAP 
devices. More specifically, the effect of functionalising ITAP substrates with 
RGD-polypeptides on HDF attachment was investigated. These experiments 
were also performed in relation to established techniques, using fibronectin, 
the  whole  molecule  counterpart  of  RGD-polypeptides.  Previous  work  by 
Middleton et al. (2007) has shown that using silanised fibronectin enhances 
the attachment of these cells. The distinct advantage of being able to use 
synthetic RGD-polypeptides means that regulatory complications associated 
with  medical  devices  and  harsh  sterilizations  treatments  may  be  avoided 
compared with the clinical use of fibronectin. It was hypothesized that RGD-
polypeptides  would  elicit  a  similar  up-regulatory  effect  on  HDF  attachment 
compared with fibronectin coatings in vitro. For significant increases in HDF 
attachment  to  occur  RGD-polypeptides  had  to  be  successfully  immobilised 
onto  the  substrate.  This  was  achieved  through  both  adsorption  and 
silanisation  protocols.  The  degree  of  HDF  attachment  varied  with 
concentration but did elicit comparable responses to fibronectin substrates. 
The essential feature in this chapter was HDF attachment was observed to 	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significantly  increase  on  RGD-polypeptide  substrates  by  24-hours. 
Functionalisation  with  RGD-polypeptides  in  vitro,  as  demonstrated  an 
increases in HFD attachment strength to titanium alloy substrates.  24-hours 
is the critical timeframe in which soft tissue must attach to ITAP devices in 
vivo.  These  data  suggested  that  RGD-polypeptide  coating  could  have 
potential use in vivo, however aspects of the functionalisation protocol had to 
be optimised first and this was investigated in Chapter 3. Despite optimizing 
the protocol, the functionalisation of titanium alloy had to increase dermal cell 
attachment strength to be a viable technique for ITAP use.   
 
Chapter  3  aimed  to  quantify  the  loading  and  release  kinetics  of  RGD-
polypeptides to ITAP substrates, in an attempt to control the concentration 
dependent variations in HDF attachment, observed in Chapter 2. This chapter 
also  tested  the  durability  of  the  functionalisation  technique  as  the  in  vivo 
environment is far removed from that of cell culture studies. Silanisation of 
titanium alloys substrates with RGD-polypeptides resulted in a more robust 
coating.  After  challenging  with  FCS,  significantly  higher  levels  of  silanised 
RGD-polypeptides  remained  on  the  substrate  compared  with  absorbed 
coatings. Silanised substrates also significantly increased HDF attachment by 
24-hours compared with controls. Evidence from Chapter 3 suggested that 
functionalising  ITAP  substrates  with  silanised  RGD-polypeptides  increased 
cell  attachment  and  could  remain  attached  when  incubated  with  serum 
proteins.  Therefore  I  postulated  that  this  technique  may h a v e   provided a n  
opportunity to functionalise an ITAP device in vivo by increasing dermal tissue 
attachment to the ITAP flange. This functionalised substrate may enhance the 
formation of a stable biological seal at the transcutaneous interface in vivo.    
 
Chapter 4 concentrated on the structural functionalisation of the ITAP flange. 
The ITAP flange was designed to increase the surface area for dermal soft 
tissue  attachment  in  vivo,  a  characteristic  possessed  by  a  natural 
transcutaneous structure- the antler of a deer. The EBM technique used to 
construct the novel porous titanium alloy created precise 3-D structures. The 
aim  of  this  chapter  was  to  test  the  hypothesis  that  a  more  open  structure 
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and vascularisation throughout the implant. Results suggested that varying 
the pore and strut diameters could lead to an optimal structure that supports 
significant increases in tissue infiltration and vascularisation. This is the first 
time  that  the  optimal  pore  and  strut  diameters  have  been  systematically 
investigated in vivo for soft tissue attachment. Bobyn et al. (1982), LaBerge et 
al. (1990), Hacking et al. (2000) all investigated the mechanical strength of 
soft tissue attachment of various porous implant structures but did not quantify 
soft tissue in-growth. Dimensions of 700µm pore diameter and 300µm strut 
diameter observed consistently high soft tissue infiltration and vascularisation. 
In light of the results, I went on to hypothesize that if these dimensions were 
incorporated into the ITAP flange, dermal tissue may have more opportunity 
to attach, thereby forming a stable skin seal at the transcutaneous interface.    
 
Chapter 5 was devised to assess the functionalisation techniques developed 
in previous chapters in an ITAP in vivo transcutaneous model. No previous 
ITAP  experimental  study  had  been  documented  in  vivo  for  longer  than  4-
weeks.  This  final  experimental  study  aimed  to  assess  the  effect  on  the 
formation of the transcutaneous implant interface over a long-term study. It 
was hypothesized that a combination of a porous flange silanised with RGD-
polypeptides  would  significantly  increase  interface  formation.  My 
functionalised  ITAP  devices  were  compared  against  the  current  clinical 
implant  for  5-months.  The  transcutaneous  interface  was  quantitatively 
characterized  by  length  of  epidermal  downgrowth  and  the  percentage  of 
epidermal attachment. Data was also collected on the percentage of dermal 
tissue infiltration to the flange and density of blood vessels and cell nuclei 
within the infiltrated tissue. The functionalisation techniques developed in my 
thesis  and  those  used  in  ITAP  clinical  practice  (Kang  et  al  2010)  did  not 
eradicate epidermal downgrowth, as no significant difference was observed 
between groups. Although	 ﾠthere was no statistical significance demonstrated 
between  the  functionalised  implant  groups  with  regard  to  epidermal 
downgrowth  and  epidermal  attachment,  there  were  significant  increases 
observed in blood vessel density and dermal tissue infiltration. These were 
attributed  to  porous  flanges  silanised  with  RGD-polypeptides.  Overall  this 	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chapter demonstrated that my functionalisation techniques had no detrimental 
effect on the formation of transcutaneous interface.        
 
There are a number of bone-anchored transcutaneous devices in clinical and 
preclinical use, including ITAP devices (Pitkin, 2013). This form of treatment 
eradicates  many  of  the  clinical  and  psychological  issues  observed  with 
conventional  treatment  and  care  of  amputations.  Un-natural  pressure 
distribution between the stump and prosthesis leads to soft tissue injuries, 
often chronic (DesGroseilliers et al 1978, Dudek et al 2005, Koc et al 2008, 
Lyon et al 2000, Portnoy 2009 and Schmalz et al 2002). Bypassing these soft 
tissues of the stump with a bone-anchored transcutaneous device alleviates 
such problems. Load from locomotion can be directly transferred from bone, 
through the device, to prosthesis. Such a device can be donned and doffed by 
the  user  with  ease  and  locomotion  itself  can  be  more  efficient  through 
osteoperception (Kang et al 2010).    
 
The aim of this thesis was to contribute to the longevity of these devices by 
developing techniques that could allow a skin implant interface to form. If this 
is achieved early and skin seals around the implant shaft, continuity of the 
skin is maintained, the passage of invading pathogens will be curtailed and 
unable to enter the body. Dermal cell attachment, to titanium alloy substrates 
in vitro, can be significantly up-regulated by biological functionalisation with 
RGD-polypeptides.  When  combined  with  porous  titanium  alloy  structures 
dermal tissue infiltration and blood vessel density can also be significantly up-
regulated in vivo.  
 
To represent my experimental work I devised a flow diagram at the end of 
Chapter  1  (Fig  1.06).  The  questions  outlined  in  my  flow  diagram  were 
experimentally answered. In summation of my thesis it is important see how 
my  work  contributes  in  the  wider  landscape  of  dermal  cell  and  tissue 
attachment and how it may be translated in the clinical locale.    
 
The current epidemiology of amputation suggests incidence of dysvascular 
related  amputation  is  rising  due  to  the  prevalence  of  diabetes 	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(http://www.bbc.co.uk/news/health-17270379). With compromised vascularity 
of the soft tissues in the stump, bone-anchored transcutaneous devices may 
not be a viable treatment option for such individuals as long-term skin implant 
interface may not formed due to the lack of blood supply. Results of my thesis 
have  the  potential  to  increase  the  number  of  viable  candidates  that  could 
benefit  from  such  novel  therapies,  should  it  be  incorporated  into  clinical 
practice.  The  porous  flanged  silanised  with  RGD-polypeptides  facilitated 
significant increases in dermal tissue infiltration and blood vessel density.  
 
Large  numbers  of  service  men  and  women  are  returning  from  recent 
warzones  suffering  from  traumatic  amputation  (Wallace,  2012).  Porous 
titanium  alloy  structures  silanised  with  RGD-polypeptides  support  the 
formation of well vascularised healthy soft tissues (as shown in Chapter 5). 
These functionalised techniques may, therefore, provide a viable treatment 
option  for  such  traumatic  injuries  where  soft  tissues  have  been  heavily 
damaged or scarred. In turn this may positively impact long-term stump heath 
and increase quality of life for another patient group.    
 
This  technology  has  the  potential  of  many  benefits,  including  those  of  the 
emerging discipline of intuitive neuromuscular control of prostheses, where 
ITAP devices (Al-Ajam et al 2013) or other bone anchored transcutaneous 
devices (Pitkin et al 2012) act as conduits to house electrodes capable to 
transmitting signals in and out of the body. The most inspiring benefits are the 
well-documented increases to quality of life to users of such devices (Kang et 
al 2010 and Lundberg et al 2011). Such devices also benefit veterinary cases 
(Fitzpatrick  et  al  2011).  Results  of  Chapter  4  are  being  used  in  “second 
generation” of a more successful ITAP device used in veterinary cases, where 
a porous flange is made by selective laser sintering. Dimensions of the pores 
were  selected  as  a  result  of  my  study  (Oral  Communication;  Combine 
Orthopedic Research Society: Venice 2013, Symposium Chaired by Prof G 
Blunn (UCL), speaker N Fitzpatrick) (Fig 6.01). 	 ﾠ 233	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Fig 6.01. PerFiTS device (Percutaneous Fixation To Skeleton) courtesy of Fitzbionics 
(Patents PCT/GB2013/052639 and 1317782.9) “Second Generation” ITAP device used in 
Veterinary cases.  
 
My  findings  suggest  it  is  possible  to  engineer  an  environment  that  does 
promote  a  long-term  stable  skin  seal,  which  prevents  harmful  pathogens 
entering  the  internal  environment.  It  is  hoped  that  these  functionalisation 
techniques will be incorporated into further pre-clinical and clinical studies of 
ITAP devices and continue to improve the lives of many amputees currently 
suffering with conventional treatment.  
 
It is hoped that further work will continue to understand the mechanisms of 
dermal cell and tissue attachment to implant biomaterials used for ITAP, and 
make  a  significant  contribution  to  science.  In  light  of  the  early  reported 
successes  with  direct  skeletally  attached  prostheses  to  human  and  animal 
subjects using ITAP devices (Fitzpatrick et al 2011 and Kang et al 2010), the 
EBM manufacturing technique utilized in Chapter 4 highlighted the dexterity 
and  precision  achievable  in  implant  structures.  This  application  may  be 
extended to subjects who are not fully-grown, because the porous metals may 
be able to accommodate changes in musculature size and soft tissue growth. 
Winter  (1974)  originally  stated  that  if  a  porous  structure  could  support  the 
influx of dermal fibroblasts during wound healing transcutaneous integration 	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might be achievable.  It therefore may be of interest to use EBM to create a 
totally  porous  titanium  alloy  device  and  test  it  in  a  transcutaneous  in  vivo 
environment.  
 
One  particular  area  of  work  that  I  believe  logically  follows  on  from  the 
biological functionalisation technique developed in my thesis is the transfer of 
this  into  a  clinical  setting.  Preparing  a  sterile,  functionalised,  titanium  alloy 
substrate that could be applied to ITAP is of particular interest. Understanding 
how  the  biological  activity  of  silanised  RGD-polypeptides  to  titanium  alloy 
substrates (in terms of cell attachment in vitro) would be influenced by harsh 
and stringent medical sterilisation protocols, such as ethylene oxide, gamma-
irradiation and heat treatment is important. How long could such a substrate 
remain biological active for? Is it possible to freeze dry substrates to increase 
shelf life? These are all valid questions that would need to be experimentally 
tested and would be the first steps in designing an “off the shelf ITAP device” 
which then may provide the opportunity for ITAP devices to become a wide 
spread  treatment  option  for  amputees.  Alternatively  it  may  possible  to 
functionalise ITAP devices with RGD-polypeptides in an aseptic environment 
just before implantation.  
 
In vivo testing of my functionalisation techniques was an important aspect in 
relation to the application of ITAP devices. Chapters 2 and 3 investigated cell 
attachment strength in vitro. I aimed to up-regulate HDF attachment strength 
using biological functionalisation of titanium alloy. Although cell attachment is 
a critical requirement for ITAP (Pendegrass et al 2006 and Kang et al 2010), it 
is  only  one  aspect  of  cellular  function.  Further  work  could  include  the 
investigation of more cellular responses, including proliferation, migration and 
possible  differentiation  of  HDFs  on  the  functionalised  substrates  to  further 
characterise the effects of the RGD-polypeptides.   
 
Fibroblast migration through porous structures in vivo must result from the 
contractile  elements  of  the  cellular  cytoskeleton  (Alberts  et  al  2002). 
Information  about  the  cellular  cytoskeleton  in  cells  migrating      on  RDG 	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functionalised   and non-treated titanium alloy surfaces both  in vitro and in 
vivo would also be of interest.    
Chapter 3 was designed to develop a functionalisation technique that could 
withstand in vivo implantation and provide a more durable coating long-term. 
My in vitro experiments were all 2D culture systems, despite trying to create a 
competitive  environment  with  serum  proteins  and  PBS.  The  silanisation  of 
RGD-polypeptides to titanium alloy was then tested in a 3D system in vivo 
over  5-months.  This  is  an  environment  far  removed  from  the  in  vitro 
experiments  I  had  performed  in  Chapters  2  and  3.    The  use  of  a  3D  cell 
culture systems may “bridge the gap” from in vitro environments to long-term 
in vivo environments. Fibroblast morphology has been shown to differ from 2D 
to 3D systems (Sheez et al 2005), which may result from different attachment 
proteins secreted in vivo.  
  
It may be of interest to develop a 3D porous substrate, such as those used in 
Chapter 4, functionalise it by silanisation of RGD-polypeptides and introduce 
dermal  fibroblasts  into  a  bioreactor.  This  may  provide  the  opportunity  to 
observe  how  biologically  functionalised  porous  titanium  alloy  (such  as  the 
group 4 in Chapter 5) behave in a 3D culture system.  
 
In  order  for  ITAP  to  be  transferable  into  widespread  clinical  use,  further 
research  has  to  be  done.  Although  the  promising  results  of  the 
functionalisation techniques tested in Chapter 5, some consideration must be 
given to the animal model used. ITAP devices were orientated perpendicular 
to  the  bone  in  a  trans-tibial  plane.  Designing  and  implementing  a  full 
amputation model may provide more realistic conditions for ITAP devices to 
be tested in. This is currently unachievable in this country due to the terms of 
the  Animals  under  the  Animals  (Scientific  Procedures)  Act  1986. 
http://www.legislation.gov.uk/ukpga/1986/14/pdfs/ukpga_19860014_en.pdf 
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Appendix 1 
 
 
Substrate Surface Profilometry Analysis  
 
 
 
Study 1 
Cell Area 
 
  Median cell area/µm
2  95% confidence intervals  
Controls  2141  2043.51-2439.22 
0.1mM Linear RGD 1h  2162  2111.55-2602.72 
0.1mM Linear RGD 4h   2272.4  1854.21-2940.6 
0.1mM Cyclic RGD 1h  2409.5  2197.9-2657.92 
0.1mM Cyclic RGD 4h   2167  1763.76-3025.44 
 
Vinculin Markers 
 
  Median  95% confidence intervals  
Controls  36  35.2-49.2 
0.1mM Linear RGD 1h  45.5  39.3-50.7 
0.1mM Linear RGD 4h   94  82.4-109.1 
0.1mM Cyclic RGD 1h  46.5  45.6-59.9 
0.1mM Cyclic RGD 4h   88  77.2-112.2 
 
Density of Vinculin Markers 
 
  Median   95% confidence intervals  	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Controls  0.0163  0.0161-0.0219 
0.1mM Linear RGD 1h  0.0163  0.0173-0.0218 
0.1mM Linear RGD 4h   0.0398  0.0357-0.0529 
0.1mM Cyclic RGD 1h  0.0214  0.0192-0.0262 
0.1mM Cyclic RGD 4h   0.0446  0.0392-0.07 
 
Study 2 
Cell Area 
 
  Median cell area/µm
2  95% confidence intervals  
Controls  2076.7  1738.1-2242.3 
0.1mM Linear siRGD  2018.5  1835.2-2156.4 
0.1mM Cyclic siRGD  2251.5  2101.5-2828.5 
 
Vinculin Markers 
 
  Median   95% confidence intervals  
Controls  63  52.7-70.7 
0.1mM Linear siRGD  85  71.1-93.9 
0.1mM Cyclic siRGD  79.5  70.8-97.5 
 
Density of Vinculin Markers 
 
  Median   95% confidence intervals  
Controls  0.032  0.0273-0.037 
0.1mM Linear siRGD  0.0439  0.0363-0.0476 
0.1mM Cyclic siRGD  0.0326  0.0303-0.0394 
 
Study 3 
Cell area 
 
  Median   95% confidence intervals 
Control  2145  1931-2498.3 
Ad RGD  2160  1966.9-2317.6 
Ad fn  2767.7  2567.8-3085.9 
Si RGD  2173.6  1865.6-2683 
Si fn  2287.5  2035-2546.4 
 
Vinculin markers 	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  Median   95% confidence intervals 
Control  30  28.3-38.1 
Ad RGD  68  63.2-81.2 
Ad fn  101  87.6-113.8 
Si RGD  61.5  53.7-76.2 
Si fn  88.5  78.6-103.8 
 
Density of Vinculin Markers 
 
  Median   95% confidence intervals 
Control  0.0159  0.0129-0.0186 
Ad RGD  0.0334  0.0301-0.0382 
Ad fn  0.0339  0.0312-0.0417 
Si RGD  0.0295  0.0256-0.0378 
Si fn  0.0428  0.0357-0.0454 
 
Study 4 
Cell area 
 
  Median   95% confidence intervals  
Control  2145  1931-2498.3 
5mM adRGD  2160  1966.9-2135.6 
10mM adRGD  2105.9  1897-2395.8 
25mM adRGD  2236  2074.6-2473.3 
50mM adRGD  2768  2251.2-3111.8 
100mM adRGD  2080  1809.5-2199.7 
  
Vinculin marker 
 
  Median   95% confidence intervals  
 Control  30  28.3-38.1 
5mM adRGD  68  63.2-81.2 
10mM adRGD  64.5  61-78 
25mM adRGD  60  66.1-69 
50mM adRGD  51  45.2-65.4 
100mM adRGD  49  43-54.4 
 
Density of Vinculin Markers 	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  Median   95% confidence intervals  
Control  0.0159  0.0129-0.0153 
5mM adRGD  0.0334  0.0301-0.0382 
10mM adRGD  0.0344  0.0286-0.0389 
25mM adRGD  0.0273  0.0248-0.0313 
50mM adsorbed RGD  0.0202  0.0179-0.0245 
100mM adsorbed RGD  0.0246  0.0214-0.0285 
 
Study 5 
Cell Area 
 
  Median  95% Confidence Interval 
Control 1h  189.1  170.2-230.7 
Control 4h  1173.7  931.3-1304 
Control 24h  1134.  1038.4-1456.7 
Control 96h  1619.9  1378.9-1801.3 
AdRGD 1h  1119.5  1119.9-1595.1 
AdRGD 4h  1083.6  939.9-1484.6 
AdRGD 24h   2142.2  1959.2-2594.1 
AdRGD 96h  1271.7  1090.2-1609.7 
Adfn 1h  1227.8  1038.6-1344.6 
Adfn 4h  1032.3  819.4-1232 
Adfn 24h  2086  1637.6-2181.4 
Adfn 96h  1740.6  1400.2-2102.5 
siRGD 1h  1166.5  470.4-2085.9 
siRGD 4h   2144.5  1461.9-2466.2 
siRGD 24h  1932.9  1822.8-2175.7 
siRGD 96h  1429.9  1322.5-1863  
Sifn 1h  731.4  584.4-1176.3 
Sifn 4h  1912  1644.9-2158.9 
Sifn 24h   1818.7  1537.8-2250.5 
Sifn 96h  1339.6  1018.4-1710.5 
 
Vinculin Markers 
 
  Median  95% Confidence Interval 
Control 1h  2  1.1-3.3 
Control 4h  20  16.4-23.6 	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Control 24h  25  19.7-27.4 
Control 96h  29.5  27.8-35.1 
AdRGD 1h  23  21.3-31.9 
AdRGD 4h  30  28.5-34.4 
AdRGD 24h   74  66.4-85.5 
AdRGD 96h  85  82.1-108 
Adfn 1h  22  18.7-25.4 
Adfn 4h  24  21-29.9 
Adfn 24h  47  40-56.8 
Adfn 96h  87  75.7-98.5 
siRGD 1h  18  5.8-35.5 
siRGD 4h   44  30.2-52.5 
siRGD 24h  70.5  60.6-78.5 
siRGD 96h  65  58.3-72.8 
Sifn 1h  13  11.3-23.3 
Sifn 4h  30.5  27.9-37 
Sifn 24h   48  38-56.5 
Sifn 96h  58.5  55.8-74.5 
 
Density of Vinculin Markers 
 
  Median  95% Confidence Interval 
Control 1h  0.0099  0.0054-0.0203 
Control 4h  0.0194  0.0138-0.0241 
Control 24h  0.0206  0.0164-0.0229 
Control 96h  0.018  0.017-0.0265 
AdRGD 1h  0.0195  0.0174-0.0216 
AdRGD 4h  0.0286  0.0238-0.0329 
AdRGD 24h   0.0333  0.0303-0.0391 
AdRGD 96h  0.0734  0.0668-0.0785 
Adfn 1h  0.0177  0.017-0.0212 
Adfn 4h  0.0251  0.0217-0.0299 
Adfn 24h  0.0261  0.022-0.0285 
Adfn 96h  0.0508  0.0453-0.0625 
siRGD 1h  0.0174  0.0122-0.0192 
siRGD 4h   0.0206  0.0193-0.0228 
siRGD 24h  0.0333  0.0303-0.0391 
siRGD 96h  0.0447  0.0381-0.0498 
Sifn 1h  0.0181  0.0167-0.0231 	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Sifn 4h  0.0178  0.0153-0.0205 
Sifn 24h   0.0247  0.0221-0.0291 
Sifn 96h  0.0447  0.0381-0.0498 
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Appendix 2   
 
YRGD-polypeptide synthesis data provided by AltaBioscience. 
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Technical Data for the iodination of YRGD-polypeptide and Fibronectin.  
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Study 1 
Cell Area 
  Median   95%Confidence Intervals 
Control  1247.5  1038.4-1456.7 
5mM YRGD  2276.6  1959.2-2594.1 
5mM RGD  2142.2  1966.9-2317.6 
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Vinculin Markers 
 
  Median   95%Confidence Intervals 
Control  23.53  19.71-27.35 
5mM YRGD  75.94  66.43-85.46 
5mM RGD  72.2  63.2-81.2 
 
FA Density 
 
  Median   95%Confidence Interval 
Control  0.0196  0.0164-0.0229 
5mM YRGD  0.0303  0.0303-0.0391 
5mM RGD  0.0341  0.0300-0.0382 
 
Study 3 
Adsorbed I
125 YRGD-Polypeptide  
  Median   95% Confidence Interval 
1  0.56  0.48-0.58 
2  1.17  1.08-1.26 
3  1.95  1.88-2.02 
4  2.55  2.51-2.58 
5  2.85  2.65-2.99 
6  3.7  3.55-3.73 
7  5.18  4.99-5.33 
8  5.39  5.30-5.45 
9  5.73  5.65-5.78 
10  6.023  5.77-6.35 
 
Silanised I
125 YRGD-Polypeptide  
 
  Median   95% Confidence Intervals 
1  0.79  0.72- 0.92 
2  1.29  1.00-1.37 
3  1.51  1.47-1.53 
4  1.74  1.67-1.84 
5  2.12  1.88-2.16 
6  3.36  3.29-3.40 
7  4.35  3.95-4.54 
8  4.43  4.25-4.63 	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9  5.1  4.62-5.35 
10  5.74  4.88-5.95 
 
Silanised I
125 Fibronectin  
 
  Median   95% Confidence Intervals  
10  6.30  5.09-7.15 
100  23.93  21.81-26.22 
250  68.02  64.98-71.07 
500  207.83  191.31-221.18 
750  262.07  247.43-282.87 
1000  336.24  308.82-363.89 
2000  569.02  533.88-591.40 
3000  833.11  814.96-859.99 
4000  936.81  870.63-980.66 
5000  946.02  808.41-1027.23 
 
Study 4 
I
125 YRGD-Polypeptide  
 
Group   Median   95% Confidence Interval  
Si I
125YRGD 5-mins  1.16  0.83-1.56 
Si I
125YRGD 2-hours  3.85  3.42-4.12 
Si I
125YRGD 20-hours  7.28  6.51-7.4 
Si I
125YRGD 140-hours  7.33  6.73-9.07 
Ad I
125YRGD 5-mins  0.97  0.64-1.11 
Ad I
125YRGD 2-hours  3.2  3.04-3.54 
Ad I
125YRGD 20-hours  3.01  2.45-3.35 
Ad I
125YRGD 140-hours  0.39  0.39-0.46 
 
I
125 Fibronectin  
 
Group   Median   95% Confidence Interval  
Si I
125fibronectin 5-mins  300.06  269.9-330.22 
Si I
125fibronectin 2-hours  612.06  561.93-794.98 
Si I
125fibronectin 20-hours  652.65  563.39-1031.81 
Si I
125fibronectin 140-hours  844.55  769.251144.06 
Ad I
125fibronectin 5-mins  163.52  139.07-178.68 
Ad I
125fibronectin 2-hours  319.33  297.69-334.54 	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Ad I
125fibronectin 20-hours  391.26  368.75-399.99 
Ad I
125fibronectin 140-
hours 
435.18  411.44-465.42 
 
Study 5  
PBS Soak 
 
I
125 YRGD-Polypeptide  
 
Group   Median   95% Confidence Interval  
Si I
125YRGD 5-mins  2.99  2.7 - 3.05 
Si I
125YRGD 2-hours  1.78  1.64 - 2.03 
Si I
125YRGD 20-hours  1.43  1.35 - 1.49 
Si I
125YRGD 140-hours  1.37  1.33 - 1.47 
Ad I
125YRGD 5-mins  2.08  1.90 - 2.19 
Ad I
125YRGD 2-hours  1.4  1.29 - 21.53 
Ad I
125YRGD 20-hours  1.09  0.96- 1.19 
Ad I
125YRGD 140-hours  0.25  0.24 - 0.26 
 
I
125 Fibronectin  
 
Group   Median   95% Confidence Interval  
Si I
125fibronectin 5-mins  46.02  40.59- 52.45 
Si I
125fibronectin 2-hours  27.44  25.69- 31.7 
Si I
125fibronectin 20-hours  26.71  23.14 - 32.42 
Si I
125fibronectin 140-hours  20.19  13.85 - 23.26 
Ad I
125fibronectin 5-mins  34.29  32.52 - 35.68 
Ad I
125fibronectin 2-hours  23.44  19.47 - 28.56 
Ad I
125fibronectin 20-hours  13.53  12.69 - 19.56 
Ad I
125fibronectin 140-
hours 
8.92  8.33- 9.48 
 
FCS Soak  
 
I
125 YRGD-Polypeptide  
 
Group   Median   95% Confidence Interval  
Si I
125YRGD 5-mins  2.58  2.28 - 2.79 
Si I
125YRGD 2-hours  2.18  2.11 - 2.23 	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Si I
125YRGD 20-hours  1.77  1.63- 1.79 
Si I
125YRGD 140-hours  1.42  1.24- 1.46 
Ad I
125YRGD 5-mins  2.13  2.07 - 2.14 
Ad I
125YRGD 2-hours  1.37  1.32- 1.39 
Ad I
125YRGD 20-hours  0.91  0.79 - 0.93 
Ad I
125YRGD 140-hours  0.59  0.58 - 14 
 
I
125 Fibronectin  
 
Group   Median   95% Confidence Interval  
Si I
125fibronectin 5-mins  89.87  70.24 - 98.14 
Si I
125fibronectin 2-hours  47.85  42.42 - 62 
Si I
125fibronectin 20-hours  35.83  30.43 - 44.5 
Si I
125fibronectin 140-hours  31.87  23.49 - 37.01 
Ad I
125fibronectin 5-mins  51.42  44.59 - 57.83 
Ad I
125fibronectin 2-hours  24.55  19.881651 - 31.47 
Ad I
125fibronectin 20-hours  11.98  9.93 - 17.59 
Ad I
125fibronectin 140-
hours 
6.01  5.28 - 6.28 
 
Study 6 
Cell Area 
 
  Median  95% Confidence Interval 
Control 1h  254  244.4-321.7 
Control 4h  344.5  321.8-442.7 
Control 24h  1026  999.4-1303.1 
Control 96h  1401  1288.1-1806.1 
AdYRGD 1h  377.5  354.7-496.4 
AdYRGD 4h  667  516.2-756.4 
AdYRGD 24h   1508.5  1280.3-1778.8 
AdYRGD 96h  2017.5  1053-2393.3 
Adfn 1h  914.5  828.4-1096.4 
Adfn 4h  1072  937.4-1198.1 
Adfn 24h  1500  1310.8-1676.4 
Adfn 96h  1346  1287.5-1705.3 
siYRGD 1h  375  358.3-578.7 
siYRGD 4h   942  879.9-1330.9 
siYRGD 24h  1558  1359.1-1797.2 	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siYRGD 96h  1575  1419.1-1794.7 
Sifn 1h  1133.5  945.4-1220.5 
Sifn 4h  1010  987.8-1303.7 
Sifn 24h   1817  1606.6-2009.8 
Sifn 96h  2006.5  1865.4-2373.2 
 
Vinculin Markers 
 
  Median  95% Confidence Interval 
Control 1h  0  0.6-2 
Control 4h  5  3.8-5.8 
Control 24h  19  17.3-23.2 
Control 96h  31  27.8-36.4 
AdRGD 1h  1  0.6-1.7 
AdRGD 4h  4  2.4-4.7 
AdRGD 24h   52  46.6-61.8 
AdRGD 96h  50  37.1-61.4 
Adfn 1h  11  10.7-15.6 
Adfn 4h  23  19.4-25.7 
Adfn 24h  47  41-52.5 
Adfn 96h  50  46.9-55.7 
siRGD 1h  2  1.8-3.2 
siRGD 4h   7  5.3-10.2 
siRGD 24h  52.5  47.6-5.9 
siRGD 96h  64  52.6-6.8 
Sifn 1h  2.5  1.9-3.4 
Sifn 4h  30.5  26.4-35.1 
Sifn 24h   58  52.4-62.8 
Sifn 96h  70  62.1-79.1 
 
FA Density  
 
  Median  95% Confidence Interval 
Control 1h  0  0.003-0.009 
Control 4h  0.01  0.01-0.02 
Control 24h  0.02  0.02-0.02 
Control 96h  0.02  0.02-0.02 
AdRGD 1h  0.002  0.002-0.004 
AdRGD 4h  0.005  0.004-0.006 
AdRGD 24h   0.04  0.03-0.05 	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AdRGD 96h  0.03  0.02-0.05 
Adfn 1h  0.01  0.01-0.02 
Adfn 4h  0.02  0.02-0.03 
Adfn 24h  0.03  0.03-0.04 
Adfn 96h  0.03  0.03-0.04 
siRGD 1h  0.005  0.004-0.007 
siRGD 4h   0.007  0.006-0.008 
siRGD 24h  0.04  0.03-0.04 
siRGD 96h  0.04  0.04-0.04 
Sifn 1h  0.002  0.002-0.004 
Sifn 4h  0.03  0.02-0.03 
Sifn 24h   0.03  0.03-0.04 
Sifn 96h  0.04  0.03-0.04 
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Appendix 3 
 
Histological Processing 
 
 
Percentage Fill Score 
 
Group  Median 
Zone 1/% 
95% 
Confidence 
Intervals 
Median 
Zone 2/% 
95% 
Confidence 
Intervals 
Medan 
Zone 3/% 
95% 
Confidence 
Intervals 
1  100    98.5  95.23-
100.44 
100  88.1-105.24 
2  100  97.54-
101.03 
100  94.22-101.5  100  87.94-
102.06 
3  40  11.84-78.66  35  18.61-53.89  25  7.27-37.73 
4  100  92.48-
103.55 
95  30.19-
125.81 
100  92.45-
103.55 
5  88  62.09-
103.57 
87.5  59.3-103.36  90  45.07-
108.26 
6  27.5  -10.14-
62.64 
22.5  -8.31-53.31  10  -20.1-55.1 
7  60  48.43-74.43  45  33.44-57.41  40  21.09-57.48 
8  60  41.43-75.14  63  34.17-68.40  60  25.64-72.93 
9  N/A  N/A  N/A  N/A  N/A  N/A 
  
Cell Nuclei Density  	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Group   Median 
Zone 
1/mm
2 
95% 
Confidence 
Intervals 
Median 
Zone 
2/mm
2  
95% 
Confidence 
Intervals 
Median 
Zone 
3/mm
2 
95% 
Confidence 
Intervals 
1  3440.50  1407.93-
4453.4 
2846  800.64-
4397.02 
3586.50  1246.15-
4728.85 
2  5059  3330.45-
6312.7 
4527  2402.37-
5439.06 
5000  3004.61-
6293.96 
3  1190  -409.57-
2953.57 
700  -392.4-
2157.9 
584.50  131.82-
970.68 
4  1389  -390.62-
7151.82 
1243  172.19-
3993.41 
1306  266.55-
4168.65 
5  815  363.3-
1315.36 
604  420.53-
749.47 
551.50  -99.65-
1662.32 
6  250  -317.35-
985.35 
268.50  -249.1-
835.11 
251  -316.48-
984.48 
7  1390  110.59-
5540.55 
1199  478.45-
1641.83 
821  71.18-
2351.4 
8  890  -187.08-
3091.36 
645  53.6-
1850.68 
720  122.22-
2097.78 
9  N/A  N/A  N/A  N/A  N/A  N/A 
 
Blood Vessel Density 
 
Group  Median  BV 
Zone1/mm
2 
95% 
Confidence 
Intervals 
Median  BV 
Zone2/mm
2 
95% 
Confidence 
Intervals 
Median  BV 
Zone3/mm
2 
95% 
Confidence 
Intervals 
1  4  1.52-9.43  5.20  0.73-13.4  2  -1.77-10.64 
2  8  4.28-10.29  10  4.52-12.05  8  2.83-11.74 
3  4.50  -1.03-9.03  1  -2.5-6.5  2.5  -1.29-6.29 
4  15  3.67-34.3  6  0.92-16.28  11  2.92-15.08 
5  3  0.48-8.52  1.5  -0.2-3.88  0   
6  0  -1.09-2.09  0  -0.55-1.05  0  -2.18-4.18 
7  9  3.25-17.9  4  0.33-5.39  0  -1.24-2.95 
8  8  2.75-12.96  4  1.44-8.0  4  -0.42-11.56 
9  N/A  N/A  N/A  N/A  N/A  N/A 
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Appendix 4 
 
Implant Dimensions  
 
Porous  Implant  Dimension/µm- C o n t r o l  a n d  
RGD 
Drilled Implant Dimension/µm- Control and RGD 
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Histological Processing  
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Animal 6034 
 
 
Microbiology 
swab results 
taken from 
exduate of 
back right 
leg in the 
proximal 
position 
from animal 
6034. 
             
Radiograph 
images of 
right hind 
leg of 
animal 6034 
 
Experimental Data  
  Median   95% Confidence Intervals  
Epidermal  Downgrowth 
(µm) 
   
Flange Control   7185.5  5941.3-7900.87 
Flange RGD  8178.0  6255.14-11299.41 
Porous Control   5359.0  4646.77-10409.23 
Porous RGD  7878  5702.48-9195.52 
Epidermal Attachment (%)     	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Flange Control  50.9  32.47-63.73 
Flange RGD  44.54  17.16-58.67 
Porous Control   39.4  22.0-57.63 
Porous RGD  27.2  21.81-49.02 
Blood  Vessel  Density 
(mm
2) 
   
Flange Control  0.00  -0.000001-0.000028 
Flange Porous   0.000001  0.000003-0.000031 
Porous Control   0.000071  0.000049-0.000098 
Porous RGD  0.000068  0.000048-0.000092 
Cell Nuclei Density (mm
2)     
Flange Control   0.000585  0.000254 – 0.00152 
Flange RGD  0.000301  0.0000648 – 0.000813 
Porous Control  0.000513  0.000385 – 0.000675 
Porous RGD  0.00054  0.000386 – 0.000735 
Dermal  Tissue  Infiltration 
(%)  
   
Flange Control   90  49.31-96.24 
Flange RGD  70  38.35-88.01 
Porous Control   90  67.76-102.24 
Porous RGD   100  97.07-101.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	 ﾠ 260	 ﾠ
Reference List 	 ﾠ 261	 ﾠ
Reference List 
 
Acram AB. 2013 EBM in Aerospace. [ONLINE] http://www.arcam.com/ 
 
Al-Ajam, Y., Lancashire, H., Pendegrass, C., Kang, N., Dowling, R., Taylor, S., 
Blunn, G. 2013 The  Use  of  a  Bone-Anchored  Device  as  a  Hard-Wired 
Conduit  for  Transmitting  EMG  Signals  From  Implanted  Muscle 
Electrodes. Biomedical Engineering, IEEE. 60(6), pp.1654-1659. 
 
Alberts,  B.,  Johnson,  A.,  Lewis,  J.,  Raff,  M.,  Roberts,  K.,  Walter,  P.  2002 
Molecular Biology of the Cell. 4
th Ed. New York: GS Garland Science  
 
Albrektsson,  T.,  Branemark,  P.-I.,  Hansson,  H.-A.,  Lindstrom,  J.  1981 
Osseointgerated titanium implants. Acta Orthop. Scand. 52, pp.155-170. 
 
Aschoff, H. H. 2011 The Endo-Exo-Femoral Prosthesis. pp.101-105. 
 
Aschoff,  H.  H.,  Kennon,  R.  E.,  Keggi,  J.  M.,  Rubin,  L.  E.  2010 
Transcutaneous, Distal Femoral, Intradmedullary Attachment for Above-
thee-Knee  Prostheses:  An  Endo-Exo  Device.  The  Journal  of  Bone  and 
Joint Surgery, Incorporated. 92(2), pp.180-186.  
 
Black, J. 1992 Biological  Performances  of  Materials:  Fundamentals  of 
Biocompatibility. 2
nd Ed.  PLACE: Marcel Dekker, Inc.  
 
Baier, R. E. and Dutton, R. C. 1969 Initial events in interactions of blood 
with  a  foreign  surface.  Journal  of  Biomedical  Materials  Research.  3(1), 
pp.191–206. 
 
Balaban,  N.  Q.,  Schwartz.  U.  S.,  Riveline.  D.,  Goichberg.  P.,  Tzur.  G., 
Sabanay. I., Mahalu. D., Safran. S., Bershadsky. A., Addadi. L., Geiger. B. 
2001 Force and Focal Adhesion assembly: A Close Relationship Studied 
using Elastic Micropatterned Substrates. Nature Cell Biology. 3, pp.466-472. 	 ﾠ 262	 ﾠ
 
Bershadsky,  A.  D.,  Tint,  I.  S.,  Neyfakh,  A.  A.,  Vasiliev,  J.  M.  1985  Focal 
Contacts of Normal and RSV-transformed Quail Cells: Hypothesis of the 
Transformation-induced  deficient  Maturation  of  Focal  Contacts. 
Experimental Cell Research. 158(2), pp.433–444. 
 
Buetner, E., H. and Jorden, R., E. 1964 Demonstration of Skin Antibodies in 
Sera of Pemphigus Vulgaris Patients by Indirect Immunoflourescent Staining. 
Society for Experimental Biology and Medicine. 117(2), pp.505-510. 
 
Bobyn,  J.  D.,  Pilliar,  R.  M.,  Cameron,  H.  U.,  Weatherly,  G.  C.  1980  The 
Optimum Pore Size for the Fixation of Porous-Surfaced Metal Implants 
by the Ingrowth of Bone. Clinical Orthopaedics & Related Research. 150, 
pp.263-270.  
 
Bobyn, J. D., Wilson, G. J., MacGregor, D. C., Pilliar, R. M., Weatherly, G. C. 
1982 Effect of Pore Size on the Peel Strength of Attachment of Fibrous 
Tissue  to  Porous-surfaced  Implants.  Journal  of  Biomedical  Materials 
Research.16(5), pp.571–584. 
 
Bothe,  R.T.,  Beaton,  L.E.,  Davenport,  H.A.,  (1940)  Reaction  of  bone  to 
multiple metallic implants. Surgery, Gynecology, and Obstetrics 71. pp598-
602
 
 
Brånemark, P.-I., Breine, U., Adell, R., Hansson, B. O., Lindström, J., Ohlsson, 
A.
 1969  Intra-Osseous  Anchorage  of  Dental  Prostheses:  Experimental 
Studies.  Journal of Plastic and Reconstructive Surgery and Hand Surgery. 
3(2), pp.81-100. 
 
Brånemark,  P.-I.,  Albrektsson,  T.,  1982  Titanium  Implants  Permanently 
Penetrating  Human  Skin.  Scandinavian  Journal  for  Plastic  and 
Reconstructive Surgery. 16, pp.17-21. 
 	 ﾠ 263	 ﾠ
Brånemark,  R.,  Brånemark,  P-I.,  Rydevik,  B.,  Myers,  R.  R.,  2001 
Osseointegration  in  Skeletal  Reconstruction  and  Rehabilitation:  A 
Review. Journal of Rehabilitation Research and Development. 38(2), pp.175-
181. 
 
British  Broadcasting  Corporation.  2012  [ONLINE] 
http://www.bbc.co.uk/news/health-17270379.   
 
Brooks, P. C., Clark, R. A., Cheresh, D. A. 1994 Requirement of vascular 
integrin alpha v beta 3 for angiogenesis. Science. 264(5158), pp569-571. 
 
Brunette,  D.  M.  1986  Fibroblasts  on  Micromachined  Substrata  Orient 
Hierarchically  to  Grooves  of  Different  Dimensions.  Experimental  Cell 
Research. 164, pp.11-26.  
 
Butts, T. E., Peterson, L. J., Allen, C. M., 1989 Early Soft Tissue Ingrowth 
onto  Porous  Block  Hydroxyapatite.  Journal  of  Oral  and  Maxilllofacial 
Surgery. 47, pp.475-479.   
 
Chapman, D. I., 1975 Antlers- Bones of Contention. Mammal Review. 5(4), 
pp.122-1172. 
 
Chehroudi,  B.,  Brunette,  D.  M.,  2002  Subcutaneous  Microfabricated 
Surfaces Inhibit Epithelial Recession and Promote Long-term Survival of 
Percutaneous Implants. Biomaterials. 23, pp.229-237. 
 
Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., Inger, D. E., 1997 
Geometric Control of Cell Life and Death. Science. 276(5317), pp.1425-
1428. 
 
Cheung,  S.,  Gauthier,  M.,  Lefebvre,  L-P.,  Dunbar,  M.,  Filiaggi,  M.  2007 
Fibroblastic interactions with high-porosity Ti-6Al-4V metal foam. Journal 
of  Biomedical  Materials  Research  Part  B:  Applied  Biomaterials.  82(B), 	 ﾠ 264	 ﾠ
pp.440–449. 
 
Chimutengwende-Gordon,  M.,  Pendegrass,  C.,  Blunn,  G.  2011  Enhancing 
the Soft Tissue Seal Around Intraosseous Transcutaneous Amputation 
Prostheses  Using  Silanised  Fibronectin  Titanium  Alloy.  Biomedical 
Materials. 6(2),  
 
Cochrane,  H.,  Orsi,  K.,  Reilly,  P.,  2001 Lower  Limb  Amputation  Part  3: 
Prosthetics-  a  10  Year  Literature  Review.  Prosthetics  and  Orthotics 
International. 25, pp.21-28. 
 
Compact Oxford English Dictionary For current Englsih  (2005) 3
rd Ed. 
Oxford: Oxford University Press 
 
Davis,  D.  H.,  Giannoulis,  C.  S.,  Johnson,  R.  W.,  Desai  T.  A.  2002 
Immobilization  of  RGD  to  <1 1 1>  silicon  surfaces  for  enhanced  cell 
adhesion and proliferation. Biomaterials. 23(19), pp.4019–4027. 
 
DesGroseilliers, J. P.,  DesJardins, J. P., Germain, J. P., Krol, A. L. 1978  
Dermatologic  problems  in  amputees.  Canadian  Medicine  Association 
Journal. 118(5), pp.535–537. 
 
Ducheyne, P., Hench, L. L., Kagan, II A., Marten, M., Bursens, A., Mulier, J. 
C., 1980 Effect of Hydroxyapetite Impregnation on Skeletal Bonding of 
Porous  Coated  Implants.  Journal  of  Biomedical  Materials  Research.  14, 
pp.225-237. 
 
Dudek,  N.,  Marks,  M.,  Marshall,  S.,  Chardon,  J.,  2005  Dermatologic 
conditions  associated  with  the  use  of  lower  extremity  prosthesis. 
Archives of Physical Medicine and Rehabilitation. 86(4), pp.659-663. 
 
El-Ghanna,  A.,  Starr,  L.,  Jones,  J.,  1997  Laminin-5  Coating  Enhances 
Epithelial  Cell  Attachment,  Spreading  and  Hemidesmosome  Assembly 	 ﾠ 265	 ﾠ
on  Ti-Al6-V4  Implant  Material  in  vitro.  Jounral  of  Biomedical  Material 
Research. 41, pp.30-40. 
 
Elmengaard, B.,
 Bechtold, E., Søballe, K. 2005 In vivo Study of the Effect of 
RGD Treatment on Bone Ingrowth on Press-fit Titanium Alloy Implants. 
Biomaterials. 26(17), pp.3521–3526. 
 
Farrell, B. J., Prilutsky, B. I., Ritter, J. M., Kelley, S., Popat, K., Pitkin, M. 
Effects of Pore Size, Implantation Time, and Nano-surface Properties on 
Rat Skin Ingrowth into Percutaneous Porous Titanium Implants. Journal 
of Biomedical Materials Research Part A. 00(A), pp.000–000. 
 
Fath, K. R.,  Edgell, C. J., and Burridge, K. 1989 The Distribution of Distinct 
Integrins  in  Focal  Contacts  is  Determined  by  the  Substratum 
Composition. Journal of Cell Science. 92, pp.67-75.  
 
Ferris, D. M., Moodie, G. D., Dimond, P. M., Giorani, C. W. D., Ehrlich, M. G., 
Valentini, R. F. 1999 RGD-coated titanium implants stimulate increased bone 
formation in vivo. Biomaterial. 20(23-24), pp.2201-2460. 
 
Fitzpatrick,  N.,  Smith,  T.  J.,  Pendegrass,  C.  J.,  Yeadon,  R.,  Ring,  M., 
Goodship,  A.  E.,  Blunn,  G.  W.  2011  Intraosseous  Transcutaneous 
Amputation  Prosthesis  (ITAP)  for  Limb  Salvage  in  4  Dogs. Veterinary 
Surgery. 40(8), pp.909-925. 
 
Gardner., W, D and Osburn., W, A., (1973) Structure of the Human Body. 
2
nd Ed. St. Lewis: W.B Saunders Company 
 
Gordon, D, J., Bhagawati, D. D., Pendegrass
*,  C. J., Middleton, C. A., Blunn. 
G.  W.  2010  Modification  of  Titanium  alloy  Surfaces  for  Percutaneous 
Implants by Covalently Attaching Laminin. Journal of Biomedical Materials 
Research. 94A(2), pp.586–593.  
 	 ﾠ 266	 ﾠ
Gottlie, B. S., Leventhal, G.S. 1951 Titanium, a metal for surgery, Journal of 
Bone and Joint Surgery 33(A), pp.473-474. 
 
Green, K. J., Jones, J. C. R., 1996 Desomsomes and Hemidesmosomes: 
Structure and Function of Molecular Components. The FASEB Journal. 
10, pp.871-881. 
 
Grinnell,  F.,  1984  Fibronectin  and  Wound  Healing.  Journal  of  Cellular 
Biochemistry. 26, pp.107-116. 
 
Gottsauner-Wolf, F., Egger, E. L., Schultz, F. M., Sim, F. H., Chao, E. Y. S. 
1994 Tendons attached to prostheses by tendon-bone block fixation: An 
experimental  study  in  dogs.  Journal  of  Orthopaedic  Research.  12(6), 
pp.814-821. 
 
Grosse-Siestrup, C . ,  Affled.  K.,  1984  Design  Criteria  for  Percutaneous 
Devices. Journal of Biomedical Material Research. 18, pp.357-382. 
 
Gupta, A., Pollock, R., Cannon, S. R., Briggs,  T. W. R.,  Skinner,  J., Blunn, G. 
A  Knee-Sparing  Distal  Femoral  Endoprosthesis  using  Hydroxyapatite-
coated  Extracortical  Plates. Journal of Bone and Joint Surgery. 88B(10), 
pp.1367-1372 
 
Hacking,  S.  A.,  Bobyn,  J.  D.,  Toh,  K.-K.,  Tanzer, M . ,   Krygier,  J.  J.,  2000 
Fibrous Tissue Ingrowth and Attachment to Porous Tantalum. Journal of 
Biomedical Material Research. 52, pp.631-638. 
Hall, C .  W . ,  Adams, L .  M . ,  Ghidoni,  J.  J.,  1975  Development  of  Skin 
Interfacing  Cannula.  Transactions - American Society for Artificial Internal 
Organs. XXI, pp.281-288. 
 
Harrison, R. G. 1912 The Cultivation of Tissues in Exteneous Media as a 
Method of Morphogenetic Study. The anatomical Record. 6, pp.181-193. 
 	 ﾠ 267	 ﾠ
Hautanen,  A.,  Gailit,  J.,  Mann,  D.  M.,  Ruoslahti,  E.  1989  Effects  of 
Modifications of the RGD Sequence and its Context on Recognition by 
the  Fibronectin  Receptor.  The  Journal  of  Biological  Chemistry.  264, 
pp.1437-1442. 
 
Hayakawa,  T.,  Yoshinari,  M.,  Nemeto,  K.  2003  Direct  Attachment  of 
Fibronectin  to  Tresyl  Chloride-activated  Titanium.  Journal  Biomedical 
Material Research. 67(A), pp.684 – 688. 
 
Heinl, P., Muller, L., Korner, C., Singer, R. F., Muller, F. 2008 Cellular Ti-6Al-
4V  Structures  with  Interconnected  Macro  Porosity  for  Bone  Implants 
Fabricated  by  Selective  Electron  Beam  Melting.  Acta  Biomaterialia. 4 ,  
pp.1536-1544. 
 
Heinl, P., Rottmair, A., Korner, C. and Singer, R. F. 2007 Cellular Titanium 
by Selective Electron Beam Melting. Advanced Engineering Materials. 9(5), 
pp.360-364. 
 
Hersel,  U.,  Dahmen,  C.,  Kesseler,  H.  (2001)  RGD  Modified  Polymers: 
Biomaterials  Stimulated  for  Cell  Adhesion  and  Beyond.  Biomaterials. 
24(24), pp. 4385–4415.   
 
Hess, C .  T . ,  a n d  Kirsner.  R.  S. 2 0 0 3  Orchestrating  Wound  Repair: 
Assessing and Preparing the Wound Bed. Advances in Skin and Wound 
Care. 16(5), pp.246-257. 
 
Holgers,  K.  M.,  Thomsen,  P.,  Tjellstrom,  A.,  Ericson,  L.  E.  1995  Electron 
Microscopic Observation on the Soft-Tissue Around Clinical Long-Term 
Percutaneous Titanium Implants. Biomaterials. 16, pp.83-90. 
 
Holland, J., Hersht, L., Bryhant, M., Onyiriuka, E., Ziegler, L. 1996 Culture of 
Human  Vascular  Endothelial  cells  on  an  RGD-containing  Synthetic 
Peptide Attached to a Starch-coated Polystyrene Surface: Comparison 
with Fibronectin-coated Tissue Grade Polystyrene. Biomaterials. 17, pp. 	 ﾠ 268	 ﾠ
2147-2156.  
 
Hormia, M. and Kononen, M. 1994 Immunolocalization of Fibronectin and 
Vitronectin  Receptors  in  Human  Gingival  Fibroblasts  Spreading  on 
Titanium Surfaces. Journal of Periodontal Research. 29(2), pp.146–152. 
 
Howe, D. F., Svare, C. W., Tock, R. W. 1974 Some Effects of Pore Diameter 
on Single Pore Bony Ingression Patterns in Teflon. Journal of Biomedical 
Materials Research. 8(6), pp.399–406. 
 
Hunter, W. M., Greenwood, F. C. 1962 Preparation of Iodine-131 Labelled 
Human  Growth  Hormone  of  High  Specific  Activity.  Nature.  194(4827), 
pp.495-496. 
 
Hunter, A., Archer, C. W.,  Walker, P. S., Blunn, G. W. 1994 Attachment and 
Proliferation  of  Osteoblasts  and  Fibroblasts  on  Biomaterials  for 
Orthopaedic Use. Biomaterials. 16(4), pp.287–295. 
 
Irvine, D. J., Hue, K. A., Mayes, A. M., Griffith, L. G. 2002 Simulations  of 
Cell-Surface Integrin Binding to Nanoscale-Clustered Adhesion Ligands. 
Biophysical Journal. 82(1), pp.120-132. 
 
Iscackson,  D.,  McGill,  L.  D.,  Bachus,  K.  N.  2011  Percutaneous  Implants 
with Porous Titanium Dermal Barriers: An in vivo Evaluation of Infection 
Risk. Medical Engineering and Physics. 33, pp.418-426. 
 
Jarcho, M., Kay, J. F., Gumaer, K. I., Doremus, R. H., Drobeck, H. P. 1977 
Tissue,  Cellular  and  Subcellular  Events  at  a  Bone-ceramic 
Hydroxylapatite Interface. Journal of Bioengineering. 1(2), pp.79-92.   
 
Jeyapalina, S., Beck, J. P., Bachus, K. N., Williams, D. L., Bloebaum, R. D. 
2012  Efficacy  of  a  Porous-structured  Titanium  Subdermal  Barrier  for 
Preventing  Infection  in  Percutaneous  Osseointegrated  Prostheses. 	 ﾠ 269	 ﾠ
Journal of Orthopaedic Research. 30(8), pp.1304–1311. 
 
Jeyapalina, S., Van Dyke, M., Sampson, A., Betz, D. H., Bloebaum, R. D. 
2013 Investigating  Keratin  as  a  Biomimetic  Coating  for  Percutaneous 
Device Applications. Society for Biomaterial: Boston 2013. #70 
 
Jin, Z-H., Furukawa, T., Waki, A., Akaji, K., Coll, J-L., Saga, T., Fujibayashi, Y. 
2010  Effect  of  Multimerization  of  a  Linear  Arg-Gly-Asp  Peptide  on 
Integrin Binding Affinity and Specificity. Biological Pharmaceutical Bulletin. 
33(3), pp.370—378. 
 
Jones,  J.  C.  R.,  Hopkinson,  S.  B.,  Goldfinger,  L.  E.  1998  Structure  and 
Assembly of Hemidesmosomes. Bioassays. 20, pp.488-494. 
 
Jose,  B.,  Antoci,  Jr.  V.,  Zeiger,  A.  R.,  Wickstrom,  E.,  Hickok,  N.  H.  2005 
Vancomycin Covalently Bonded to Titanium Beads Kills Staphylococcus 
aureus. Chemistry & Biology. 12, pp.1041-1048. 
 
Kämmerer, P. W., Heller, P., Brieger, J., Klein, M. O., Al-Nawas, B., Gabriel, 
M. 2011 Immobilization of Linear and Cyclic RGD-peptides on Titanium 
Surfaces and their Impact on Endothelial Cell Adhesion and Proliferation. 
European Cells and Materials. 21, pp.364-372. 
 
Kang,  N.,  Pendegrass,  C.,  Blunn,  G.  2010  Osseointegration  of  an  ITAP 
used  in  a  Reconstruction  of  a  Transhumeral  Amputee:  Case  Report. 
Journal of Hand Surgery. 35(A), pp.1130-1134. 
 
Kanitakis,  J. 2 0 0 2  Anatomy,  Histology  and  Immunohistochemistry  of 
Normal Human Skin. European Journal of Dermatology. 12(4), pp.390-401. 
Kasemo, B. and Gold, J. 1999 Implant Surfaces and Interface Processes. 
Journal of Dental Research. 13(1), pp.8-20. 
 
Kantlehner,  M.,  Schaffner,  P.,  Finsinger,  F.,  Meyer,  J.,  Jonczyk,  A., 	 ﾠ 270	 ﾠ
Diefenbach, B., Nies, B., Hölzemann, G., Goodman, S. L., Kessler, H. 2000 
Surface  Coating  with  Cyclic  RGD  Peptides  Stimulates  Osteoblast 
Adhesion and Proliferation as well as Bone Formation. ChemBiochem. 1, 
pp.107-114. 
Kasemo,  B.,  Gold,  J.  1999  Implant  Surfaces  and  Interface  Processes. 
Journal of Dental Research. 13(1), pp.8-20. 
 
Klebe, R. J. 1974 Isolation of a collagen dependent cell attachment factor. 
Nature. 221, pp. 248-251   
 
Koc, E., Tunca, M., Akar, A., Erbil, A. H., Demiralp, B. and Arca, E. 2008 Skin 
problems  in  amputees:  a  descriptive  study.  International  Journal  of 
Dermatology. 47, pp.463–466. 
Kohler, P., Lindh, L., Bjorklind, A., 1989 Bacteria on stumps of amputees 
and the effects of antiseptics. Prosthetics and Orthotics International. 13, 
pp.149-151. 
 
Koike, M., Martinez, K., Guo,  L., Chahine, G., Kovacevic, R., Okabe, T. 2011 
Evaluation  of  Titanium  Alloy  Fabricated  using  electron  Beam  Melting 
System  for  dental  Applications.  Journal  of  Materials  Processing 
Technology. 211, pp.1400–1408. 
 
Koivunen, E., Wang, B., Ruoslahti, E. 1994 Isolation of a Highly Specific 
Ligand for the Alpha5Beta1 Integrin from a Phage Display Library. The 
Journal of Cell Biology. 124(3), pp.373-380. 
 
Krawczyk, W. S. and Wilgram, G. 1973 Hemidesmosome and Desmosome 
Morphogenesis  during  Epidermal  Wound  Healing.  Journal  of 
Ultrastructure Research. 45, pp.93-101. 
 
Kroese-Deutman H. C., Van Den Dolder, J., Spauwen, P. H. M., Jansen, J. A. 	 ﾠ 271	 ﾠ
2005 Influence of RGD-Loaded Titanium Implants on Bone Formation in 
Vivo. Tissue Engineering. 11(11/12), pp. 1867-1875. 
 
Kubo, M., Van De Water, L., Plantefaber, L. C., Mosesson, M. W., Simon, M., 
Tonnesen, M. G., Taichman, L., Clark, R. A. F. 2001 Fibrinogen and Fibrin 
are  Anti-Adhesive  for  Keratinocytes:  A  Mechanism  for  Fibrin  Eschar 
Slough  During  Wound  Repair. The Journal of Investigative Dermatology. 
117, pp.1369-1381.  
 
LaBerge, M., Bobyn, J. D., Rivard, C. H., Drouin, G., Duval, P. 1990 Study of 
Soft  Tissue  Ingrowth  into  Canine  Porous  Coated  Femoral  Implants 
Designed  for  Osteosarcomas  Management.  Journal  of  Biomedical 
Materials Research. 24(7), pp.959–971. 
 
Landete-Castillejos,  T.,  Estevez,  JA.,  Ceacero,  F.,  Garcia,  AJ.,  Gallego,  L. 
2012 A Review of Factors Affecting Antler Composition and Mechanics. 
Frontiers in Bioscience. E4, pp.2328-2339. 
 
Lanza, R. P., Langer, R., Vacanti, J. 2000 Principles of Tissue Engineering. 
2
nd Ed. Waltham: Academic Press  
 
Le  Gros  Clark.,  W.  E.  1946  The  Tissues  of  the  Human  Body.  2
nd  Ed. 
Oxford: Oxford at the Clarendon Press. 
 
Leventhal, G. S., 1951 Titanium, A Metal for Surgery. The Journal of Bone 
and Joint Surgery. 33(2):473-474 
 
Levy, S. 1956 Skin  problems  of  the  lower  extremity  amputee.  Artificial 
Limbs. 3, pp.20-35 
 
Levy, S. 1980 Skin problems of the leg amputee. Prosthetics and Orthotics 
International. 4, pp.37-44. 
 	 ﾠ 272	 ﾠ
Li, C., Mackintosh, C. G., Martin, S. K., Clark, D. E. 2007 Identification of 
Key Tissue Type for Antler Regeneration Through Pedicle Periosteum 
Deletion. Cell Tissue Research. 328, pp.65-75. 
 
Li.  C.,  Sutteie.  J.,  Clark.  D. 2 0 0 5  Histological  Examination  of  Antler 
Regeneration  in  Red  Deer  (Cervus  elaphus).  The  Anatomical  Record. 
282(A), pp.168-174. 
 
Lin.  Y-S.,  Wang,  S-S.,  Chung,  T-W.,  Wang,  Y-H.,  Chiou,  S-H.,  Hsu,  J-J., 
Chou, N-K., Hsieh, K_H., Chou, S-H. 2001 Growth of Endothelial Cells on 
Different Concentrations of Gly-Arg-Gly-Asp Photochemically Grafted in 
Polyethylene  Glycol  Modified  Polyurethane.  Artificial  Organs.  25(8),  pp. 
617-621. 
 
Lodish, H., Berk, A., Kaiser, C., Krieger, M., Scott, M., Bretscher, A., Ploegh, 
H., Matsudaira, P. 2008 Molecular Biology of the Cell. 6
th Ed. New York: 
W.H Freeman and Company. 
 
Luff, R. Amputee statistical Database for the United Kingdom: 2006/07 
Report 
 
Liu,  X.,  Chu,  P.  K.,  Ding,  C.  2004  Surface  Modification  of  Titanium, 
Titanium  Alloys,  and  Related  Materials  for  Biomedical  Application. 
Materials Science and Engineering: R: Reports. 47(3-4), pp.49-121. 
 
Lundberg, M., Hagberg, K., Bullington, J. 2011 My Prosthesis as a part of 
me: a qualitative analysis of living with an osseoinegratd prosthetic limb. 
International Society for Prosthetcis and Orthotics. 35(2), pp.207-214. 
 
Lundborg,  G.,  Branemark,  P-I.,  Rosen,  B.  1996  Osseointegrated  Thumb 
Prostheses: A Concept for Fixation of Digit Prosthetic Devices. Journal 
of Hand Surgery. 21(A), pp.216-221.  
  
Lyon,  C.,  Kulkarni,  J.,  Zimersonc,  E.,  Van  Ross,  E.,  Beck,  M.  2000  Skin 	 ﾠ 273	 ﾠ
Disorders in Amputees. Journal of the American Academy of Dermatology. 
42(3), pp.501–507. 
 
McDonald, J. H. 2009 Handbook of Biological Statistics. 2nd ed. Baltimore: 
Sparky House Publishing. 
 
Main, A. L., Harvey, T. S., Baron, M., Boyd, J., Campbell, I. D. 1992. The 
Three-dimensional Structure of the tenth Type III Module of Fibronectin: 
An Insight into RGD-mediated Interactions. Cell. 71, pp.671–678 
 
Malone, J., Moore, W., Leal, J., Childers, S. 1981 Rehabilitation for Lower 
Extemity Amputation. Arch Surg. 116, pp.93-98. 
 
Marchalonis, J. J. 1969 An Enzymatic Method for the Trace Iodination of 
Immunoglobunlins  and  Other  Proteins.  Journal  of  Biochemistry.  113, 
pp.299-305. 
 
Martin. P., 1997 Wound Healing- Aiming for Perfect Skin Regeneration.  
Science. 276, pp.75-80. 
 
Merritt, K., Shafer, J. W., Brown, S. A. 1979 Implant  Site  Infection  Rates 
with  Porous  and  Dense  Materials.  Journal  of  Biomedical  Materials 
Research. 13, pp.101-108.   
 
Middleton,  C.,  Pendegrass,  C.,  Gorden,  D.,  Jacob,  J.,  Blunn,  G.,  (2007) 
Fibronectin silanised titanium alloy: A bioinductive and Durable Coating 
to Enhance Fibroblast Attachment in vitro. Journal of Biomedical Materials 
Research. 83(A), pp.1032-1038. 
   
Nagai,  M.,  Hayakawa,  T.,  Fukatsu,  A.,  Yamamoto,  M.,  fukumoto,  M., 
Nagahama, F., Mishima, H., Yoshinari, M., Nemoto, K. 2002 In Vitro Study 
of  Collagen  Coating  of  Titanium  Implants  for  Initial  Cell  Attachment. 
Dental Materials Journal. 21(3), pp.250-260.  
 	 ﾠ 274	 ﾠ
Nanci, A., Wuest, J. D., Peru, L., Brunet, P., Sharma, V., Zalzal, S., McKee, M. 
D.  1988  Chemical  Modification  of  Titanium  Surfaces  for  Covalent 
Attachment  of  Biological  Molecules.  Journal  of  Biomedical  Material 
Research. 40, pp.324-335. 
 
Niessen, C, N. 2007 Tight Junction/Adherens Junctions: Basic Structure 
and Function. Journal of Investigative Dermatology. 127, pp.2525-2532.  
 
Nelson,  R.  J.,  Goldberg,  L.,  White,  R.  A.,  Shors,  E.,  Hirose,  F.  M.  1983 
Neovascularity of a Tracheal Prosthesis/tissue Complex. The Journal of 
Thoracic and Cardiovascular Surgery. 86(6), pp.800-808. 
 
Nygren, H., Eriksson, C., Lausmaa, J. 1997 Adhesion  and  Activation  of 
Platelets  and  Polymorphonuclear  Granulocyte  Cellsat  TiO2  Surfaces. 
Journal of Laboratory  and Clinical Medicine. 129, pp.35-46 
 
Obara, M., Yoshizato, K. 1995 Possible Involvement of the Interaction of 
the  α5  Subunit  of  α5β1  Integrin  with  the  Synergistic  Region  of  the 
Central  Cell-binding  Domain  of  Fibronectin  in  Cells  to  Fibronectin 
Binding. Experimental Cell Research. 216, pp.273–276. 
 
Obara, M., Kang, M., Yamada, K. 1988 Site-Directed Mutagenesis of the 
Cell-Binding Domain of Human Fibronectin: Separable, Synergistic Sites 
Mediate Adhesive Function. Cell Press. 53, pp.649-657 
 
Parthasarathy, J., Starly, B., Raman, S., Christensen, A. (2010) Mechanical 
Evaluation of Porous Titanium (Ti6Al4V) structures with electron beam 
melting.  Journal  of  the  Mechanical  Behaviur  o  f  Biomedical  Materials.  3 
pp249-259 
 
Patel, P. R., Kiser, R. C., Lu, Y. Y., Fong, E., Ho, W. C., Tirrell, D. A., Grubbs, 
R. H. 2012 Synthesis and Cell Adhesive Properties of Linear and Cyclic 
RGD Functionalized Polynorbornene Thin Films. Biomacromolecules. 13, 
pp.2546−2553. 	 ﾠ 275	 ﾠ
 
Pendegrass, C., Goodship, A., Blunn, G. 2006 Development of a soft tissue 
seal  around  bone-anchored  transcutaneous  amputation  prostheses. 
Biomaterials. 27, pp.4183-4191. 
  
Pendegrass, C., Goodship, A., Price, J., Blunn, G. 2006 Nature's answer to 
breaching  the  skin  barrier:  an  innovative  development  for  amputees. 
Journal Anatomical Society. 209, pp.59-67. 
 
Pendegrass,  C.,  Middleton,  C.,  Gorden,  D.,  Jacob,  J.,  Blunn,  G.  2008 
Measuring the strength of dermal fibroblast attachment to functionalized 
titantium alloys in vitro. Journal of Biomedical Materials Research. 92(A), 
pp.1028-1037. 
 
Pettersson, E., Luning, B., Mickos, H., Heinehard, D. 1991 Synthesis, NMR 
and  Function  of  an  O-Phosphorylated  Peptide,  Comprising  the  RGD-
Adhesion  Sequence  of  Osteopontin.  Anta  Chemica  scandinavica. 4 ,  
pp.604-608. 
 
Pierschbacher, M. D., Ruoslahti, E. 1984a. The Cell Attachment Activity of 
Fibronectin  can  be  Duplicated  by  Small  Fragments  of  the  Molecule. 
Nature 309, pp.30–33. 
 
Pierschbacher, M., Ruoslahti, E. 1987 Influence of Stereochemistry of the 
Sequence Arg-Gly-Asp-X on Binding Specificity in Cell Adhesion. The 
Journal of Biological Chemistry. 262(36), pp.17294-17298. 
 
Pitkin,  M.,  Cassidy,  C.,  Muppavarapu,  R.,  Edell,  D.  2012  Recording  of 
Electric Signal Passing Through a Pylon in Direct Skeletal Attachment of 
Leg  Protheses  With  Neuromuscular  Control.  IEEE  Transcations  on 
Biomedical Engineering. 59(5), pp.1349-1353.  
 
Pitkin, M. 2013 Design features of implants for direct skeletal attachment 
of  limb  prostheses.  Journal  of  Biomedical  Materials  Research.  00(A), 	 ﾠ 276	 ﾠ
pp.000-000.  [only  available  on-line] 
http://onlinelibrary.wiley.com/doi/10.1002/jbm.a.34606/abstract?deniedAccess
CustomisedMessage=&userIsAuthenticated=false 
 
Pohjolainen,  T.,  Alaranta,  H.,  Urkuinen,  M.  1990  Prosthetic  Use  and 
Functional and Social Outcome Following Major Lower Limb Amputation. 
Prosthetics and Orthotics International. 14, pp.75-79. 
 
Pollack, S. 1984 The Wound Healing Process. Clinics in Dermatology. 2(3), 
pp.8-16. 
 
Ponader, S., von Wilmowsky, C., Widenmayer, M., Lutz, R., Heinl, P., Korner, 
C., Singer, R. F., Nkenke, E., Neukam, F. W., Schlegel, K. A. 2010 In vivo 
Performance  of  Selective  Electron  Beam-melted  Ti-6Al-4V  Structures. 
Journal of Biomedical Material Research. 92(A), pp.56-62. 
 
Porte-Durrieu, M. C., Guillemot, F., Pallu, S., Labrugere, C., Brouillaud, B., 
Bareille,  R.,  Amedee,  J.,  Barthe,  N.,  Dard,  M.,  Baquey,  C. 2 0 0 4  Cyclo-
(DfKRG) Peptide Grafting onto Ti–6Al–4V: Physical Characterization and 
Interest Towards Human Osteoprogenitor Cells Ahesion. Biomaterials. 25, 
pp.4837–4846. 
 
Portnoy, S., Siev-Nev, I., Yizhar, Z., Kristal, A., Shabshin, N., Gefen, A. 2009 
Surgical  and  Morphological  Factors  that  Affect  Internal  Mechanical 
Loads  in  Soft  Tissues  of  the  Transtibial  Residuum.  The Journal of the 
Biomedical Engineering Society. 37(12), pp.2583-2605. 
 
Price, J. S., Allen, S., Faucheux, C., Althnaian, T., Mount, J. G. 2005 Deer 
antlers:  a  Zoological  Curiosity  or  the  Key  to  Understanding  Organ 
Regeneration in Mammals? Journal of Anatomical Society. 207, pp.603-618. 
 
Puleo, D. A. 1995 Activity of Enzyme Immobilized on Silanised Co-Cr-Mo. 
Journal of Biomedical Materials Research. 29, pp.951-957.  
 	 ﾠ 277	 ﾠ
Pytela,  R.,  Pierschbacher, M .  D.,  Ruoslahti,  E.  1985a.  Identification  and 
Isolation of a 140 Kilodalton Cell Surface Glycoprotein with Properties of 
a Fibronectin Receptor. Cell. 40, pp.191–98. 
 
Pytela, R., Pierschbacher, M. D., Ruoslahti, E. 1985b.  A  125/115  KD  Cell 
Surface Receptor Specific for Vitronectin Interacts with the Arg-Gly-Asp 
Adhesion Sequence Derived from Fibronectin. Proceedings of the National 
Academy of Sciences USA. 82(57), pp.66–70. 
 
Rao,  S.  S.  and  Winter,  J.  O.  2009  Adhesion  Molecule-Modified 
Biomaterials for Neural Tissue Engineering. Frontiers in Neuroengineering. 
2(6), pp.1-14. 
 
Reed, J., Hull, W. E., von der Lieth, C.-W., Kiibler, D., Suhai, S.,& Kinzel, V. 
1988  Secondary  Structure  of  the  Arg-Gly-Asp  Recognition  Site  in 
Proteins  Involved  in  Cell-surface  Adhesion.  European  Journal  of 
Biochemistry. 178, pp.141-154. 
 
Ruoslahti, E., Vaheri, A. 1974 Novel Human Serum Protein from Fibroblast 
Plasma Membrane. Nature (London). 248, pp.789-791. 
 
Ruoslahti, E., Vaheri, A., Kuusela, P., Linder, E. 1973 Fibroblast  Surface 
Antigen: A new Serum Protein. Biochimica et Biophysica Acta. 322, pp.352-
358. 
 
Rouslahti, E. 1996 RGD and Other Recognition Sequences For Integrins. 
Annual Review of Cell and Developmental Biology. 12, pp.697-715. 
 
Roy, D. M. and Linnehan, S. K. 1974 Hydroxyapeptite Formed from Coral 
Skeletal Carbonate by Hydrothermal Exchange. Nature: Letters to Nautre. 
247, pp.220-222. 
 
Saligo, C. and Muller, A. E. 1999 Nails and Claws in Primate Evolution. 
Journal of Human Evolution. 36, pp.97-114. 
 	 ﾠ 278	 ﾠ
Sauberlich, S., Klee, D., Richer, F-J., Hocker, H., Spiekermann, H. 1999 Cell 
Culture Tests for Assessing the Tolerance of Soft Tissue to Variously 
Modified Titanium Surfaces. Clinical Oral Implant Research. 10, pp.379-393. 
 
Schmalz,  T.,  Blumentritt,  S.,  Jarasch,  R.  2002  Energy  Expenditure  and 
Biomechanical  Characteristics  of  Lower  Limb  Amputee  Gait:  The 
Influence of Prosthetic Alignment and Different Prosthetic Components. 
Gait and Posture. 16, pp.255-/263. 
 
Schroeder, A., van der Zypen, E., Stich, H., Sutter, F.1981 The Reactions of 
Bone,  Connective  Tissue,  and  Epithelium  to  Endosteal  Implants  with 
Titanium- Sprayed Surfaces. Journal of Maxillofacial Surgery. 9,  pp.15-25. 
 
Schultz,  P.,  Vautier,  D.,  Charpiot,  A.,  Lavalle,  P.,  Debry,  C.  2007 
Development of Tracheal Prostheses made of Porous Titanium: a Study 
on Sheep. European Archives of Otorhinolaryngology. 264, pp.433–438. 
 
Sedgwick, P. 2012 Multiple Significance Tests: the Bonferroni Correction. 
British Medical Journal. 344(e509) 
 
Sheez  
 
Shin,  H.,  Jo,  S.,  Mikos,  A.  G.  2003  Biomimetic  Materials  for  Tissue 
Engineering: Review. Biomaterials. 24, pp.4353–4364. 
 
Singer, I. I., Scott, S.,  Kawka, D. W., Kazazis, D. M., Gailit, J., Ruoslahti E. 
1988 Cell Surface Distribution of Fibronectin and Vitronectin Receptors 
Depends  on  Substrate  Composition  and  Extracellular  Matrix 
Accumulation. The Journal of Cell Biology. 106, pp.2171-2182. 
 
Simmons,  C.  A.,  Valiquette,  N.,  Pilliar,  R.  M.  1999  Osseointegration  of 
Sintered  Porous-surfaced  and  Plasma  Spray–coated  Implants:  An 
Animal  Model  Study  of  Early  Postimplantation  Healing  Response  and 	 ﾠ 279	 ﾠ
Mechanical Stability. Journal of Biomedical Material Research. 47, pp.127–
138. 
 
Soligo, C., Muller, A. E. 1999 Nails and claws in primate evolution. Journal 
of Human Evolution. 36, pp.97–114. 
 
Squier,  C.  A.,  Collins,  P.  1981  The  Relationship  Between  Soft  Tissue 
Attachment,  Epithelial  Downgrowth  and  Surface  Porosity.  Journal  of 
Peridontal Research. 16, pp.434-440.   
 
Stoker,  M.,  O’Neill,  C.,  Berryman,  S.,  Waxman,  V.  1968  Anchorage  and 
Growth Regulation in Normal and Virus-Transformed Cells. International 
Journal of Cancer. 3, pp.683-693. 
  
Sullivan,  J.,  Uden,  M.,  Robinson,  K.  P.,  Soorriakumaran,  S.  2003 
Rehabilitation  of  the  Trans-femoral  Amputee  with  an  Osseoinegrated 
Prostheis:  The  United  Kingdom  Experience.  International  Society  for 
Prosthetcis and Orthotics. 27, pp.114-120. 
  
Suzuki, S., Oldberg, A., Hayman, E. G., Pier-Schbacher, M. D., Ruoslahti, E. 
1985. Complete  amino  Acid  Sequence  of  Human  Vitronectin  Deduced 
from  cDNA.  Similarity  of  Cell  Attachment  Sites  in  Vitronectin  and 
Fibronectin. European Molecular Biology Organization Journal. 4, pp.2519–
2524. 
 
Takahashi,  S.,  Leiss,  M.,  Moser,  M.,  Ohashi,  T.,  Kitao,  T.,  Heckmann,  D., 
Pfeifer, A., Kessler, H., Takagi, J., Erickson, H. P., fassler, R. 2007 The RGD 
Motif  in  Fibronectin  is  Essential  for  Development  but  dispensable  for 
Fibril Assembly. The Journal of Cell Biology. 178(1), pp.167-178. 
 
Taylor,  D.  F.  and  Smith,  F.  B.  1972  Porous  methyl  methacrylate  as  an 
Implant  Material.  Journal  of  Biomedical  Materials  Research.  6(1), 
pp.467–479. 	 ﾠ 280	 ﾠ
 
Thurston,  A. 2 0 0 7  Pare  and  prosthetics:  the  early  history  of  artificial 
limbs. ANZ Journal of Surgery. 77(12), pp.1114-1119. 
 
Truskey, G. A. and Pirone, J. S. 1990 The  Effect  of  Fluid  Shear  Stress 
Upon  Cell  Adhesion  to  Fibronectin-Treated  Surfaces.  Journal  of 
Biomedical Materials Research. 24, pp.1333-1353. 
  
University College London. 2013 UCL Safety Services, Ionizing Radiations. 
[ONLINE] 
http://www.ucl.ac.uk/estates/safetynet/guidance/radiation/ionising/index.htm 
 
University  College  London.  2013  UCL  School  of  Life  and  Medical 
Sciences:  Statement  on  the  Uses  of  Animals  in  Research.  [ONLINE] 
http://www.ucl.ac.uk/slms/research/animal-use  
 
Unwin, N. 2000 Epidemiology of lower extremity amputation centres in 
Europe,  North  America  and  East  Asia. British Journal of Surgery. 87(3), 
pp.328-337. 
 
Van  Ness,  J.,  Kalbfleisch,  S.,  Petne,  C.  R.,  Reed,  M.  W.,  Tabone,  J.  C., 
Vermeulen,  N.  M.  J.  1991  A  Versatile  Solid  Support  System  for 
Oligodeoxynucleotide Probe-based Hybridization Assays. Nucleic. Acids 
Research. 19 (12), pp.3345-3350 
 
Van Noort, R. 1987 Titanium:  The  Implant  Material  of  Today. Journal of 
Material Science. 22, pp.3801-3811. 
 
von Recum., A. F. 1984 Applications and Failure modes of Percutaneous 
Devices:  A  Review.  Journal of Biomedical Material Research. 18, pp.323-
336. 
 
Vrana, N. E., Dupret, A., Coraux, C., Vautier, D., Debry, C., Lavalle, P. 2007 
Hybrid  Titanium/Biodegradable  Polymer  Implants  with  an  Hierarchical 	 ﾠ 281	 ﾠ
Pore Structure as a Means to Control Selective Cell Movement. Public 
Library of Science. 6(5), pp.1-10. 
 
Vroman, L., Adams, A. L., Fischer, G. C., Munoz, P. C. 1980 Interaction of 
High Molecular Weight Kininogen, Factor XII, and Fibrinogen in Plasma 
at Interfaces. Blood. 55(1), pp.156–159. 
 
Walboomers, X .  F . ,  Monaghan, W . ,  Curtis,  A.  S.  G.,  Jansen,  J.  A.  1999 
Attachment  of  Fibroblasts  on  Smooth  and  Microgrooved  Polystyrene. 
Journal of Biomedical Material Research. 46, pp.212–220. 
Wallace, D. 2012 Trends in traumatic limb amputation in allied forces in 
Iraq and Afghanistan. Journal of Military and Veterans Health. 20(2), pp.31-
35.  
 
Webster, J. B., Levy, C. E., Bryant, P. R., Prusakowski, P. E. 2001 Sports 
and Recreation for Persons with Limb Deficiency. Achieves of Physical 
Medicine and Rehabilitation. 82(3,1), pp.S34-S38.  
 
Weiss, P. 1945 Experiments  on  the  Cell  and  Axon  Orientation  In  Vitro 
The  role  of  Colloidal  Exudates  in  Tissue  Organisation.  Journal  of 
Experimental Zoology. 100, pp.353-386. 
 
Wen, C. E., Yamada, Y., Shimojima, K., Chino, Y., Asahina, T., Mabuchi, M. 
2002  Processing  and  Mechanical  Properties  of  Autogenous  Titanium 
Implant Materials. Journal of Materials Science: Materials in Medicine. 13, pp. 
397-401. 
  
Werner, S., Huck
, O., Frisch, B., Vautier, D., Elkaim, R., Voegel, J-C., Brunel, 
G.,  Tenenbaum
,  H.  2009  The  Effect  of  Microstructured  Surfaces  and 
Laminin-derived  Peptide  Coatings  on  Soft  Tissue  Interactions  with 
Titanium Dental Implants. Biomaterials. 30(12), pp. 2291–2301 
 	 ﾠ 282	 ﾠ
Wilson, C. J., Clegg, R. E., Leavesley, D. I., Pearcey, M. J. 2005 Mediation 
of Biomaterial–Cell Interactions by Adsorbed Proteins: A Review. Tissue 
Engineering. 11(1/2), pp.1-18. 
 
Winter.  G.  W. 1 9 7 4  Transcutaneous  Implants:  Reactions  of  the  Skin-
Implant interface. Journal of Biomedical Material Research Symposium. 5(1), 
pp.99-113. 
 
Xu, J., Clarke, R. A. F. 1996 Extracellular Matrix Alters PDGF Regulation 
of Fibroblast Integrins. The Journal of Cell Biology. 132(1&2), pp.239-249. 
 
Yamada,  K.,  Yamada,  S.,  Pastan,  I.  1976  Cell  Surface  Protein  Partially 
Restores  Morphology,  Adhesiveness,  and  Contact  Inhibition  of 
Movement  to  Transformed  Fibroblasts.  Proceedings  of  the  National 
Academy of Science of the USA. 73(4), pp.1217-1221.  
 
Yamada, K. M. and Kennedy, D. W. 1984. Dualistic  Nature  of  Adhesive 
Protein  Function:  Fibronectin  and  its  Biologically  Active  Peptide 
Fragments can Autoinhibit Fibronectin Function. Journal of Cell Biology. 
99, pp.29–36. 
 
Yang,  Y.,  Cavin,  R.,  Ong,  J.  L.,  2003  Protein  Adsorption  on  Titanium 
Surfaces  and  their  Effect  on  Osteoblast  Attachment.  Journal  of 
Biomedical Materials Research. 67A(1), pp.344–349.     
 
 
 